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The kidneys play a pivotal role in maintaining fluid and electrolyte homeostasis and 
regulating blood pressure. Multiple vasoactive peptides interact to exert autocrine and 
paracrine influences on the renal circulation, tubular function and mitogenesis. Endothelin-
1 is now known to be the most potent vasoconstrictor yet described, with natriuretic and 
mitogenic effects. Endothelin-1 exerts its effects via two receptors: the ETA receptor 
mediates vasoconstriction; the ETs receptor functions as a clearance receptor and has 
vasodilator effects by clearing endothelin-1 from the circulation as well as promoting 
natriuresis and diuresis. The natriuretic peptides exert potent natriuretic and diuretic 
effects. Circulating atrial natriuretic peptide is produced primarily in response to increased 
intravascular volume. Elevated levels of atrial natriuretic peptide are present in 
hypertension, nephrotic syndrome and acute and chronic renal failure. Kinins bind to their 
receptors at target organs and exert potent effects in vasodilatation, blood pressure 
reduction, vascular permeability, smooth muscle contraction, natriuresis, diuresis and renal 
blood flow. The kinin B2 receptor is the constitutive receptor and mediates most of the 
actions of kinins; the BI receptor is induced by inflammation. The connecting tubule cells 
show a loss of the kinin generating enzyme, tissue kallikrein in hypertension and renal 
failure. 
Aim: 
The aim of this thesis was to study a group of vasoactive peptides of differing 
physiological actions, namely, endothelin-1, atrial natriuretic peptide and kinins in models 
XIX 
of human renal inflammation, namely acute renal allograft rejection and 
glomerulonephritis. The hypothesis is that these peptides are closely inter-related, both 
anatomically and functionally and counter-balance each other's molecular and cellular 
effects. 
Methods: 
Ethical permission for the study was obtained from the Ethics Committee of the Medical 
School, University of Natal. 
1. Blood and urine samples and renal biopsies were collected from renal transplant
recipients with acute rejection and patients with renal parenchymal disease who underwent 
routine diagnostic renal biopsies. Blood and urine samples were collected from renal 
donors and normal volunteers; normal kidney tissue was obtained from forensic autopsies 
carried out within 24 hours of death. Plasma and urinary endothelin-1 was measured by 
ELISA; plasma and urinary atrial natriuretic peptide by radio-immunoassay; basal and 
generated kinins were measured in urine by ELISA; urinary tissue kallikrein by an 
enzymic assay as well as by ELISA. 
2. Immunocytochemistry was carried out on renal biopsy material for endothelin-1
and its receptors (ET A and ETs) using the peroxidase-anti peroxidase (PAP) method, 
immunofluorescent technique with confocal microscopy and immuno-electron microscopy. 
In addition endothelin-1 mRNA expression was detected by in situ reverse transcriptase­
polymerase chain reaction in acute rejection biopsies and control kidney tissue. Atrial 
natriuretic peptide immunolabelling was carried out by the PAP method. Tissue kallikrein 
immunofluorescent labelling was examined by confocal microscopy. The PAP images 
were analysed by the Kontron KS 300 (Zeiss GmbH, Germany), running on Windows 
xx 
95™ . Confocal images were analysed by the Analysis 2.1 Pro system (Soft-Imaging 
GmbH, Germany). 
3. Total body water was measured by bioelectrical impedance in 5 renal transplant
patients, 4 patients with renal disease and 3 control subjects. Renal plasma flow was 
measured using sodium 131 iodohippurate in 6 renal transplant patients. 
Results: 
I. Endothelin-1 and ET A and ETs receptors
Plasma endothelin-1 levels were elevated in patients with chronic renal failure on dialysis, 
decreased after renal transplantation, rose again during acute rejection and subsequently 
decreased after treatment of rejection. Urinary endothelin-1 excretion was increased during 
acute rejection. Plasma endothelin-1 concentrations were elevated in both proliferative and 
non-proliferative glomerulonephritis, with the highest levels 111 proliferative 
glomerulonephritis, hypertensive glomerulonephritis patients and those on dialysis. 
Immunocytochemistry showed increased endothelin-1 labelling of distal tubules and the 
luminal brush border of proximal tubules during acute rejection. In addition endothelin-1 
label was demonstrated in lymphocytes and plasma cells of the interstitial inflammatory 
infiltrate in acute rejection. Endothelin-1 immunolabelling was increased in proximal and 
distal tubules in proliferative glomerulonephritis. The ETA receptor was upregulated in 
both acute rejection and glomerulonephritis in the proximal and distal tubules and 
collecting ducts. The ETs receptor immunolabelling was decreased in glomeruli, proximal 
and distal tubules and collecting ducts in acute rejection and glomerulonephritis. Immuno­
electron microscopy revealed endothelin-1 and endothelin receptor labelling in epithelial 
cells of proximal and distal tubules, endothelial cells of blood vessels and glomerular 
capillaries. Label was found in the intercellular system and within secretory vesicles and 
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vacuoles as well as mitochondria. Endothelin-1 label was demonstrated in lymphocytes 
and plasma cells during acute rejection. Endothelin-1 mRNA was upregulated in tubular 
epithelial cells and capillary endothelial cells, as well as the inflammatory infiltrate d_uring 
acute rejection. 
2. Atrial natriuretic peptide
Plasma and urinary atrial natriuretic peptide concentrations were elevated during acute 
rejection. Atrial natriuretic peptide immunolabelling of glomeruli and collecting ducts was 
decreased in acute rejection and glomerulonephritis, while labelling of distal tubules and 
blood vessels was similar to controls. 
3. Tissue kallikrein and kinins
Urinary tissue kallikrein enzymic activity was reduced in dialysis patients pnor to 
transplant, rose after transplant, decreased during acute rejection and rose again after 
treatment of rejection. Urinary tissue kallikrein enzymic activity and basal kinin excretion 
was reduced in stable transplant recipients and in kidney donors after nephrectomy; basal 
kinin urinary excretion rose during acute rejection. Kinin generation in the urine was 
decreased in renal transplant patients during acute rejection as well as the donors after 
nephrectomy. Urinary tissue kallikrein excretion was decreased in glomerulonephritis. 
Basal kinins in urine were similar in patients with glomerular disease and controls; 
however significantly decreased kinins were generated in glomerulonephritis patients. 
Reduced tissue kallikrein immunolabelling was observed in the distal tubule during acute 
rejection and with renal parenchymal disease. 
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4. Total body water was increased during acute rejection; effective renal plasma flow
was reduced during acute rejection. 
Discussion and Conclusions: 
This thesis is the first study of endothelin-1 and its receptors in human renal inflammation 
and provides evidence of upregulation of ET A receptors and downregulation of ETa 
receptors in the kidney in renal inflammatory conditions (acute rejection and 
glomerulonephritis ). 
I) The downregulation of ETB receptors may account for the fluid retention and
hypertension that occur during acute rejection and glomerulonephritis; ETB receptors in the 
tubule inhibit sodium and water reabsorption in the distal tubule; ETa receptors are also 
clearance receptors and play a role in clearing circulating endothelin-1, thereby reducing 
its predominantly ET A-mediated pressor actions. Elevated plasma endothelin-1 levels may 
be as a result of its impaired clearance, as well as increased production by mononuclear 
cells (macrophages and monocytes) in renal inflammation. Cytokines produced during 
rejection and glomeruloneplu·itis may also be responsible for the elevation in plasma 
endothelin-1. None of the patients had histological or biochemical evidence of 
cyclosporine toxicity; cyclosporine therefore probably did not play a major role 111 
increasing plasma endothelin-1 in this study. 
2) The elevated plasma and urinary atrial natriuretic peptide levels are probably a
response to increased intravascular volume and hypertension in these patients; in addition, 
atrial natriuretic peptide production may be stimulated by the increased endothelin-1 
present. Reduced atrial natriuretic peptide immunolabelling in collecting ducts may be a 
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reflection of impaired natriuresis and diuresis, resulting in the fluid retention observed in 
these patients. 
3) Decreased urinary tissue kallikrein activity may be a reflection of reduced distal
nephron function and may mediate the hypertension that accompanies renal disease. 
Multiple vasoactive mediators have an impact on renal function; future therapy should be 
inclusive of the functions regulated by endothelin-1, atrial natriuretic peptide and kinins. 
Current therapy suggestive of this approach are angiotensin converting enzyme inhibitors, 
which block angiotensin II and decrease endothelin-1 while enhancing nitric oxide, 




1.1 VASOACTIVE PEPTIDES IN THE KIDNEY 
1.1.1 VASOACTIVE MODULATORS OF RENAL FUNCTION 
Many vasoactive substances, both circulating and local, influence the tone of the afferent 
and efferent glomerular arterioles (Fig 1.1-1 ). These include a variety of vasoconstrictor 
molecules such as angiotensin, catecholamines, vasopressin and endothelin (ET)- I as well 
as vasodilator substances, such as bradykinin, adrenomedullin, natriuretic peptides, 
adenosine and prostaglandins (Egido, 1996). Whereas some of these regulators of vascular 
tone are either released into or formed in the circulation, others are produced by endothelial 
cells, including those lining the glomerulus. 
Systemic 
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Fig 1.1-1: Vasoactive substances influencing tone and resistance in renal vasculature. 
Ref.: Johnstone CI et al. (1998). Journal of Hypertension, 16 (4): Sl-7 (S4) 
Abbreviations: RA =afferent artery; RE =efferent artery; BP= blood pressure; NO= nitric 
oxide 
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The endothelium is a monolayer of cells that forms the inner lining of all blood vessels. 
Endothelial cells synthesize many active substances, including large molecules [such as 
fibronectin and heparan sulphate, interleukin (IL)-1, tissue plasminogen activator] and 
various growth-promoting factors as well as smaller molecules [such as prostacylin, 
endothelium-derived relaxing factor (EDRF)/nitric oxide (NO), platelet-activating factor 
and ET-1]. The outer surface of endothelial cells contains angiotensin-converting enzyme, 
which catalyses the formation of angiotensin II from its inactive precursor angiotensin I. It 
also inactivates bradykinin (reviewed by Vane et al., 1990). In this way, many of them 
interact with EDRF / NO which mediates signal transduction. Nitric oxide is a powerful 
regulator of intrarenal haemodynamics and its release is stimulated by pressure and sheer 
stress (Webb, 1997), as is ET-1 and angiotensin II. 
Vasoconstrictors not only increase blood pressure but are also anti-natriuretic and neuro­
excitatory, and stimulate growth and hypertrophy. In contrast, vasodilators lower blood 
pressure and are also natriuretic and neuro-inhibitory, and inhibit growth and hypertrophy. 
Some growth factors, such as transforming growth factor (TGF)-P and platelet-derived 
growth factor (PDGF), may be vasoactive. Both angiotensin II and ET-1 are potent stimuli 
for cytokine production and extracellular matrix formation (Egido, 1996). 
The relationship between ET-1 and cytokines is dual. Renal cells stimulated by TGFP, 
PDGF and IL-1 p, secrete endothelin-1. Endothelin-1 induces the expression and synthesis 
of various cytokines in mesangial cells. Interleukin-6 synthesis has been reported to be 
stimulated by ET-1, angiotensin II and arginine vasopressin in mouse mesangial cells 
(Fujibayashi et al, 1991 ). It is likely that vasoactive hormones, growth factors and 
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cytokines are activated and, conversely, inhibited by the same stimuli, including 
mechanical stress, stretch and pressure transmission and immunological injury. 
Many vasoactive substances directly affect glomerular permeability and mesangial cell 
function. In the renal cortex, angiotensin II and ET-1 act as vasoconstrictors to decrease 
renal blood flow and glomerular filtration rate, whereas bradykinin causes vasodilation and 
increases glomerular capillary permeability. In the medulla, angiotensin II and ET cause 
vasoconstriction of the outer medullary descending vasa recta and thereby decrease vasa 
recta and papillary blood flow, whereas bradykinin exerts opposite effects (Navar et al., 
1996). Receptor-mapping studies in the rat kidney have shown that the distribution of 
angiotensin II subtype 1 (AT 1), endothelin A and B (ET A and ET 8) and kinin B2 receptors 
closely overlaps at several anatomical sites, including the renal vasculature, glomeruli, and 
the inner stripe of the outer medulla. In the cortex, the distribution of A T 1 and ET 8 
receptors is similar in glomeruli and proximal tubules. In contrast, B2 receptor density is 
low in the cortex. AT 1 receptors are predominantly in mesangial cells whereas ET 8 
receptors are present mainly in endothelial cells of glomerular capillaries. In the medulla, 
ET 8 and B2receptors are abundant in the inner medulla towards the tip of the papillae, 
whereas AT 1 receptors are not readily detected in this region. However, receptor binding 
sites for these peptides all occur in the inner stripe of the outer medulla, suggesting their 
role in the regulation of renal medullary haemodynamics, tubular transport processes and 
probably long-term blood pressure homeostasis. These peptides also promote cell 
proliferation and extracellular matrix synthesis in renal medullary interstitial cells (Zhuo et 
al., 1998). 
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1.1.2 ENDOTHELINS IN THE KIDNEY 
Yanagisawa and colleagues (1988a) reported an endothelium-derived factor (a 21 ammo 
acid peptide) as the most potent vasoconstrictor ever described to date. This substance was 
named endothelin (ET). Subsequent studies showed that ET was one of a family of 3 
isopeptides, all of which were formed through a 2-step processing pathway from their 
respective precursor peptides that shared high sequence homology but were encoded by 
distinct genes. Endothelin isopeptides share a marked structural similarity to the 
sarafotoxins (SRTX), peptides isolated from the Israeli burrrowing asp, Atractaspis 
engaddensis [Kloog et al., 1988; (Fig 1.2-1)]. The ETs and SRTXs act through common 
receptors to evoke a multitude of biological effects. Isoforms of SRTX have been utilised 
as tools for the characterisation of ET receptors (Sokolovsky, 1994 a and b ). 
ET-I is the major isopeptide produced by human endothelial cells and is present in the 
greatest concentration in blood. The concentrations of ET- I, though detectable in the 
human circulation, are very low (in the picomolar range). However, as ET- I is released 
predominantly in an abluminal direction towards the underlying smooth muscle (Wagner et 
al., 1992), the tissue concentration is likely to be sufficiently high to activate local 
receptors. Recent studies, using inhibitors of ET synthesis or receptor antagonists, suggest 
that ET-I is released tonically to maintain basal systemic vascular resistance in humans 
(Haynes and Webb, 1994). In this way, ET-I might balance out the dilator effects of nitric 
oxide (NO), which is also thought to be released in a tonic manner [(Vallance et al., 1989; 








Fig 1.2-1: Amino acid sequence of endothelin isopeptides 
Ref: Brenner B Met al. (1989), Journal of Clinical Investigation, 84: 13 73-13 78 (1375) 
While the synthesis of NO can be increased within minutes in response to various stimuli, 
ET-1 synthesis is regulated at the transcriptional level with a resultant delay in release 
(Yanagisawa et al., 1988b; Boulanger and Lilscher, 1990). Nitric oxide has a short half-life, 
and its effects can be terminated quickly by cessation of release; in contrast endothelial ET-
1 binds to its receptors on smooth muscles irreversibly, and its constrictor and pressor 
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Fig 1.2-2: Endothelium-derived factors that regulate vascular smooth muscle 
Ref: Kohan D E (1997), American Journal of Kidney Disease, 29: 2-26 (5) 
Abbreviations: ER= endoplasmic reticulum; IP3= inositol triphosphate; PLC= phospho­
lipaseC; [Ca2+]= calcium concentration; PGii= prostacyclin; PKC= protein kinase C; 
PLA2= phospho-lipase A2
Intensive research into the ET system has greatly improved our understanding of the genes 
that encode for ET-1 and its isopeptides, of the enzymes involved in its synthesis and the 
receptors that by activating signaling pathways mediate its actions. 
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1.1.2.1 ENDOTHELIN GENERATION AND CLEARANCE 
1.1.2.1.1 Endothelin genes and regulation 
At least 3 genes encoding ET- like sequences in mammalian genomes (Inoue et al., 1989b), 
have been shown to encode the precursors of ET-2 and ET-3, in addition to prepro ET-I. In 
the human genome, the ET-1 gene is found on chromosome 6 (Bloch et al., 1989 a; Hoehe 
et al., 1993), the ET-2 gene on chromosome 1 (Bloch et al., 1991) and the ET-3 gene on 
chromosome 20 (Bloch et al, 1989 b ). Endothelin gene expression has been demonstrated 
in the brain and spinal cord, lung, kidney, gut, eye, pituitary and amnion (reviewed by 
Simonson, 1993). The endothelium is the major site of ET gene expression. The genes 
encoding ET precursors have promoter regions through which external factors are able to 
modulate transcription (Hilkert et al., 1992; Benatti et al., 1994). Extracellular factors can 
influence ET-1 generation both positively and negatively through liberation of a series of 
intracellular mediators that modulate gene transcription. Several agents, including insulin, 
thrombin, low density lipoprotein, angiotensin II, vasopressin and ET-1 itself (Emori et al., 
1991; Boulanger et al., 1992; Emori et al., 1992; Kohno et al., 1992; Benatti et al., 1994) 
enhance ET-I generation via activation of protein kinase C [(PKC); Table 1.2-1]. 
Responsiveness to PKC is mediated by binding of the proto-oncogenes,jun and/as to the 
Activator Protein-I (AP-1) transcription regulatory element of the ET-1 promotor (Curran 
and Franza, 1988; Lee et al., 1991 ). PKC activation is also thought to be a mechanism by 
which low levels of shear stress (1.8 dyne/cm2) enhance endothelial ET-I release (Kuchan 
and Frangos, 1993; Wang et al., 1993). Higher levels of shear stress (>6 dyne/cm2) activate 
another mechanism that inhibits ET-1 mRNA transcription (Kuchan and Frangos, I 993; 
Malek et al., 1993). This effect is prevented by inhibitors of NO synthesis and by 
methylene blue, an inhibitor of guanylate cyclase, suggesting that endothelial cells release 
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NO in response to shear stress, and inhibit ET-I synthesis through formation of cyclic 
GMP. Synthesis of ET-I is inhibited by thrombin (Boulanger and Liischer, 1990), heparin 
(Yokokawa et al., 1993), atrial and brain natriuretic peptides (Kohno et al., 1991) and by 
the prostanoids, prostaglandin E2 and prostacyclin (Prins et al., 1994). One action of cyclic 
GMP is to reduce the availability of intracellular calcium, which may be relevant for the 
inhibition of ET-I synthesis, as calcium chelation similarly reduces ET-I release from 
endothelial cells (Emori et al., 1992). 
1.1.2.1.2 Processing of endothelin precursors 
Endothelin isopeptides arise from post-translation processing of large isopeptide-specific 
prohormones in a manner analogous to other peptides. The 212-amino acid pre-proET-1 
undergoes proteolytic cleavage between Lys 52-Arg 53 and Arg
90
-Arg91 to release the 38 
amino acid precursor, big ET-I; this step may be dependant on one of the proprotein 
convertases (Steiner et al., 1992; Seidah et al., 1993). Furin, a proprotein convertase of the 
constitutive secretory pathway, has been proposed as a likely candidate (Laporte et al., 
1993). Big ET-I is less active than ET-I for displacement of binding to ET receptors and in 
stimulating vascular contraction in vitro (Hirata et al., 1990). The release of the 
biologically active 21 amino acid ET-I requires selective cleavage of the Trp21 -Va!22 bond 
in the carboxy terminal portion of big ET-1, catalysed by endothelin-converting enzyme 
activity [(ECE); Fig 1.2-3]. Several ECE-like enzyme activities representing different 
endopeptidase classes have been identified (reviewed by Opgenorth et al., 1992; Turner 
and Murphy, 1996). These include serine proteases (Yanagisawa et al., 1988 b; McMahon 
et al., 1989; Takaoka et al., 1990a; Kaw et al., 1992; Wypij et al., 1992), aspartate 
proteases such as pepsin (Takaoka et al., 1990 b) and Cathepsin D (Sawamura et al., 1990), 
and soluble thiol protease (Deng et al., 1992). The physiologically relevant ECE is a 
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membrane-bound, zinc-containing metalloprotease that is inhibited by phosphoramidon, a 
neutral (metallo) endopeptidase (NEP 24.11) inhibitor (Opgenorth et al., 1992). The 
activity of this ECE is not affected by thiorphan (another NEP inhibitor) or by inhibitors of 
the neutral metalloprotease angiotensin converting enzyme (ACE). Human ECE - I has a 
neutral pH optimum and is inhibited by phosphoramidon (Schmidt et al., 1994; Yorimitsu 
et al., 1995). A second novel enzyme, ECE-2 has been cloned more recently (Emoto and 
Yanagisawa, 1995); this enzyme is also inhibited by phosphoramidon. ECE-1 is widely 
distributed but not found in neurons and glia in the brain. ECE-2, in contrast, seems to be 
most abundantly expressed in neural tissues (Emoto and Yanagisawa, 1995). Both ECE-1 
and ECE-2 are predicted to be integral membrane proteins and therefore the primary site 
for cleavage of endogenous big ET-1 could be at the plasma membrane or at an intra­
membranous site. 
Exogenous big ET-1 can be converted to ET-1 in vivo (McMahon et al., 1991 ), in vitro
(Auguet et al., 1992) and in cos cells transfected with the ECE-1 gene (Xu et al., I 994), 
consistent with localisation of ECE at an accessible plasma membrane site. Endogenous 
big ET-1 is most likely to be converted during its transit through the intracellular 
constitutive secretory pathways, especially within the Golgi apparatus. Formation of ET-I 
in secretory vesicles that can recognise transport pathways could explain the directional 
release ofET-1 towards the abluminal surface of endothelial cells (Wagner et al., 1992). 
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Fig 1.2-3: Processing pathway of ET-1
Ref: Gray, GA and Webb, DJ (1996). Pharmacology and Therapeutics, 72: 109-148 (114)
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1.1.2.1.3 Sites of endothelin synthesis and secretion 
Endothelin-1 is secreted by a constitutive pathway but recent evidence suggests that in 
some cells, ET can be secreted by a regulated pathway via secretory granules. Endothelial 
cells in culture secrete about 80% of ET-I into the basolateral compartment (Wagner et al., 
1992). Stimulation with thrombin doubles ET-I secretion. Numerous cells in culture, 
including endothelial cells (Yanagisawa et al., 1988a; Bloch et al., 1989a; Saito et al., 
1989), vascular smooth muscle cells (Resink et al., 1990a; Yu and Davenport, 1995), 
mesangial cells (Sakamoto et al., I 990; Zoja et al., 1991 ), and glial cells (MacCumber et 
al., 1990), secrete a constant level of ET into the culture supernatant, suggesting a 
constitutive pathway for secretion, which is supported by immunocytochemical studies on 
endothelial cells (Nakamura et al., I 990). Immunoreactive ET-I is detected primarily in the 
endothelial cell layer in human blood vessels (Howard et al., 1992; Tokunaga et al., 1992; 
Saetrum Opgaard et al., I 994; Properzi et al., I 995), consistent with the idea that ET-I is 
released by endothelial cells to act on the underlying smooth muscle cells. In situ
hybridisation for ECE-1 mRNA also shows the most intense labelling over vascular 
endothelial cells of most tissues (Xu et al., 1994). The secretory pathway involves the 
rough endoplasmic reticulum, Golgi cisternae, Golgi vesicles and small exocytic vesicles 
directly beneath the plasma membrane. A variety of stimuli increase ET secretion, as 
shown in Table 1-1. In most cases induction of ET-I secretion above basal levels requires 
2-5 h, and most likely results from ET gene induction. ET-I secretion by endothelial cells
is inhibited by atrial natriuretic factor (Saijonmaa et al., 1990; Kohno et al., 1991; Hu et al., 
1992) and by co-culture with cells of the vascular media (Stewart et al., 1990), which might 
protect vascular target cells from excessive ET-I production. Endothelial secretion is also 
inhibited by activation of protein kinase A (Sakamoto et al., 1992). 
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Table 1-1. Factors that influence ET-1 biosynthesis 
Fluid-mechanical shear stress 
Hypoxia 
Thrombin 
Transforming growth factor-� 
Interleukin- I 
Tumour necrosis factor 
Bradykinin 
Arginine vasopressin 
Epidermal growth factor 
Endo toxin 
Oxidized low-density lipoprotein 
Insulin 










Immunoreactive ET peptides have been demonstrated in secretory vesicles in the posterior 
pituitary of the rat (Yoshizawa et al., 1990). These are depleted upon water deprivation, 
suggesting that ET-I is secreted in response to changes in extracellular fluid volume or 
osmolarity and might be involved in neurosecretion and osmolar regulation. Glomerular 
immunoreactive ET-I is localised primarily in the endothelium and to a lesser extent, in the 
mesangium. Focal staining was also observed in the proximal tubule brush border (Wilkes 
et al., 1991 ). Experiments with primary cultures ( derived from nephron segments) reveal 
that renal tubule cells secrete abundant amounts of ET-I >ET-3; ET synthesis is much 
greater from medullary tubular segments with inner medullary collecting duct > medullary 
thick ascending limb > cortical collecting tubule >> proximal tubule (Kohan, 1991 ). It is 
thus possible to conclude that ET acts at multiple sites in the kidney, including the 
glomerulus (probably at afferent and efferent vascular smooth muscle and mesangial cells), 
medulla (probably loop of Henle and collecting ducts), vasa recta bundles and perhaps at 
the proximal tubules. ET might act at other renovascular sites, including the interlobular 
and arcuate arteries and possibly the vascular smooth muscle cells in the postglomerular 
medullary circulation. The proximal location of cells in the cortex and medulla expressing 
ET binding sites and preproET mRNA transcripts suggests that ET acts as an autocrine or 
paracrine peptide (Simonson, 1993). 
1.1.2.1.4 Clearance and degradation of endothelin 
The plasma half-life of ET-I in humans is less than 1.5 min because of its efficient 
extraction by the splanchnic and renal vascular beds (Weitzberg et al., 1991; Gasic et al., 
1992). Although ET-1 is also taken up by the lungs, pulmonary clearance is less important 
in humans than in other species (Ray et al., 1992; Hemsen et al., 1995). Extraction of ET-I 
follows binding to cell surface receptors, which are then internalised, allowing degradation 
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to be carried out within the cell, perhaps in lysosomes (Loffler et al., 1991 ). ET 8 receptors 
may have a role in clearance of ET-1, as suggested by increased circulating concentrations 
of ET-I with mixed ET A/ET s receptor antagonists (Loffler et al., 1993 ), or a ET 8 selective 
receptor antagonist (Fukuroda et al., 1994) but not by ET A selective antagonists. A soluble 
protease found in human platelets, vascular smooth muscle and endothelial cells may be a 
possible candidate for an intracellular degrading enzyme (Jackman et al., 1992, 1993). A 
deamidase with similar characteristics was purified from rat kidney (Deng et al., 1994; 
Janas et al., 1994). The ETs can also be degraded by neutral endopeptidases [NEPs, (E.C. 
24.11 )], which are associated with arterial and venous endothelial cell plasma membranes 
(Llorens-Cortes et al., 1992). Activated polymorphonuclear leucocytes are able to rapidly 
inactivate ET-1 through release of a protease, believed to be cathepsin G, which degrades 
ET by cleavage of His 16- Leu 17 (Fagny et al., 1992; Patrignani et al., 1992); this process 
may have a role in acute inflammation following adhesion of polymorphonuclear 
leucocytes to vascular endothelial beds. 
1.1.2.2. ENDOTHELIN RECEPTORS 
The ETA type receptor is characterised by its very high (subnanomolar) affinity for ET-I 
and ET-2, and its 70-100 fold lower affinity for ET-3, while the ET8receptor has high and 
equal affinity for all 3 isopeptides. The cDNAs encoding the human ET A and ET B receptors 
predict 427 and 442 aminoacids respectively (Fig 1.2-4), and the overall identity between 
the two mature proteins is reported to be between 55% and 64%, depending on the tissue 
studied. The ET A and ET 8 receptor genes, located on chromosomes 4 (Hosoda et al., 1992) 
and 13 (Arai et al., 1993) respectively, have similar structural organisation, suggesting that 
they originated from the same ancestral gene. 
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Fig 1.2-4: Transmembrane topography of endothelin receptors. 
Ref: Sakamoto H et al. (1993), J Biol Chem, 268: 8547-8553 (8548) 
The number of amino acids ( circles) is based on the ETA sequence; striped circles depict 
the sequence introduced to ETB and the insertions by arrows. Closed circles denote amino 
acid residues that are identical in ET A and ETB receptors; open circles the non-identical 
residues. Position of the restriction sites used to construct chimeric receptors are shown 
with arrowheads with the names of the enzymes. Abbreviations: N= amino terminal; C= 
carboxy terminal; aa= amino acid. 
Screening of amphibian cDNA libraries has revealed the existence of 2 alternate receptor 
clones: ETc receptor subtype showing relative selectivity for ET-3, cloned from Xenopus 
dermal melanophores (Kame et al., 1993); ET AX, cloned from Xenopus heart, has a 
relatively high affinity for ET-1 (like the ETA receptor) but an uncharacteristic low affinity 
for the ETA selective ligand BQ-123 (Kumar et al., 1994). 
As with the ET genes, the nontranscribed 5' flanking regions of the ET receptor genes 
contain a number of regions in the regulation of gene transcription (Hosoda et al., 1992; 
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Arai et al., 1993). Exogenous factors can act through these regions to increase receptor 
transcription, namely upregulation of ET receptor mRNA by insulin (Frank et al., 1993), or 
ET 8 receptor mRNA by angiotensin II (Kanno et al., 1993). These mechanisms may be 
important in the regulation of responsiveness to the ETs in pathophysiological states. One 
of the major factors that reduces ET receptor numbers at the cell surface is prolonged 
exposure to ET-I, because of down-regulation or feedback inhibition of receptor 
expression (Hirata et al., 1988) or both in combination. All of the cloned ET receptor genes 
predict a heptahelical membrane spanning structure, common to members of the G-protein 
coupled receptor superfamily and similar to many neuropeptide receptors (Fig 1.2-4; 
Burbach and Meijer, 1992). The seven transmembrane domains and cytoplasmic loops of 
the receptors are highly conserved and the N-terminal and extracellular domains exhibit 
differences in both length and amino acid sequences (Ogawa et al., I 991; Elshourbagy et 
al., 1993; Sakamoto et al., 1993). The extracellular terminal regions of peptide G-protein 
coupled receptors are known to be important for ligand binding (Nagayama et al., I 991 ). 
The amino acid loops of the receptor proteins have been a speci fie source for the harvesting 
of anti-peptide antibodies. 
In vascular tissue, ETA receptor mRNA is expressed predominantly in smooth muscle. 
while ET 8 receptor mRNA is most abundant in endothelial cells, suggesting that 
constriction of vascular smooth muscle is mediated predominantly by ET A receptors, and 
that constriction is modified by release of relaxing factors from the endothelium via 
stimulation of ET 8 receptors (reviewed by Gray and Webb, 1996). Any analysis of the 
renal actions of ET requires an understanding of the distribution and molecular 
characterization of ET receptors. Both glomeruli and the inner medulla express abundant 
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binding sites for 125 I-ET-1 autoradiography (reviewed by Simonson, 1993). Precise cellular 
localizations are unavailable. Equilibrium binding studies in cultured medullary interstitial 
cells confirm the existence of high affinity (Kd=57pM) ET receptors in the medulla. A high 
density of ET-1 binding sites is also present in longitudional bands over the inner stripe of 
the outer medulla. In humans, the distribution of binding sites for ET-1, ET-2 and ET-3 and 
sarafotoxin 6b is similar, supporting the notion that different ET isopeptides act on the 
kidney (Waeber et al., 1990). ET-1 binds nearly irreversibly to its receptor and is not 
displaced by peptides such as angiotensin II, atrial natriuretic peptide and arginine 
vasopression, and is unaffected by dihydropyridine, phenylalkylamine and benzothiazepine 
calcium channel blockers (Kohzuki et al., 1989; Orone et al., 1990). Equilibrium binding 
studies with the ET 8 specific agonist sarafotoxin 6c and theET A receptor antagonist 
BQ 123 demonstrate that the kidney cortex expresses equal numbers of ET A and ET s 
receptors (Nambi et al., 1992). Steady-state mRNA levels for both ET A and ET B receptors 
have been observed by Northern blot analysis in adult rat kidney. In situ hybridisation 
reveals differential localization of ETA and ET B receptors. ET A mRNA is expressed in 
renal arteries and in afferent and efferent glomerular arterioles, implicating ET A receptors 
in the intense renal vasoconstriction induced by ET-1. ET A receptors have also been 
characterized from microdissected nephron segments of the glomerulus, vasa recta bundle 
and arcuate artery. ET 8 receptors are abundantly expressed by glomerular endothelial cells 
and in vasa recta bundles; weak hybridization signals corresponding to ET 8 mRNA were 
also observed over epithelial cells in thin segments of Henle's loop and over interstitial 
cells but not over epithelial cells of collecting ducts. In constrast, mRNA transcripts for 
ET A and ET 8 have been demonstrated by RT-PCR of RNA isolated from inner medullary 
collecting ducts in vitro (reviewed by Simonson, 1993). These studies demonstrate that ET 
binds to high-affinity, saturable, cognate receptors in the kidney. Moreover, the distribution 
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of ETA and ET s receptors suggests multiple actions on renal haemodynamics, glomerular 
function, medullary blood flow and perhaps, proximal tubular reabsorption or secretion. A 
large number of ET receptor antagonists (peptide and non-peptide, selective and non­
selective) have become available and have confirmed the role of ET-1 in pathology, the 
first report using BQ-123 (Moreland, 1994). 
1.1.2.3 MODE OF ACTION 
Low levels of plasma ET-1 are consistent with the predominantly basolateral secretion of 
ET-1 by endothelial cells. Thus it would appear that circulating ET-1 simply reflects 
spillover from local ET-1 release. The peptide is rapidly cleared from the plasma and 
degraded, consistent with a predominantly autocrine/paracrine action of ET. In some 
instances, circulating ET might be biologically active. Doubling of plasma ET levels by 
exogenous infusion causes a significant increase in peripheral and renal vascular resistance 
without affecting coronary vascular resistance or mean arterial pressure (Lerman et al., 
1990). Moreover, elevated ET plasma concentrations have been reported in some 
pathophysiological states that might activate high-affinity ET receptors (Lerman et al., 
1991 ). 
1.1.2.3.1 Transmembrane signalling by endothelin 
Endothelin peptides evoke complex, tightly regulated pathways of signal transduction that 
result in short-term (i.e. contraction, secretion) and long-term (i.e. mitogenesis) biological 
actions (Simonson and Dunn, 1990). Endothelin initially activates a membrane 
transduction process comprising a G protein-coupled cell surface receptor, coupling G-
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protein(s) and phospholipase C or other G protein-activated effectors (Fig 1.2-5). 
Endothelin rapidly induces a dose-dependent increase in phosphatidylinositol turnover. 
Activation of phospholipase C by ET produces at least 2 second messengers: 1,4,5-
triphosphate which diffuses to specific receptors on specialised compartments of the 
endoplasmic reticulum to release intracellular calcium; and 1,2-diacylglycerol, which 
remains in the plasma membrane and (with cofactors calcium and phosphatidylserine) 
activates phospholipase C. Calcium signalling is thought to mediate some short-term 
effects of ET such as vasoconstriction in the kidney and in other organ systems. Calcium 
signalling appears to be a nearly universal response to ET receptor activation (reviewed by 
Simonson, 1993). Calcium signalling induced by ET-1 requires conversion of proET-1 to 
ET- I. Endothelin peptides release calcium from intracellular stores. Endothelin-1 increases 
calcium influx from the extracellular space by activating multiple types of calcium 
channels in the plasma membrane. Evidence suggests that protein kinase C mediates both 
short and long-term events of ET. Evidence also suggests that ET-1 stimulates 
phospholipase A activity resulting in increased arachidonic acid-derived mediators such as 
prostaglandins and thromboxane. Both ETA and ET 8 receptors can stimulate phospholipase 









exchange has been demonstrated to sensitise cardiac myofilaments to 
intracellular calcium, thereby contributing to the inotropic activity of ET (Kramer et al., 




-Cr co transport system in
vascular smooth muscle cells (Rosati et al., 1990). 
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Fig. 1.2-5 Transmembrane signalling by ET-1 
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In addition to activating the serine/threonine-specific protein kinase C, ET also activates S6 
kinase (Resink et al., 1990 b ), which phosphorylates the sixth protein on the small 
ribosomal subunit, and is thought to contribute to mitogenic signalling. Endothelin-1 
causes tyrosine and threonine phosphoryation and activation of mitogen-activated protein 
(MAP) kinase in mesangial cells, which is also postulated to contribute to mitogenic 
signalling (Wang et al., 1992). 
1.1.2.3.2. Signal transduction in the nucleus 
Cells proliferate when stimulated by high concentrations of ET. Endothelin has been 
reported to increase the expression of several genes including collagenase, prostaglandin 
endoperoxidase synthase and platelet-derived growth factor A and B chains. Further, ET-1 
enhances the ability of epidermal growth factor to induce colony formation in semi-soft 
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agar. Endothelin-1 elevates the expression of transcription factors such as c-fos, c-jun, c­
myc and VL-30. Induction of both c-fos and c-jun by ET is rapid and transient, consistent 
with a role for these trans-acting factors as a genetic switch. It is also likely that by 
induction of trans-acting factor genes, ET contributes to long-term changes in cell 
phenotype (reviewed by Simonson, 1993). 
1.1.2.4 REGULATION OF RENAL HAEMODYNAMICS 
Renal haemodynamics influence renal function by controlling, in part, glomerular filtration, 
tubular secretion and reabsorption, and urine concentration and dilution. Changes in renal 
haemodynamics act by regulating blood flow and hydraulic pressure in the glomeruli, 
peritubular and medullary micro-circulation (Dworkin et al., 1991 ). Renal vascular tone is 
regulated by a-and P-adrenergic sympathetic output, and by the levels of circulating 
vasoactive compounds such as angiotensin II, prostaglandins, arginine vasopressin, atrial 
natriuretic peptide and kinins. Renal vasomotor tone is exquisitely sensitive to ET-1 
(Simonson, 1993). Systemic infusions of ET-1 cause a marked increase in renal vascular 
resistance (RVR), and a decline in renal plasma flow (RPF) and glomerular filtration rate 
(GFR). Changes in RPF occur rapidly and are dose-dependant: maximal decreases occur 
20-30 min after infusion, after which RPF gradually increases and returns to baseline after
1-2 h. The increase in RVR following ET-1 infusion results from intense contraction of
glomerular arterioles (afferent> efferent), and arcuate and interlobular a11eries. ET-1 may 
induce renal vasoconstriction via platelet-activating factor and increase in cytosolic free 
calcium (Simonson and Dunn, 1992). Direct infusion of ET-1 into the renal artery in dogs 
causes a rapid transient increase in RPF followed by a marked long-lasting decrease (Stacy 
22 
et al., 1990). The decline in RPF is partially attenuated by dihydropyridine calcium channel 
blockers and by atrial natriuretic peptide (Katoh et al., 1990). On a molar basis, ET-1 is 30 
times more potent than angiotensin II and 50 times more potent than noradrenaline (Cairns 
et al., 1989). 
Hypotheses for a role for ET in local control of blood flow in the kidney and autoregulation 
are: (i) an increase in blood flow may be sensed at the endothelium by shear stress 
receptors, which then transduce a signal to increase the rate of ET-I secretion by 
endothelial cells. Endothelin-1 would then diffuse to nearby vascular smooth muscle cells, 
bind to specific receptors and induce a phospholipase C-dependant signalling cascade to 
initiate contraction of the blood vessel via an excitation-contraction coupling, signal 
transduction process. The resultant increase in vasomotor tone would oppose the increase 
in blood flow, and function as a myogenic mechanism of autoregulation. Secretion of ET 
by endothelial cells would counteract the vasodilatory signals released by endothelial cells, 
such as endothelium derived relaxing factor (EDRF), kinin-forming enzymes and 
prostacyclin. Thus, ET-1 would function in concert with other endothelium-derived 
vasoactive factors to produce regional regulation of blood flow; (ii) a second hypothesis is 
that ET contributes to tubulo-glomerular feedback in response to increased NaCl delivery 
at the macula densa by inhibiting renin secretion (Simonson, 1993). 
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1.1.2.5 EFFECTS ON GFR AND GLOMERULAR FUNCTION 
1.1.2.5.1 Endothelin and GFR 
Single nephron GFR (SNGFR) is the product of net filtration pressure (P ur) across the 
glomerular capillary and the ultrafiltration coefficient (Kr). ET-I acts on both variables to 
regulate SNGFR. Mildly pressor doses of ET-1 cause a greater increase in efferent than 
afferent arteriolar contraction thereby increasing Pur (King et al., 1989). While this would 
favour filtration, a decline in Kr and a modest decline in glomerular capillary flow rate (QA) 
cause SNGFR to remain relatively constant at these low doses of ET-1. Higher doses of 
ET-I cause profound increases in afferent and efferent resistance, and a decline in QA and 
Kr, thereby reducing GFR. ET-1 evokes contraction of glomerular mesangial cells via 
excitation-contraction coupling, suggesting that a reduction in filtering surface area might 
mediate the fall in Kr by ET (reviewed by Simonson, 1993). 
1.1.2.5.2. Endothelin and mesangial cells 
Mesangial cells are specialized microvascular pericytes located in the central region of the 
glomerular tuft between capillary loops. Mesangial cells help regulate GFR by controlling 
Kr; they also process macromolecules (including immune complexes) trapped within the 
mesangium. In addition, mesangial cells synthesize and assemble the mesangial matrix, 
which is a major determinant of the visco-elastic properties of the mesangium. Endothelins 
have both contractile and pro-mitogenic actions on mesangial cells, which might contribute 
to the glomerular response to injury. Prostaglandins help regulate contraction and 
mitogenesis of mesangial cells in culture. ET-1 evokes arachidonic acid release and 
production of PGE2 from mesangial cells. ET-1 is a potent growth factor for mesangial 
cells and stimulates quiescent mesangial cells to enter 0 1 and proliferate. ET-I also 
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increases mesangial DNA topoisomerase-1 activity by a pertussis toxin-sensitive pathway. 
Mesangial cells in vivo are normally quiescent. Mesangial proliferation is a common 
finding in glomerular inflammation suggesting that local overproduction of ET-1 might 
serve as a pro-inflammatory signal in glomerular injury. Pro-inflammatory agents such as 
IL-1 and TGF p stimulate ET secretion in endothelial and mesangial cells, supporting this 
hypothesis. ET-I induces platelet-derived growth factor (PDGF) A and B chain expression 
in human mesangial cells; AP-I transcription factors probably mediate induction of the 
collagenase gene by ET-I in mesangial cells (reviewed by Simonson, 1993). 
1.1.2.6 EFFECTS ON SODIUM 
A major function of the kidney is to regulate extracellular fluid volume (ECFV) and thus 
mean arterial pressure, both of which may be regulated by ET. ECFV is primarily 
determined by total exchangeable sodium and therefore alterations in renal sodium 
excretion, which represents the difference between the filtered load of sodium and the 
amount of sodium reabsorbed at various tubular sites. ET-I appears to have diverse effects 
on renal sodium handling and the precise role of ET-1 in renal sodium excretion is unclear. 
Systemic infusions of ET-1 decrease sodium excretion in some studies (Goetz et al., 1988; 
Hirata et al., 1989; Miller et al., 1989), but in others (King et al., 1989; Garcia et al., I 990), 
ET-1 was modestly natriuretic despite a decline in RBF. lntrarenal infusions of ET-1 cause 
no change in sodium excretion, whereas higher doses decrease sodium excretion (Katoh et 
al., 1990; Stacy et al., 1990), suggesting that ET has an intrarenal natriuretic effect but that 
the influence of other extra- and intrarenal mechanisms might oppose this action. 
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1.1.2.6.1 Endothelin and the filtered load of sodium 
ET-I reduces GFR and would therefore be expected to reduce the filtered load of sodium, 
resulting in decreased sodium excretion. The haemodynamic actions of ET-1 would reduce 
the peritubular capillary Starling pressures, thereby leading to enhanced removal of sodium 
from the peritubular interstitial space into the peritubular capillaries. 
1.1.2.6.2 Endothelin and the Renin-Angiotensin-Aldosterone System 
The renin-angiotensin system is the chief regulator of ECFV. Angiotensin II (All) increases 
proximal tubular fluid reabsorption via alterations in renal haemodynamics and by directly 
stimulating proximal tubule sodium reaborption. All also stimulates adrenal aldosterone 
secretion, which stimulates sodium reabsorption by the late distal tubules and collecting 




exchanger and the basolateral Na
+ 
-H co-3 
cotransporter (Eiam-Ong et al., 1992). Both the haemodynamic and proximal tubular 
actions of ET-1 might be similar to those of AIL ET-I infusion increases circulating levels 
of aldosterone (Goetz et al., 1988; Miller et al., 1989). Systemic infusion of ET- I sharply 
increases plasma renin activity (Goetz et al., 1988; Miller et al., 1989) which may reflect 
activation of the intrarenal baroreceptor and macula densa-mediated pathways of renin 
secretion. In vitro experiments with superfused juxtaglomerular cells, cortical slices and 
isolated rat glomeruli demonstrate inhibition of renin release by ET-I (Takagi et al., 1989). 
The inhibitory effect of ET-I is attenuated in the absence of extracellular calcium. 
ET-1 therefore has variable effects on renin release: when ET-I is secreted locally, it likely 
inhibits renin release via a calcium-dependent mechanism, resulting in decreased 
aldosterone secretion, thereby reducing sodium reabsorption and increasing sodium 
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excretion; high levels of circulating ET-I would increase renin secretion either directly at 
the adrenal glomerulosa, or indirectly as a result of profound renal vasoconstriction, 
resulting in increased aldosterone, enhanced sodium reabsorption and decreased sodium 
excretion. Thus the net effect of ET-I on renal sodium handling would depend on whether 
ET-I functions as a circulating or local peptide hormone. 
1.1.2.6.3 Endothelin and atrial natriuretic peptide secretion. 
Atrial natriuretic peptide (ANP), released from cardiac atrial myocytes in response to atrial 
stretch, regulates sodium excretion by directly stimulating natriuresis through guanylate 
cyclase linked ANP receptors, increases GFR by enhancing the filtered load of sodium and 
concomitantly inhibiting sodium reabsorption at the collecting duct. ANP also indirectly 
decreases sodium reabsorption by inhibiting renin secretion and AII-induced aldosterone 
release. ET-I infusion elevates circulating levels of ANP (Goetz et al., 1988; Miller et al., 
1989). ANP is a potent vasodilatory compound and the major function of ANP secretion 
could be to antagonise the contractile effects of ET-I and AII on vascular smooth muscle 
and on glomerular mesangial cells (Neuser et al., 1990). 
1.1.2.6.4 Endothelin and sodium-potassium-ATP in the collecting duct 
Systemic infusions of ET-I (at doses that do not markedly impair GFR) produced modest 





-ATPase activity in the medullary collecting duct (Zeidel et al., 1989), 
thereby reducing the electrochemical gradient favouring sodium reabsorption. ET-!­




-ATPase is abolished by ibuprofen, suggesting that the 
inhibitory action 1s mediated by prostanoids. Table 1-2 summarizes the possible 
mechanisms by which ET modifies sodium excretion by the kidney. 
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Table 1-2. Effects of Endothe]in-1 on renal sodium regulation 
Natriuretic actions of endothelin 
Inhibition of renin secretion: local effect on JG cells 
Increase of atrial natriuretic peptide secretion: direct action at 





-ATPase in medullary collecting ducts: 
mediated by prostaglandin synthesis 
Anti-natriuretic actions of endotheJin 
Reduction in filtered load of Na
+
: reduction in glomerular 
filtration rate 
Increase in plasma aldosterone: direct effect on adrenal 
glomerulosa or from decreased renal haemodynamics 
Possible stimulation of Na
+ 
reabsorption by direct action of 
endothelin-1 on proximal tubule 




1.1.2.7 ENDOTHELIN AND RENAL WATER REABSORPTION 
Renal water reabsorption is regulated indirectly by plasma osmolality, which evokes 
changes in pituitary arginine vasopressin (AVP) release. In the absence of A VP, collecting 
ducts are highly impermeable to water. A VP acts on renal collecting duct cells to stimulate 
insertion of preformed water channels into their apical membrane, causing the cells to 
become permeable to water. This results in movement of water from the tubular lumen to 
the interstitium. These effects of A VP are mediated by V 2 A VP receptors with consequent 
activation of adenylate cyclase (reviewed by Simonson, 1993). ET-1 increases urine flow 
rate despite a decrease in RBF and GFR (Goetz et al., 1988; Badr et al., 1989), suggesting 
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that ET-I might also regulate water reabsorption. Infusion of ET-I into conscious dogs 
decreases urine osmolality despite a constant level of circulating A VP (Goetz et al., 1989). 
Evidence suggests that ET- I can antagonise A VP-dependent cyclic AMP accumulation. In 
microdissected nephron segments, ET-1 dose-dependently (0.1-1 0.0nM) inhibits A VP­
evoked cAMP accumulation in the cortical collecting duct, outer medullary collecting duct 
and inner medullary collecting duct (Tomita et al., 1990). ET-I has no effect on A VP­
dependent cAMP accumulation in other nephron segments. This inhibitory effect is 
independent of calcium channel activity or prostaglandin synthesis but is dependent on 
protein kinase C activity. 
Immunoreactive ET peptides have been demonstrated in secretory vesicles in the rat 
posterior pituitary, and the vesicles were depleted by water deprivation (Ptashne, 1988). 
Therefore ET-I secretion, stimulated by water deprivation, could reduce water excretion 
directly by inhibiting baroreceptor reflexes or reducing GFR. 
1.1.2.8 ENDOTHELIN IN RENAL PA THOPHYSIOLOGY 
Endothelins affect three major aspects of renal physiology (i) vascular and mesangial tone, 
(ii) cell proliferation and matrix formation and (iii) sodium and water excretion. The
evidence for a pathophysiologic role of ET-1 in renal dysfunction is reviewed. 
1.1.2.8.1 Ischaemic acute renal failure 
This is commonly precipitated by an initial episode of severe renal ischaemia followed by 
several days or weeks of the kidneys failing to function normally. Reduction of renal blood 
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flow is the hallmark of this maintenance phase of ischaemic acute renal failure. Increased 
tissue concentrations of ET-1 during the initial 24 hours of the maintenance phase 
(Shibouta et al., 1990), a 5-10 fold increase in ET-I mRNA in glomeruli and inner 
medullary collecting ducts (Terada et al., I 992) and in renal tissue homogenate (Firth and 
Ratcliffe, 1992) during the first 48 hours, suggest a role for ET-I in this phase of ischaemic 
acute renal failure. Elevated plasma ET- I concentrations have been reported in patients 
with acute renal failure (Nakanishi et al., 1990). Beneficial effects of infusions of anti-ET 
antibody have been described on functional (Kon et al., 1989; Shibouta et al., 1990; Lopez­
Farre et al., 1991 ), histologic and biochemical parameters (Shibouta et al., I 990) of the 
kidney. Anti-ET antibody treatment during the maintenance phase caused a fall in elevated 
afferent and efferent arteriolar resistances, improved glomerular plasma flow and increased 
single nephron filtration rate (Kon et al., 1989); however normal control values were not 
re-established by this treatment. Subsequent studies in rats and dogs have shown that 
administration of ET receptor antagonists ameliorated impaired GFR, RBF and sodium 
excretion following transient renal artery or abdominal aortic occlusion (Stingo et al., 
1993; Brooks et al., 1994; Chan et al., 1994; Gellai et al., 1994, 1995; Krause et al., 1995; 
Kusumoto et al., 1994). Endothelin-1 production and binding were increased in ischaemic 
kidneys (Firth and Ratcliffe, 1992; Nambi et al., 1993). Increased ET-1 production may be 
due to hypoxia and oxygen radical production. Renal ischaemia causes tissue hypoxia 
which can increase renal ET-1 production. When renal perfusion is restored, there is an 
increase in reactive oxygen species due to metabolic impairment induced during ischaemia. 
These oxygen radicals ( especially hydrogen peroxide) may augment ET-I production 
(Hughes et al., 1996). Hence, once the initial ischaemic event is resolved, prolonged release 
of ET-I may perpetuate a reduced RBF and GFR. 
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1.1.2.8.2 Nephrotoxic acute renal failure 
Endothelin-1 may be involved in the pathogenesis of many toxic nephropathies, including 
that due to cyclosporine A (CyA), radiocontrast and endotoxaemia. 
1.1.2.8.2.1 Cyclosporine 
Endothelin-1 mediates acute Cy A-induced renal vasoconstriction. Cyclosporine and related 
immunosuppressants such as Tacrolimus (FK506) directly stimulated ET-1 release from 
mesangial and /or endothelial cells (Langman and Yatscoff, 1994; Goodall et al., 1995; 
Kohno et al., 1995). Cyclosporine A increased renal ET-1 mRNA expression (Iwasaki et 
al., 1994). Anti-ET antibodies and ET receptor antagonists ameliorated acute CyA-induced 
renal vasoconstriction (Kon and Awazu, 1992; Lanese and Conger, 1993; Conger et al., 
1994; Brooks and Contino, 1995; Kon et al., 1995). Salt-depleted rats given CyA daily for 
5 weeks developed a reduced GFR and tubulo-interstitial fibrosis. The decrease in GFR 
was ameliorated by concurrent administration of an ET A/ET 8 receptor antagonist, while 
fibrotic changes were unaltered (Kon et al., 1995), suggesting that ET-1 is a mediator of the 
vasoconstrictor but not fibrotic effects of Cy A. 
1.1.2.8.2.2 Radiocontrast nephropathy 
An increased risk of radiocontrast-induced acute renal failure is well known in the setting 
of the elderly patient suffering from diabetes mellitus, hypertension, arteriosclerosis and/or 
reduced renal function. Endothelin-1 stimulation has been observed with both ionic and 
non-ionic radiocontrast agents (Nakayama et al., 1991; Obialo et al., 1991). Decrease in 
renal blood flow by a third was demonstrated in rats following radiocontrast 
administration; however simultaneous infusion of the ET antagonist CP 170687 partially 
prevented this (Cantley et al., 1992). Endothelin-1 receptor antagonists markedly inhibited 
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the decrease in renal perfusion induced by radiocontrast agents (Oldroyd et al., 1995). If 
prostaglandin formation is unimpaired, both the vasoconstrictive response to the 
radiocontrast and the degree of protection offered by ET receptor blockade are greatly 
reduced (Cantley et al., 1993). 
1.1.2.8.2.3 Bacterial toxins 
Gram-negative bacterial sepsis and endotoxaemia cause systemic vasodilatation and renal 
vasoconstriction. The endotoxin lipopolysaccharide directly stimulated endothelial cell ET­
I release and increased renal tissue levels of ET-1 (Nambi et al., I 994; Kaddoura et al., 
1996). Anti-ET-I antibodies or ECE-blockade ameliorated the renal vasoconstrictor effects 
of endothelin in this condition (Morise et al., 1994). Nonspecific ET receptor blockage may 
further reduce systemic blood pressure in septic shock, suggesting that ET-I protects 
against lipopolysaccharide-induced hypotension (Kohan, 1997). Urinary ET-I was elevated 
in children with post-diarrhoeal haemolytic-uraemic syndrome, while serum from these 
children increased endothelial cell ET-1 production (Kohan et al., 1994). Purified Shigella 
toxin stimulated ET-I release by human glomerular endothelial cells (Kohan, I 997). 
Endothelin-1 also increased von Willebrand factor release, induced micro-thrombosis and 
caused a consumptive coagulopathy (Halim et al., 1994; Schulz et al., 1995). These studies 
suggest that ET-I is involved in the pathogenesis of post-diarrhoeal haemolytic-uraemic 
syndrome. 
1.1.2.8.3. Miscellaneous disorders 
The following disorders are associated with increased renal ET-I production: 
nephrotoxicity due to amphotericin B and cisplatin, glycerol-induced myoglobinuric renal 
failure, hepatorenal failure (Kohan, 1993; Karam et al., 1995), obstructive uropathy (Klahr 
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et al., 1991; Kelleher et al., 1992), acute vascular renal transplant rejection (Watschinger et 
al., 1991 ), renal vasculitides (Kan o et al., 1990), erythropoietin-induced hypertension 
(Sekino et al., 1991) and hypertensive disorders of pregnancy (Kamoi et al., 1990). 
1.1.2.8.4 Proliferative glomerular disease 
There is evidence to suggest that ET-1 is involved in the pathogenesis of proliferative 
glomerulonephritis. Renal ET-1 production was increased in experimental and human 
glomerulonephritis (Murer et al., 1994; Roccatello et al., 1994; Nakamura et al., 1995a; 
Yoshimura et al., 1995), while ET 8 receptor expression was upregulated in 
glomerulonephritis in the rat (Yoshimura et al., 1995). ET-1 is a potent mitogen and partly 
mediated the proliferative effects of several cytokines (Bakris and Re, 1993; Kohno et al., 
1994; Nitta et al., 1995). Inflammatory cytokines and proteinuria per se augmented renal 
ET-1 production (Zoja et al., 1995). ET-I may activate and be chemotactic for monocytes, 
which can in turn secrete ET-1 (Martin-Nizzard et al., 1991; Achmad and Rao, 1992). ET 
receptor antagonists reduced mesangial cell proliferation in experimental mesangial 
proliferative glomerulonephritis (Fukuda et al., 1996) and decreased renal injury in murine 
lupus nephritis (Nakanmra et al., 1995b ). Renal ET-1 mRNA levels were elevated in 
polycystic kidney disease (Nakamura et al., 1993; Hocher et al., 1998). 
1.1.2.8.5 Renal fibrosis 
Endothelin-1 also contributes to excessive accumulation of extracellular matrix 
components and fibrosis by increasing renal cell fibronectin and collagen production, tissue 
inhibitor of metalloprotease levels and the release of cytokines that stimulate matrix 
accumulation (Ong et al., I 994; Ruiz-Ortega et al., 1994). ET-I antagonism decreased 
matric accumulation in experimental models of glomerulonephritis (Fukuda et al., 1996). 
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Chronic treatment with an ET receptor antagonist attenuated increases in glomerular 
mRNA levels of collagen, laminin, tumour necrosis factor, TGF-P, PDGF and basic 
fibroblast growth factor in diabetic rats (Nakamura et al., 1995c). Once substantial renal 
scarring occurs, there is an inevitable progression to end stage kidney disease, a process 
involving gradual glomerular sclerosis and interstitial fibrosis. Endothelin receptor 
blockade reduced proteinuria and glomerulosclerosis and protected against hypertension 
and elevations in serum creatinine in the 5/ 6 nephrectomy rat model (Benigni et al., 1993 
and 1996). 
1.1.2.8.6 Renal endothelin-1 in essential hypertension 
Alterations in ET-1 in the renal vasculature and renal tubules have differing effects on 
blood pressure. In the vasculature, increases in ET-1 predominantly cause vasoconstriction 
with a hypertensive effect. Increased ET-1 in the nephron probably enhances sodium and 
water excretion, favouring hypotension (reviewed by Markewitz and Kohan, 1995; 
Schiffrin, 1995). Renal vascular responsiveness to ET-1 in animal models of essential 
hypertension is controversial with both enhanced and unchanged renal vascular 
responsiveness reported. Whole kidney ET-1 expression has been reported to be increased, 
unchanged or decreased in hypertensive animals in different studies. Infusion of anti-ET 
antibodies into spontaneously hypertensive rats (SHR) resulted in a 50% increase in RBF 
while having no effect on Wistar Kyoto (WKY) rats (Ohno et al., 1992). ET A receptor 
blockade increased RBF in SHR and DOCA-salt hypertensive rats but not in their 
normotensive controls (Fujita et al., 1996). Thus evidence suggests that enhanced intrarenal 
ET-1 activity augments renal vasoconstriction in animals with genetic hypertension. 
Urinary ET-1 excretion was markedly reduced in patients with essential hypertension 
(Hoffman et al., 1994). ET-1 production was much lower in inner medullary collecting duct 
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(IMCD) cells and in the outer and inner medulla from hypertensive SHR rats compared 
with WKY controls (Hughes et al., 1992). Bosentan, a mixed ETA/ET 8 receptor antagonist, 
administered to patients with mild-moderate essential hypertension was as effective as 
enalapril (inhibitor of angiotensin converting enzyme) in controlling blood pressure, 
suggesting that ET-I contributes to hypertension in these patients (Krum et al., 1998). 
1.1.2.8. 7 Chronic renal failure and hypertension 
Plasma ET-I levels are frequently elevated in patients with chronic renal failure or on 
dialysis (Shichiri et al., 1990; Warrens et al., 1990; Stockenhuber et al., 1992). Further 
fractionation by gel permeation chromatography revealed borderline increased plasma ET­
I with marked elevations of big ET-I and other large forms of ET, with an increase of 
about 500% above control (Saito et al., 199 I). Although plasma ET-I levels correlate with 
the degree of hypertension in chronic renal failure patients, this observation has not been 
uniformly noted. The kidney is a major site of ET-1 metabolism (Abassi et al., 1992); 
plasma ET-1 half-life was increased in bilaterally nephrectomised rats (Kohno et al, 1989). 
Dialysis may elevate ET-I levels. The type of dialysis membrane may influence plasma 
ET-I levels (Niwa et al., 1993; Ross et al., 1993 ); plasma ET-I levels were reduced when 
high flux membranes are used. Thus patients with chronic renal failure or end stage renal 
disease have borderline elevated plasma ET-I levels due partly to reduced ET-I clearance 
while intrarenal generation of ET-1 may be increased. 
1.1.2.8.8 Renal transplantation 
Plasma ET-I levels were reported to be elevated in predialysis patients with chronic renal 
failure and in patients on regular haemodialysis; plasma ET-I levels were normal in stable 
renal transplant patients treated with CyA (Stockenhuber et al., 1992). An association 
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between increased plasma ET-I levels and CyA was first suggested in a renal transplant 
patient receiving high doses of CyA (Fogo et al., 1990). After administration of CyA, 
plasma ET-I levels increase transiently in transplant patients because ET- I is rapidly 
metabolised and cleared from the systemic circulation (Grieff et al., 1993). The 
inflammatory process of acute cellular rejection is predominantly confined to the 
interstitium and marked intragraft upregulation of ET-I may occur without significant 
changes in ET-I plasma concentrations (Watschinger et al., I 995), unless there is 
endothelial damage as occurs with vascular rejection (Watschinger et al., 1994). Activated 
mononuclear cells that infiltrate the allograft secrete a variety of cytokines (Blancho et al., 
1993; Halloran et al., 1993; Hancock 1984), that have been shown to influence the 
production of ET-I by other cells in vitro. Tumour necrosis factor a increased ET-1 mRNA 
and ET-I release in capillary endothelial cells, epithelial cells and rat mesangial cells 
(Kohan 1991); IL-IP induced ET-I release from renal epithelial cells (Ohta et al., 1990). 
Platelet activation and intravascular coagulation (attributable to endothelial injury) 
appeared to trigger the release of TGFP, thromboxane A2, POOF and thrombin from 
platelets accumulating in the graft. This resulted in ET-I secretion and upregulation of ET-
I gene expression in endothelial, vascular smooth muscle and renal mesangial and 
epithelial cells (Kurihara et al., 1989; Watschinger and Sayegh, 1996). Renal allografts 
with chronic rejection and transplant-associated arteriosclerosis were reported to express 6-
fold more ET-I in the neointima of the vasculature, when compared to allografts with acute 
rejection or normal control kidneys (Simonson et al., 1998). 
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1.1.3 ATRIAL NATRIURETIC PEPTIDE IN THE KIDNEY 
Fallowing the observation by de Bold and colleagues (1981) that infusion of extracts of 
atrial tissue caused a copious diuresis, atrial natriuretic peptide, the first member of a 
family of peptides with potent natriuretic, diuretic and vasorelaxant activity was isolated 
and later cloned (Kangawa and Matsuo, 1984). 
1.1.3.1 BIOCHEMISTRY 
Three peptides comprise the natriuretic peptide family: atrial natriuretic peptide (ANP), 
brain natriuretic peptide (BNP) and C-type natriuretic peptide [(CNP) Fig 1.3-1). ANP is 
produced primarily from cardiac atria, with increased atrial wall tension (reflecting 
increased intra vascular volume) as the major stimulus. Various substances for example 
endothelin, arginine vasopressin and catecholamines, directly stimulate the secretion of 
ANP. The precursor protein (pro ANP) is composed of 126 amino acids; cleavage releases 
a 98 amino acid amino-terminal fragment and a 28 amino acid carboxy-terminal portion 
that is the mature ANP (Fig 1.3-2). Both fragments circulate in the plasma and their 
concentrations are increased in patients with increased intravascular volume (for example, 
congestive heart failure). The ANP gene is also expressed in the kidney and a 32-amino 
acid peptide called urodilantin is generated from the precursor in the urine (Schulz-Knappe 
et al., 1988). Urodilantin may be important for the local regulation of sodium and water 
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Fig 1.3-1: Amino acid sequence of the natriuretic peptides in humans 
Ref: Gunning ME and Brenner BM (1992), Kidney Int, 42: S127-133 (S128) 
In the kidney, ANP has been localised to the renal artery wall (Koseki et al., 1986), 
glomeruli (Koseki et al., 1986), descending vasa recta (Koseki et al., 1986; Naruse et al., 
1988), inner medullary collecting tubule (Koseki et al., 1986; Bianchi et al., 1987) and 
distal convoluted tubular cells, intercalated cells of the connecting tubules and collecting 
ducts (Figueroa et al., 1990). BNP, a 32-amino acid molecule which is released from a I 08 
amino acid precursor, is present in brain and cardiac ventricles. It circulates in the plasma 
and concentrations are increased in patients with ventricular hypertrophy or congestive 
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heart failure (Levin et al., 1998). Two C-type natriuretic peptides (22 and 53 amino acids in 
length) have been identified. The 22 amino acid peptide predominates in the central 
nervous system, anterior pituitary, kidney and vascular endothelial cells. Its concentration 
in plasma is very low. Other related peptides, guanylin and uroguanylin, are 15- and 16-
amino acid peptides produced primarily in the gastro-intestinal tract. They may regulate 
salt and water transport across the intestinal mucosa and co-ordinate intestinal reabsorption 
with renal excretion of sodium. 
Fig 1.3-2: Processing pathway of ANP 
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Ref: Vesely D L (1994). Kidney: A Current Survey of World Literature, 3: 4-8 (5) 
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1.1.3.2 NATRIURETIC PEPTIDE RECEPTORS 
Natriuretic peptides exert their effects through interaction with high-affinity receptors on 
the surface of target cells. Natriuretic peptide receptors A and B are linked to the cGMP­
dependent signalling cascade, and mediate many of the cardiovascular and renal effects by 
activation of guanylylcyclase. The A receptor binds both ANP (preferentially) and BNP; 
the B receptor binds C-type natriuretic peptide. The A receptor is the most abundant type in 
large blood vessels (which also have some B receptors). B receptors predominate in the 
brain. Both receptors are present in adrenal glands and the kidney. 
All three peptides bind with equal affinity to the natriuretic peptide receptor C, which is 
involved in clearance of the peptides. The natriuretic peptides bind to it, are internalized 
and enzymatically degraded, after which the C receptor returns to the cell surface (Maack 
et al., 1987). Circulating natriuretic peptides are also inactivated by cleavage by neutral 
endopeptidases present within renal proximal tubular cells and vascular cells. The plasma 
half-life of immunoreactive ANP is 2.5-4.5 min. Multiple organs (liver, kidney and lower 
limb) extract ANP from the blood. The kidneys clear approximately 20% of the total ANP 
(Vierhapper et al., 1990). The A receptor is expressed in the kidney, lung, heart and 
adipose tissue with its mRNA expressed in the renal glomerulus, adrenal zona glomerulosa, 
anterior pituitary, cerebellum and heart. The B receptor is present in the brain, lung, kidney. 
placenta and heart. Its mRNA is detected in the adrenal medulla, cerebellum and pituitary 
gland. The C receptor is abundantly present in the renal cortex, lung, placenta and heart: its 
mRNA is distributed in the renal glomerulus, adrenal gland, cerebral cortex, cerebellum 
and heart (reviewed by Nakao et al., 1996). 
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1.1.3.3 ACTIONS OF NATRIURETIC PEPTIDES 
1.1.3.3.1 Renal Actions 
The natriuretic and diuretic actions of natriuretic peptides are due to both renal 
haemodynamic and direct tubular actions. ANP causes dilatation of afferent arterioles and 
constriction of efferent arterioles, resulting in increased pressure within the glomerular 
capillaries (Marin-Grez et al., 1986). This causes a rise in GFR. ANP also increases cGMP 
in mesangial cells, relaxing these cells and thereby increasing the effective surface area for 
filtration (Fried et al., 1986; Stockand and Sansom, 1997). However, plasma concentrations 
of ANP that do not increase GFR cause natriuresis, indicating that ANP has direct tubular 
actions for example by locally produced peptides (such as urodilantin) or by systemic ANP. 
ANP can inhibit angiotensin II-stimulated sodium and water transport in proximal 
convoluted tubules (Harris et al., 1987). It inhibits tubular water transport in collecting 
ducts by antagonizing the action of vasopressin (Dillingham and Anderson, 1986), and
stimulates cGMP production in the inner medullary collecting duct, blocking sodium 
reabsorption (Sonnenberg et al., 1986; Zeidel, 1995). 
Infusions of ANP, that raise their plasma concentrations slightly above normal, result in 
diuresis and natriuresis without changes in blood pressure; they reduce plasma renin and 
aldosterone concentrations and inhibit angiotensin II-stimulated aldosterone secretion. HS-
142-1, a competitive natriuretic peptide antagonist binding to receptor A or B, blocks
natriuresis and diuresis, increases renal vascular resistance and increases plasma renin, 
aldosterone and catecholamine concentrations in normal, diabetic and cirrhotic rats with 
ascites (Sano et al., 1992; Angeli et al., 1994; Zhang et al., 1994 ). 
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In summary, ANP affects many aspects of renal function. It increases renal blood flow, 
and by selective action on glomerular arterioles, increases glomerular capillary hydraulic 
pressure and GFR. Glomerular ultrafiltration coefficient is also increased via inhibition by 
ANP of the actions of angiotensin II and ADH. In the proximal tubule, ANP opposes 
angiotensin II-mediated sodium reabsorption and in the distal tubule, aldosterone-mediated 
sodium reabsorption. In the collecting duct, ANP inhibits ADH-mediated water 
reabsorption and directly inhibits inner medullary collecting duct sodium transport. These 
effects, together with increased vasa recta blood flow and hydraulic pressure, favour 
increased excretion of sodium from the renal medullary interstitium into the urine. ANP 
directly inhibits renin secretion by the juxtaglomerular cells and aldosterone secretion by 
the adrenal zona glomerulosa. 
1.1.3.3.2.Cardiovascular actions 
Sustained low dose infusions in animals reduce peripheral vascular resistance (PVR) and 
lower blood pressure (Charles et al., 1993) but high doses increase PVR despite the 
decrease in blood pressure (Lappe et al., I 985). The decrease in blood pressure results 
partly from a reduction in cardiac preload caused by shift of fluid from the intravascular 
into the extravascular compartment. ANP increases venous capacitance and promotes 
natriuresis and also reduces sympathetic tone in the peripheral vasculature. CNP is a more 
potent dilator of veins than the other two peptides. 
Natriuretic peptides have anti-mitogenic activity: ANP and CNP inhibit mitogenesis in 
cultured vascular cells and in balloon-injured carotid arteries in rats (ltoh et al., 1990; 
42 
Furuya et al., 1993), thereby modulating growth within the vascular wall in disorders such 
as atherosclerosis, hypertension and post-angioplasty restenosis. 
1.1.3.3.3 Actions on the Central Nervous System 
ANP and BNP do not cross the blood-brain barrier but they reach sites in the CNS outside 
this barrier for example the subfomical organ, hypothalamic median eminence and area 
postrema. All 3 natriuretic peptides (but especially CNP) are produced in the brain. Pressor 
substances for example endothelin, vasopressin and norepinephrine stimulate the release of 
ANP from cultured hypothalamic neurons. Natriuretic peptides in the brain inhibit the 
appetite for salt and water drinking, and inhibit the secretion of vasopressin and 
corticotrophin, thus co-ordinating central and peripheral actions in controlling fluid and 
electrolyte homeostasis. 
1.1.3.4 ANP AND RENAL PATHOLOGY 
1.1.3.4.1 Hypertension 
Levels of ANP and BNP are elevated in hypertension, with a positive correlation between 
the severity of hypertension and degree of peptide elevation (Cheung and Brown, 1994). 
ANP immunoreactivity was reduced in hypertensive nephrosclerotic distal tubules, 
probably as a result of reduced renal tubular mass (Figueroa et al., 1990). Upregulation of 
the A receptor subtype occurred in hypertensive rats, together with increased levels of ANP 
and BNP (Yoshimoto et al., 1995). Restriction fragment length polymorphism exists in the 
second intron of the human ANP gene, a candidate gene for familial susceptibility to 
hypertension (Ramasawmy et al., 1994). Furthermore, restriction fragment length 
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polymorphism at the ANP gene locus has been reported in hypertension associated with 
aldosterone-producing adenoma (Tunny et al., 1994). Animal studies have defined the role 
of natriuretic peptides in preventing the development of hypertension: transgenic mice, that 
showed over-expression of the genes for ANP or BNP, had plasma natriuretic peptide 
levels that were at least 10 times that of normal litter mates, and systolic blood pressures 
that were 20-30 mmHg lower. Mice with homozygous inactivation of the ANP gene on a 
low salt diet had slightly elevated blood pressures; it rose markedly on a high salt diet. 
Heterozygotes (with a normal basal blood pressure) had a similar response. Mice with 
inactivation of the A receptor had an elevated basal blood pressure but did not respond to 
salt loading with increases in blood pressure (John et al., 1995). During aldosterone 
hypersecretion or exogenous mineralocorticoid administration, sodium is retained for a few 
days, after which there is an escape from sodium-retention; plasma ANP concentration 
rises, coincident with escape (Yokota et al., 1994). Administration of ANP reduced BP and 
promoted sodium excretion in patients with essential hypertension (Weder et al., 1987). 
1.1.3.4.2 Nephrotic syndrome 
Endogenous plasma ANP levels were increased in nephrotic syndrome (Woolf et al., 
1989). A blunted natriuretic response, observed during head-out water immersion studies 
in nephrotic syndrome patients with avid sodium retention, suggests a relative hypo­
responsiveness of the distal tubule to ANP (Peterson et al., 1988). Exogenous ANP caused 
an increase in proteinuria in patients with nephrotic syndrome (Zietse and Schalekamp, 
1988), which may lead to further sodium retention. 
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1.1.3.4.3 Acute renal failure 
Plasma levels of ANP and its second messenger cGMP were elevated during acute renal 
failure and tended to return towards normal values at recovery. ANP and cGMP correlated 
significantly with total blood volume and the fractional excretion of sodium (Kanfer et al., 
1989). In a randomised controlled study of 53 patients, ANP administered parenterally to 
patients with acute renal failure due to acute tubular necrosis resulted in a significant 
improvement in GFR and reduced the need for dialysis (Rahman et al., 1994a). These 
results were not substantiated in a larger multicentre, randomized double-blind, placebo­
controlled trial of anaritide (ANP) in 504 critically ill patients with acute tubular necrosis 
(Allgren et al., 1997). Prophylactic use of Ularitide (previously called Urodilantin), a 
natriuretic peptide recovered from human urine, resulted in significant reduction in 
requirement for haemodialysis or haemofiltration in patients with acute renal failure 
following cardiac surgery or organ transplantation (Meyer et al., 1996). 
1.1.3.4.4 Chronic renal failure 
Plasma concentrations of all three natriuretic peptides were elevated in clu·onic renal 
failure, probably because of reduced clearance (Prins et al., 1996). Infusion of doses of 
ANP slightly above the physiological range in patients with moderate chronic renal failure 
secondary to glomerulonephritis resulted in a natriuretic response similar to that of normal 
controls, together with a marked increment in the urinary excretion of urea, potassium and 
phosphate (De Nicola et al., 1997). The elevated levels of ANP in patients with chronic 
renal failure were significantly lowered by haemodialysis (Hasegawa et al., 1986; Niwa et 
al., 1993), in particular by haemodialysis with fluid removal or haemofiltration (Shiota et 
al., 1990). Plasma concentrations of ANP were not generally elevated in children on 
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peritoneal dialysis; in some children with elevated ANP levels, plasma ANP concentrations 
declined to normal values with fluid withdrawal (Bald et al., 1994). 
1.1.3.4.5 Renal transplantation 
ANP concentrations ( elevated before transplantation) decreased after successful and 
increased after failed renal transplantation (Zuber et al., 1993). Studies in renal transplant 
recipients (Bricker et al., 1956), and in subjects with autonomic failure (Gill and Bartter, 
1966) suggest that renal denervation impairs sodium conservation in the presence of dietary 
sodium restriction. Renal sympathetic nerve activity profoundly affects all aspects of renal 
function. Efferent sympathetic nerve stimulation increases tubular sodium and water 
reabsorption and produces a fall in GFR and renal blood flow mediated by preglomerular 
vasoconstriction (Kopp and Di Bona, 1982). Head-out water immersion studies in stable 
renal transplant recipients showed a diuretic and natriuretic response with elevation in 
plasma ANP and increased urinary tissue kallikrein excretion; plasma renin activity did not 
suppress with water immersion, probably as a result of a reduction in sympathetic nerve 
traffic to the juxtaglomerular apparatus (Al-Haidary et al., 1990). Low dose ANP infusion 
to stable renal transplant recipients resulted in immediate natriuresis and urinary cyclic 
GMP excretion as well as albuminuria, in contrast to the delayed response seen in normal 
subjects (Lipkin et al., 1992). Intravenous infusion of ANP during acute renal allograft 
rejection in a canine model resulted in increased urine flow rates and an increase in GFR, 
together with a fall in mean arterial pressure in the presence of an unchanged haematocrit 
(Lewis et al., 1993). 
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1.1.4 KININS IN THE KIDNEY 
The early indication of tissue kallikrein in urine became evident when Abelous and Barder 
(1909) detected the presence of a hypotensive substance in normal human urine that they 
called urohypotensin. Further experiments on the kinin-forming enzymes commenced in 
1926 when Frey and colleagues reported that injections of pancreatic extract, pancreatic 
secretion and urine into anaesthetized, normotensive dogs reduced arterial blood pressure 
(Frey, 1926; Frey et al., 1930; Frey and Werle, 1933). The active principle in urine was 
assumed to be identical with that in the pancreas, and therefore the hypotensive substance 
was named kallikrein from the Greek word "kallikreas" for pancreas. A decade later Rocha 
e Silva and colleagues (1949) found that incubating dog plasma with snake venom and 
trypsin produced an agent that lowered blood pressure, and in vitro caused a slowly 
developing contraction of guinea pig ileum. This peptide agent was named bradykinin from 
the Greek word "slow moving" because of the slow contraction of the guinea pig ileum. 
The vasoactive peptides formed by kallikrein (kallidin) and trypsin (bradykinin) from 
endogenous protein substrates (kininogens) were given the generic name of kinins. 
In humans there are two kinin-forming enzymes, namely plasma and tissue (glandular) 
kallikrein and two substrates, high and low molecular weight, H-kininogen (HK) and L­
kininogen [(LK); Fig 1.4-1 ]. Plasma prekallikrein (PPK), a cofactor of coagulation, is 
activated by factor Xlla to form plasma kallikrein (PK), which in turn, cleaves bradykinin 
(BK) from H-kininogen. Tissue kallikrein (TK), on the other hand, is either released mainly 
in its active form or requires to be proteolytically cleaved to an active state. Tissue 
kallikrein cleaves lysyl-BK (kallidin) from L-kininogen (Fig 1.4-2). The regulatory role of 
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plasma and tissue kallikrein-kinin systems is different and functions independently of each 
other in vivo. The proportion in active forms varies in the different biological fluids. 
Fig 1.4-1 The two kinin release systems involving plasma and tissue kallikrein 
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Kinins bind to their receptors at target organs and exert potent effects in vasodilatation, 
blood pressure reduction, vascular permeability, smooth muscle contraction, pain 
generation, natriuresis, diuresis and renal blood flow. The systemic half-life of kinins is 
very short ( 15-30 sec); however concentrations in biological fluids although low (10·11 
mmol) in human plasma, have a longer half life. The binding capacity of tritiated BK along 
the nephron of the rabbit is maximal at cortical collecting ducts and outer medullary ducts 
(Kauker, 1980; Tomita and Pisano, 1984). 
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Fig 1.4-2: Overview of the kallikrein-kininogen-kinin- cascade 
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1.1.4.1 RENAL TISSUE KALLIKREIN 
Tissue kallikrein is present in the plasma but the organ or tissue source is not known 
(Nustad et al., 1979; Geiger et al., 1980). The activity of TK is regulated by inhibitors 
present in plasma (Lawton et al., 1981) and urine. In spite of such inhibition, kinins are 
generated but in negligible measurable amounts (Scicli et al., 1982 and 1983). 
1.1.4.1.1 Localisation 
More than 85% of the active and inactive tissue kallikrein in the rat kidney is localised in 
the granular portions of the distal tubules and cortical collecting ducts [Tomita et al., 1981; 
Omata et al., 1982; Vio and Figueroa, 1985; (Fig 1.4-3)]. Kallikrein is present in the 
granular cells of the connecting tubule of the distal nephron, where it is concentrated 
mainly on the luminal side of the cells and at both sides of the nuclei, and to a lesser extent, 
is associated with plasma membranes and basolateral infoldings. The immunoreactivity is 
related to free polyribosomes, rough endoplasmic reticulum and Golgi complexes, 
suggesting that kallikrein is actively synthesised in these cells (Figueroa et al., 1984; Vio 
and Figueroa, 1985). Tissue kallikrein mRNA is expressed predominantly in the cells of 
the distal tubules but reported also in the vascular pole of the glomeruli (Xiong et al., 
1989), and in the connecting tubules of the outer cortex (El-Dahr and Chao, 1992). Tissue 
kallikrein mRNA and protein are present in the walls of renal blood vessels (Cumming et 
al., 1994). 
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Ref.: Katori M and Majima M (1996). Japanese Journal of Pharmacology, 70: 95-128 (99). 
Abbreviations: GL=glomerulus; PCT=proximal convoluted tubule; DCT=distal convoluted 
tubule; PST=proximal straight tubule; MD=macula densa; CNT=connecting tubule; 
CCT=cortical collecting tubule; MCT=medullary collecting tubule 
1.1.4.1.2 Stimuli for renal tissue kallikrein secretion 
Renal perfusion pressure may be one of the major factors controlling urinary kallikrein 
excretion (Bevan et al., I 974; Lauar et al., 1982; Bhoola and Lauar, 1983; Misumi et al.. 
1983). A low sodium diet or salt deprivation accelerated renal kallikrein synthesis and 
excretion in humans (Geller et al., 1972; Bascands et al., 1987). The effects of a high 
sodium intake are controversial: acute sodium loading in rats induced an increase in urinary 
kallikrein excretion (Marin-Grez et al., 1984). Feeding rats a high salt diet for IO days 
decreased the total immunoreactive kallikrein in the urine and kidney (Lieberthal et al.. 
1983). The increased kallikrein excretion due to prolonged sodium deprivation may be 
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mediated by aldosterone release through activation of the renin-angiotensin system and was 
reversed by spironolactone (Margolius et al., 1974a). 
Experiments with isolated perfused rat kidney demonstrated the stimulatory effect of 
potassium on the secretion of tissue kallikrein (Lauar et al., 1982; Lauar and Bhoola, 1986). 
Patients with hyperaldosteronism excreted higher amounts of kallikrein in the urine 
(Margolius et al., 1972 and 19746 ). Administration of spironolactone to patients with 
hyperaldosteronism decreased the high urinary kallikrein excretion (Margolius et al., 
1974b ). Removal of aldosterone-producing tumours reversed the increased excretion of 
urinary kallikrein (Miyashita, I 971 ). Urinary kallikrein excretion varied directly with 
potassium intake and parallelled aldosterone excretion in both normal and hypertensive 
subjects. The increase in urinary kallikrein in hypertensive subjects by potassium intake 
was less than that in normotensive subjects; the increase in white subjects was higher than 
in black subjects (Horwitz et al., 1978). Electron microscopy showed that a high potassium 
diet produced hypertrophy and hyperplasia of the kallikrein-containing cells of the 
connecting tubule, including hyperplasia of the Golgi complex and rough endoplasmic 
reticulum and secretory vesicles containing kallikrein (Vio and Figueroa, 1987). 
Intravenous infusion of vasopressin stimulated both the release of urinary kallikrein and the 
intrarenal formation of kinin in dogs and rats (Fejes-Toth et al., I 980). Other hormones 
affecting synthesis, activity or release of renal kallikrein are oestrogens, mineralocorticoids, 
glucocorticoids, testosterone, thyroxine, insulin, catecholamines and angiotensin (Bhoola et 
al., 1992; Margolius, 1995). 
53 
1.1.4.1.3 Gene expression of tissue kallikrein 
Tissue kallikrein belongs to a multi-gene family, is clustered on chromosome 19 at q 13.2-
13.4, is composed of 5 exons and 4 introns with its length being 4.5 kilobase pairs (Inoue et 
al., 1989a; Berg et al., 1992). The family is strictly conserved and comprises members with 
close sequence homology. In humans until recently, 3 genes were known: hKLK 1 
(glandular kallikrein), hKLK3 (prostatic specific antigen) and hKLK2, and present on the 
long arm of chromosome 19 (Riegman et al., 1992; Clements, 1994 and 1998; Mahabeer 
and Bhoola, 2000). Recent evidence suggests a larger family than hitherto realised, with the 
discovery of a new hKLK-L2 human gene (Yousef and Diamandis, 1999), hKLK4 
(Stephenson et al., 1999) and hKLK-L4 (Yousef et al., 1999), and several other kallikrein­
like genes (KLK-L) in humans (Diamandis, 2000). Table 1-3 shows the localisation of 
tissue kalikrein genes in different organs. 
Table 1-3. Expression of Tissue Kallikrein Genes in Human Tissue 
Kidney Salivary Pancreas Breast Endo Ovary Prostate 
metrium 
KLKl hKLKl KLKl KLKl KLKl KLKl KLKl 
KLKl* KLK3 
KLK3* KLK3* KLK3 KLK2 KLK2 
KLK3* KLK2 KLK3 KLKl* 
KLK4 * KLK3* KLK2 
KLK3* 
*Induction in tumours
New kallikrein-like gene family 
KLK-Ll, -L2, L-3, L-14, L-15, L-16 (Yousef and Diamandis, 2000) 
Organization of the human kallikrein gene (hKLK) family on chromosome 19q13.4-
q13.3 
hKLKl - tissue prokallikrein (Mahabeer and Bhoola, 2000); 
hKLK3 - prostate specific antigen (Rae et al., 1999) 
hKLK2 - trypsin-like protease (Yousef et al., 2000) 
hKLK4 - matrix serine protease (Stephenson et al., 1999) 
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Gene induction of tissue kallikrein and the subsequently formed kinins enhances the 
proliferation of tumour cells (Rae et al., 19999). KLK-L2 and KLK-Ll are upregulated by 
oestrogens and other hormones in the breast cancer cell line BT-474 (Yousef and 
Diamandis, 1999; Yousef et al., 1999); while KLK-L4 is downregulated in breast cancer 
(Yousef et al., 2000) and NES 1 in breast and possibly other cancers (Diamandis et al., 
2000). 
1.1.4.1.4 Inhibitors of tissue kallikrein 
Kallistatin, a tissue kallikrein inhibitor belonging to the serpin superfamily, inhibits human 
tissue kallikrein activity (both kininogenase and amidolytic activity) towards either 
kininogen or a tripeptide substrate (Chao et al., 1990, Zhou et al., 1992). Its major site of 
synthesis is the liver, with lower levels of expression levels in the pancreas and kidney. The 
mRNA of this protein is expressed in the inner medullary ducts of the kidney with small 
amounts in the outer medullary collecting duct, proximal convoluted tubules and the 
glomerulus (Yang et al., 1994). The human kallistatin gene displays the 5 exon-4 intron 
gene structure and is located on chromosome 14q3 l-32. l (Chai et al., I 994 ). The 
circulating inhibitor of TK is a 1-antitrypsin inhibitor, which also inhibits urinary tissue 
kallikrein (Geiger and Mann, 1976). 
1.1.4.2 KININOGENS 
The human kininogen gene, which codes the endogenous protein substrate for the 
kallikreins is localised to chromosome 3q26➔qter (Fong et al., 1991). Kininogen has been 
detected in human urine (Hial et al., 1976; Pisano et al., 1978). lmmunoreactive kininogen 
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was localized in the principal cells of the collecting duct and restricted to the luminal 
portion of the principal cells (Figueroa et al., 1988). The close relationship between the 
cells containing tissue kallikrein and its substrate, kininogen suggests that kinins could be 
generated in the lumen of the collecting tubules. The mRNA of L-kininogen is expressed in 
the renal cortex and medulla, suggesting the biosynthesis of L-kininogen in the distal 
tubule (Iwai et al., 1988). Infusion of partially purified rat L-kininogen into mutant 
kininogen-deficient Brown Norway-Katholiek rats increased kinin excretion in ureter urine, 
whereas infusion of kininogen caused only a slight increase in kinins in the urine 
(Hagiwara et al., 1994), suggesting that the kidney secretes L-kininogen, and that urinary 
kallikrein releases urinary kinin mainly from L-kininogen. 
1.1.4.3 KININASES 
The turnover of kinins depends on both the rate of formation and the rate of destruction. 
After kinins are formed, they are rapidly destroyed by the enzymic action of peptidases. 
Kininases, which inactivate plasma kinins, are distributed in 2 major portions of the 
nephron: in the proximal tubules and the medullary collecting ducts. Kininase 11 
(angiotensin converting enzyme) is concentrated along the brush border membrane of 
proximal tubule cells and the S3 segments of the proximal tubules (Marchetti et al., 1987; 
Ikemoto et al., 1990). Almost all of the [3H] BK injected into the proximal tubules is 
destroyed in the proximal tubules (Carone et al., 1976). Microdissection techniques 
indicate that kininase activity is present in both proximal tubules and medullary collecting 
ducts (Marchetti et al., 1987). Neutral endopeptidase (NEP) accounts for more than half of 
the renal kininases in humans (Ura et al., 1993), while accounting for 68% of the total 
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kininase activity in rat urine, with kininase II and kininase I accounting for 23% and 9% 
respectively (Ura et al., 1987). Neutral endopeptidase is present in the outer surface of the 
brush border of proximal tubules and to a lesser extent, in the vesicular organelles in the 
apical cytoplasm and basal infoldings of the proximal tubule cells (Schulz et al., 1988). 
Carboxypeptidases (M and N) cleave the C-terminal arginine of kinins, suggesting a ready 
source of substrate (arginine) for the endothelial synthesis of nitric oxide by NOS (Sakuma 
et al., 1988). 
1.1.4.4 KININ RECEPTORS 
Presently, kinin receptors are characterized as B 1, B2 and perhaps B3 (Regoli and Barabe, 
1980). B 1 receptors are induced especially after an insult for example, with E Coli 
endotoxin or lipopolysaccharide, whereas B2 are constitutive and are present universally in 
mammalian tissues. The constitutive B2 receptor, that accounts for the majority of the 
physiological effects of kinins, is a member of the superfamily of G-protein-coupled (Ga 
and Gq) rhodopsin-like receptors characterized by seven transrnembrane regions connected 
by three extracellular and three intracellular loops (Burch and Axelrod, 1987). Homology 
to other receptors of this family is most pronounced in the transmembrane regions, whereas 
the loop regions are more divergent in their sequence. The B2 receptor protein consists of 
364 amino acids, is highly glycosylated, exists in multiple isoforms at 69 kDa with 
isoelectric points of pH 6.8-7.1, and contains the kinin binding site at the amino-terminal 
part of the third extracellular loop [(Figure 1.4-4); Abu Alla et al., 1993; 1996]. The human 
B2 receptor density is highest in the kidney but is also present in heart, lung, brain, uterus 
and testes (McEachern et al., 1991; Hess et al., 1992). In the rat kidney, the B2 receptor has 
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been found in the straight portions of the proximal tubules, distal straight tubules, 
connecting tubules and collecting ducts (Figueroa et al., 1995). The B2 receptors are 
present in the luminal membranes, basal infoldings of the tubular cells and in smooth 














Figure 1.4-4: Comparison of the amino-acid sequences of human B 1 and B2 receptors 
Each circle represents a single amino acid, identical amino acids being denoted in white, 
differences in black and deletions in the B 1 receptor in light grey. Deletions in the B2 receptor are 
shown in dark grey. The seven putative transmembrane-spanning domains are also shown. A 
putative disulfide bond between two cystine residues in the extracellular loops is shown by the 
line. 
The B2 receptors are co-localized with tissue kallikrein and kininogen in connecting 
tubules and collecting duct cells respectively. The localization of the B2 receptor has been 
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mapped to chromosome l 4q32, comprises more than 28kb and is organised in 3 exons and 
2 intrans (Powell et al., 1993; Ma et al., 1994). B2 binding sites, following chronic ACE 
inhibitor treatment and using the radio-labelled analogue c i25I-HPP-HOE 140) of the B2
receptor antagonist HOE 140, have been ultrastructurally mapped to the vasa recta bundles, 
capillary endothelial cells, epithelial cells of the thin limbs, distal tubule, collecting duct 
and renal medullary interstitial cells (RMIC) in the inner stripe of the outer medulla. In the 
inner medulla, B2 binding sites were localised to RMICs, loops of Henle, capillary 
endothelium and collecting duct epithelial cells (Dean et al., 1997). Kinins, acting via B2 
receptors, increase intracellular calcium concentration, inhibit adenylate cyclase activity, 
stimulates the formation of inositol phosphates. 
The kinin BI receptor, which was initially defined as the one mediating the contractile 
effect of kinins on the isolated rabbit aorta (Regoli et al., 1977), apparently is rapidly 
upregulated in immunopathology under the influence of inflammatory mediators [ cytokines 
(IL-1 P), endotoxins (lipopolysaccharides)] and growth promoters (Marceau, 1995). 
Structurally, this receptor also has the characteristics of a classical G-protein-coupled 
receptor, and is composed of 353 amino acids, which have a 36% homology to the amino 
acid sequence of the B2 receptor [Figure 1.4-4; (Menke et al., 1994)]. The Bl receptor has 
been localised to chromosome l 4q32 (Bachvarov et al., 1996, I 998; Chai et al., 1996). In 
smooth muscle, the B 1 receptor appears to signal via phosphatidylinisitol hydrolysis (Butt, 
et al., 1995), while stimulation of BI receptors on macrophages by the kinin degradation 
product des-Arg9-BK, causes the release of IL-I (interleukin) and TNF [tumour necrosis 
factor; (Tiffany and Burch, 1989)]. In vivo BI receptor mediation includes the effect on 
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blood pressure (Tokamasu et al., 1995), persistent hyperalgesia (Perkins et al., 1993) and 
plasma extravasation (Cruwys et al., 1994). 
Cellular actions following kinin binding to these G-protein coupled receptors are mediated 
by all of the known second messenger systems including the phospholipases C and A2,
which increases the synthesis of inositol triphosphate and arachidonic acid respectively 
(Mahan and Burch, 1990), as well as the participation of NO, especially on neurones and 
blood vessels. The metabolism of BK to des-Arg9BK and L-arginine by the kininase 1 
group of enzymes, either close to or within endothelial cells or in synaptic clefts, provides 
the primary substrate for the formation of NO [endothelium derived relaxing factor 
(EDRF)]. The released L-arginine acts as the substrate for NO synthetase, which rearranges 
the guanidino nitrogen to produce NO (Erdos, 1990; Bhoola et al., 1992). 
The affinity of BI receptors for kinin and kinin analogues differ markedly from that of B2 
receptors. The effects of BK and lys-BK are mediated by the B2 receptors while those of 
the metabolites desArg
9-BK and lys-desArg9 -BK are mediated by the B 1 receptor 
(Marceau, 1995). A third kinin receptor (B3) or a subtype may exist in bovine aortic 
endothelial cells, in microvasculature of guinea pig hindbrain and in cultured guinea pig 
smooth muscle cells (Burch et al., I 993; Pyne and Pyne, 1993). At these sites, variant 
responses to BI and B2 agonists and antagonists suggest a possible interaction with another 
receptor subtype. 
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1.1.4.5 KININ ANTAGONISTS 
As a result of the recent cloning of kinin receptor genes, considerable advances in kinin 
research have seen the emergence of numerous potent and highly specific kinin receptor 
antagonists that may have therapeutic value. Modifications saw the emergence of Lys­
(Leu8)des-Arg9BK as a high-affinity B 1 antagonist (Rego Ii and Barabe, I 980) and more 
recently, Ac-Lys-(MeAla
6
, Leu8)-des-Arg9BK was found to be a metabolically multi­
resistant B 1 antagonist (Drapeau et al., 1993). lcatibant (HOE-140), a selective B2 
antagonist more potent than NPC-567, was found to display greater resistance to 
degradation as it was metabolically stable (Hock et al., 1991 ). HOE 140 and NPC-17761, a 
bis-maleimidohexane-dimer analogue of HOE-140, became the "second-generation" kinin 
antagonists. The "third-generation" single-chain kinin antagonists (B-9224, B-9430, and B-
9668), which have high potency at both B 1 and B2 receptors (Burkard et al., 1996; Stewart 
et al., 1996) contain the novel amino acids a-(2-indanyl)-glycine at position 5 and D-a(2-
indanyl)-glycine at position 7. B-9878 has been fashioned as a bi-kinin-Iike peptide. 
Thus, several hundred analogues of the kinin nonapeptide have since been synthesized and 
have given mixed results due to their antagonistic behaviour towards other agonists. The 
"second-generation" kinin antagonists have been used in clinical trials with some success 
in allergic rhinitis (Austin et al., 1994) and atopic asthma (Akbary et al., 1996). The "third­
generation" kinin antagonists have been shown to be selectively cytotoxic for cells of 
SCLC in vitro (Chan et al., 1996) and in vivo (Stewart et al., 1997). The recent discovery of 
the first nonpeptide competitive B2 receptor antagonist WIN 64338 (Sawutz et al., I 994), 
which is stable to proteolytic degradation, may have therapeutic roles in the near future. In 
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animals, kinin antagonists have also been shown to block kinin-induced hypotensive shock, 
as well as non-specific stimulus-induced pain, nasal allergies, and carageenan-and 
thermally-induced oedema (Rodell et al., 1995). 
Inhibitors of ACE, a member of the K-11 group of enzymes that rapidly inactive kinins, 
and also convert the decapeptide angiotensin 1 to an octapeptide angiotensin 11, are 
probably the best examples of drugs acting on the kinin system that are used in clinical 
medicine. The mode of action of ACE inhibitors as antihypertensive agents have been 
shown to be due to both the inhibition of angiotensin 11 (a potent vasoconstrictor) 
production, as well as an increase in circulating levels of kinins (Shimamoto et al., 1990). 
The hypotensive efficacy of these inhibitors has also been shown to correlate with the 
reduced activity of ACE in brain, kidney, and vascular smooth muscle (Unger et al., 1987). 
Recent studies on isolated bovine coronary arteries indicate that the hypotensive effect of 
ACE inhibitors (moexiprilat and ramiprilat) are due to the relaxation of vascular smooth 
muscle, facilitated by the accumulation of endothelium-derived kinins in or at the vessel 
wall (Hecker et al., 1993). 
1.1.4.7 KININS AND BLOOD PRESSURE 
The observation of reduced urinary excretion of tissue kallikrein in untreated hypertensives 
was made as early as 1934 by Elliot and Nuzum, and confirmed more than 3 decades later 
in hypertensive humans and rats (Margolius et al., 1971 and 1974b; Carretero and Scicli. 
1971 ). It has been reported that 20% of patients with essential hypertension have low 
kallikrein excretion (Zschiederich et al., 1980). White patients with uncomplicated 
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essential hypertension have been reported to have normal kallikrein excretion rates with 
normal plasma renin activity and aldosterone (Lawton and Fitz, 1977); only hypertensives 
over the age of 40 excreted a significantly lower kallikrein (Koolen et al., I 984a). Black 
people (adults and children) excreted markedly less kallikrein compared to whites, 
regardless of blood pressures, with black hypertensive subjects showing the lowest 
excretion of kallikrein (Zinner et al., 1976; Levy et al., I 977). 
Gender differences in renal kallikrein excretion have been reported, with females excreting 
more kallikrein than males (Hughes et al., 1988); urinary kallikrein levels rise during the 
luteal phase and return to levels similar to males and postmenopausal females during the 
follicular phase (Albano et al., 1994). Urinary kallikrein activity increased in white females 
during the luteal phase but did not change in blacks (Kailasam et al., 1998). 
Japanese patients with low renin hypertension showed significant reductions in urinary 
kallikrein and kinin excretion, together with increased levels of a kallikrein inhibitor and 
kininase in urine and with reduced levels of kininogen (Nakahashi et al., 1986). South 
African Indians with essential hypertension showed lower urinary kallikrein excretion 
compared to Black South Africans (Seedat et al., I 999). The urinary kallikrein excretion 
was significantly lower in salt-sensitive hypertensives than in salt-resistant hypertensives 
and showed an inverse correlation with plasma atrial natriuretic peptide levels (Ferri et al., 
1994). Patients with malignant essential hypertension excreted less urinary kallikrein than 
those with non-malignant essential hypertension and normotensive control subjects (Hilme 
et al., 1992). A recent study involving 57 Utah subjects' pedigrees indicated that a 
dominant allele expressed as high urinary kallikrein excretion may be associated with a 
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decreased risk of essential hypertension (Berry et al., 1989): the "low homozygotes" would 
have a high risk of hypertension; the heterozygote genotype on a low potassium intake 
would have a high susceptibility to hypertension, whereby a low potassium diet in this 
group predisposes them to hypertension. This study showed a direct association between 
urinary kallikrein and urinary potassium and the risk of developing hypertension. A high 
potassium diet administered to SHRs resulted in a greater amount of urinary kallikrein 
excreted, paralleled by a reduction in blood pressure (Barden et al., 1988). Potassium 
appears to be a stimulus for tissue kallikrein (Lauar and Bhoola, 1986), increasing 
kallikrein excretion in the urine as well as producing hypertrophy and hyperplasia of CNT 
cells together with an increase in the number of immunoreactive secretory vesicles in these 
cells (Vio and Figueroa, 1987). 
In the two kidney, one clip Goldblatt hypertensive rat, kallikrcin levels were low in the 
urine from the stenotic kidney and normal or less reduced in the contralateral kidney 
(Girolami et al., 1983). B2 receptor density was increased to a greater extent in the 
contralateral kidney than in the stenotic kidney (Emond et al., 1991 ). Reduced urinary 
kallikrein excretion has been reported in genetically hypertensive rat models (Dahl, Milan, 
New Zealand, Fawn-hood, Sabra), in rats made hypertensive by deoxycorticosterone plus 
1 % salt, and in the Okamoto-Aoki spontaneously hypertensive rat (reviewed by Katori and 
Majima, 1996). Kininogen-deficient Brown Norway Katholiek rats became hypertensive on 
a moderate salt intake and non-pressor doses of angiotensin II. 
Kallikrein gene therapy, in the form of human kallikrein DNA constructs under the control 
of the metallothionein metal response element, the cytomegalovirus promoter/enhancer or 
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the Rous sarcoma virus 3 1 -LTR, caused a prolonged reduction in blood pressure for 8-10 
weeks following a single injection given to the SHR adult male intravenously, 
intramuscularly, intraperitoneally, into the portal vein and intracerebroventricular route 
(Chao and Chao, 1997). This hypotensive effect was reversed by a subcutaneous injection 
of aprotonin, a potent tissue kallikrein inhibitor. Icatibant acetate (HOE 140), a B2 receptor 
antagonist, given together with captopril, attenuated the hypotensive effect of captopril by 
53% in black and white subjects on a low sodium diet (Gainer et al., 1998). This study 
provides evidence that kinins contribute substantially to the hypotensive effects of ACE 
inhibition. 
1.1.4.8 KININS AND RENAL DISEASE 
1.1.4.8.1 Nephrotic Syndrome 
Urinary kallikrein excretion was found to be markedly increased in patients with nephrotic 
syndrome, irrespective of the level of renal function (Cumming and Robson, 1985), while 
patients with glomerulonephritis (without nephrotic syndrome) had reduced urinary 
kallikrein excretion compared to healthy volunteers. Kallikrein excretion correlated with 
plasma renin activity but not with plasma volume (Cumming et al., 1989). Infusion of 
kallikrein into the renal artery of dogs caused proteinuria, which was abolished by aprotinin 
(Murakami et al., 1968). Kinins are potent stimulators of phospholipase A2 and promote 
synthesis of arachidonic acid metabolites, including thromboxane A2 (Regoli and Barabe, 
1980). Increased glomerular synthesis of thromboxane has been suggested as a cause of 
proteinuria in nephrotic syndrome (Remuzzi et al., 1985). 
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1.1.4.8.2. Parenchymal renal disease and renal failure 
Patients with renal parenchymal disease and hypertension with impaired renal function had 
a more marked decrease in urinary kallikrein excretion compared to hypertensive subjects 
with normal renal function, who also had a reduced urinary kallikrein excretion but less so 
(Mitas et al., 1978). Spontaneously hypertensive rats at 78 weeks showed a dramatic 
decrease in the number of tubules and cells immunostaining for tissue kallikrein, while 
there was no difference between SHR and WKY rats during 4-52 weeks. In humans with 
advanced hypertensive nephropathy similarly, there was a reduction in the percentage of 
tubules (CNT) and cells with immunoreactive tissue kallikrein (Figueroa et al., 1992). 
Prevalence of the 0699 ➔ C polymorphism of the Bl receptor was found to be present 
significantly less frequently in several aetiological subgroups of uraemic patients 
(Bachvarov et al., 1998). Thus, the polymorphism of the B 1 receptor promotor may be a 
marker of prognostic significance for the preservation of renal function. 
1.1.4.8.3 Dialysis 
Patients with end stage renal failure on haemodialysis have fluctuations in their sodium and 
volume status. While urinary tissue kallikrein excretion was decreased in patients before 
haemodialysis, a significant increase in 24 hour urinary tissue kallikrein was observed in all 
patients after haemodialysis (Girolami et al., 1991 ). Immediate hypersensivity or 
anaphylactoid reactions have been reported within the first 10 minutes of commencing 
haemodialysis. Plasma kinin levels were noted to be significantly increased during 
hypersensitivty reactions during haemodialysis (Verresen et al., 1994). A higher incidence 
of hypersensitivity reactions was observed in patients treated with ACE inhibitors while 
undergoing haemodialysis with polyacrilonitrile membranes (Tielemans et al., 1990; 
Verresen et al., 1990). In vitro studies showed that plasma kallikrein activation and release 
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of bradykinin was related to electronegativity of the dialyzer membrane, as well as plasma 
dilution with residual saline rinsing solution at the commencement of dialysis and a fall in 
pH (Renaux et al., 1999). 
1.1.4.8.4 Renal transplantation 
Hypertension frequently accompanies renal transplantation. Proposed mechanisms for 
hypertension include acute rejection, chronic rejection, therapy with steroids and 
cyclosporine, renal insufficiency, presence of the recipient's own diseased kidneys, 
transplant renal stenosis, increased activity of the vasoconstrictor systems ( eg. renin­
angiotensin, endothelin) and decreased activity of vasodilator systems. Urinary kallikrein 
excretion was found to be decreased in hypertensive patients and in those with renal 
complications (more markedly decreased with acute tubular necrosis than acute rejection). 
Urinary kallikrein excretion was also lower in cadaver graft recipients who tend to be more 
hypertensive (O'Connor et al., 1982). 
Urinary excretion of tissue kallikrein was reduced in renal transplant recipients and more 
markedly so following acute rejection (Moodley et al., 1996). TK immunoreactivity was 
reduced in acute rejection both on immunocytochemistry and electron microscopy; while 
TK was observed mainly at the luminal side of distal connecting tubules and collecting 
ducts, there was a shift in immunolabelling to the basolateral membranes (Ramsaroop et 
al., 1997). A marked rise in urinary kallikrein excretion occurred 1-3 days before the 
clinical diagnosis of acute rejection was made (Brouhard et al., 1982; Kool en et al., 1984b ). 
Lower urinary kallikrein excretion was found in transplant recipients compared to controls, 
probably related to reduced renal function or reduced renal mass (Koolen et al., 1984b; 
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Marin-Grez et al., 1982). It has been suggested that tissue kallikrein excretion rate might be 
a useful indicator of functional distal tubular mass: kallikrein excretion was significantly 
decreased in renal transplant recipients and uninephrectomized donors (Spragg et al., 
1985). Decreased kallikrein excretion followed cylosporine administration (Spragg et al., 
1988; Martinez et al., 1990). Short term cyclosporine administration decreased kallikrein 
and kinin B2 receptor mRNA expression in rat kidney cortex (Bompart et al., 1996). 
1.1.4.8.5 Obstructive uropathy 
Intrarenal vasoconstrictor-vasodilator imbalance has been observed in obstructive uropathy, 
resulting in a marked increase in renal vascular resistance and profound reduction in renal 
blood flow and GFR. Excessive production of angiotensin II, thromboxanes, leukotrienes, 
vasopressin and endothelin-1 has been described. In rats with unilateral ureteric ligation, 
systolic pressure, plasma angiotensin II levels, plasma renin activity, angiotensin I and 
plasma angiotensin converting enzyme (ACE) - kininase II activity was elevated. Blockade 
of angiotensin II receptors with losartan normalised blood pressure. Renin mRNA content 
and angiotensin II were elevated in obstructed kidneys. ACE-kininase II activity was 
elevated in both the obstructed and contralateral kidneys. Total immunoreactive kallikrein 
content and tissue kallikrein mRNA levels were markedly reduced in obstructed kidneys 
(El-Dahr et al., 1993). Reduced intrarenal kinin generation may therefore aggravate 
vasoconstriction produced by high local levels of angiotensin II and ET-I in the obstructed 
kidney. 
1.1.4.8.6 Endotoxaemia 
Lipopolysaccharide (LPS) induces arterial hypotension in endotoxaemia by releasing kinins 
via activation of plasma prekallikrein by limited proteolysis of H-kininogen (Kalter et al., 
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I 983; Muller-Ester! and Fritz, I 984). Administration of selective kinin antagonists to rat 
models with endotoxic shock has produced conflicting results: Weipert et al. ( 1988) 
reported attenuation of the hypotensive effect while Berg et al. (1989) found no effect on 
the hypotensive response to LPS. Bacterial LPS strongly induced the expression of B 1 
receptor mRNA in the efferent arteriole, the medullary and inner medullary thin limb and 
the distal tubule, with more moderate expression in the glomerulus, proximal tubules and 
medullary thick ascending limb and slight expression in the cortical duct (Marin-Castano et 
al., 1998); BI-receptor mRNA was not detected under physiological conditions. Induction 
of BI receptor mRNA expression resulted in functional receptor expression, as increases in 
intracellular calcium were observed during B 1-agonist stimulation. LPS treatment also 
increased expression of B2 receptor mRNA in all segments of the nephron except the 
glomerulus, inner medullary thin limb and outer medullary collecting duct; however no 
changes in intracellular calcium were found. 
1.1.4.8. 7 Nephrotoxic acute renal failure 
Gentamycin is an antibiotic commonly used in life threatening gram-negative bacterial 
sepsis. Nephrotoxicity occurs in approximately a third of patients treated with gentamcyin 
for more than 7 days (Mathew, 1992). Gentamycin suppressed the urinary excretion of 
endogenous tissue kallikrein in rats. Systemic delivery of the human tissue kallikrein gene 
in the rat model of gentamycin-induced acute renal failure significantly increased renal 
blood flow, GFR and urine flow while attenuating renal tubular damage, cell necrosis and 
luminal protein casts (Murakami et al., 1998). The mechanism of improved renal function 
following kallikrein gene delivery appears to be mediated via kinin through a nitric oxide 
signal transduction pathway. 
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1.2. RENAL DISORDERS 
1.2.1 ACUTE RENAL ALLOGRAFT REJECTION 
Renal transplantation is the treatment of choice for patients with end stage renal disease. 
Success in transplantation is limited by the availability of donor organs and the occurrence 
of complications such as acute rejection, infections and chronic allograft nephropathy. 
1.2.1.1 Immunology 
Renal allograft rejection depends on the co-ordinated activation of alloreactive T cells and 
antigen-presenting cells (for example, monocyte-macrophages, dendritic cells and B cells). 
This process involves the activity of antibodies and inflammatory mediators, adhesion 
molecules, chemokines and cytokines (Fig 2-1 ). The extent and severity of the rejection 
response depends on genetic similarities between donor and recipient, circumstances 
surrounding organ harvest and early graft dysfunction, the type of tissue engrafted and 
effectiveness of immunosuppresion. The characteristic feature of acute rejection is the 
infiltration of the graft by host mononuclear cells (lymphocytes and macrophages). 
Immunohistologically these have been characterized as T and B lymphocytes, macrophages 
and natural killer cells (Medawar, 1944; Mason and Morris, 1986). Stimulated B 
lymphocytes differentiate into antibody-producing plasma cells which secrete nonspecific 
and specific anti-donor antibodies (Tilney et al., 1979). The immunological host response 
to foreign tissue comprises 2 limbs: an afferent or sensitizing limb and an efferent or 
effector limb (Gowans et al., 1962). T cell activation begins when T cells recognize 
intracellularly processed fragments of foreign proteins embedded in the groove of the 
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major histocompatibility complex (MHC) proteins, expressed on the surface of antigen 
presenting cells (Krensky et al., 1990; Weiss and Littman, 1994). 
CD4 and CDS proteins, expressed on peripheral blood T cells, bind to human leucocyte 
antigen (HLA) class II and class I molecules respectively (Miceli and Parnes, 1991 ). The 
complex of T cell-antigen receptor and CD3, CD4 and CDS proteins physically associate 
with and activate several intracellular protein tyrosine kinases, resulting in mobilization of 
ionized calcium from bound intracellular stores by inositol triphosphate. The increased 
intracellular free calcium and sustained activation of protein kinase C function 
synergistically in promoting the expression of several nuclear regulatory proteins, and in 
the transcriptional activation and expression of genes central to T cell growth (Krensky et 
al., 1990; Weiss and Littman, 1994). Calcineurin, a calcium and calmodulin-dependent 
serine-threonine phosphatase, participates in signal transduction. Inhibition of the 
phosphatase activity of calcineurin is central to the immunosuppressant activity of 
cyclosporine and tacrolimus (Liu et al., 1991; Fruman et al., 1992). 
Cytokines are soluble mediators of cellular communication and mediate interactions 
between leucocyte populations, and between leucocytes and cells m the donor organ. 
Cytokines of the interleukin (IL) family, derived from antigen-presenting cells (namely IL­
I and IL-6), also provide co-stimulatory signals that result in T cell activation. T cell­
derived cytokines (for example IL-2 and IL-4) and contact between T and B cells through 
specific pairs of receptors and co-receptors provide signals essential for B-cell stimulation 
(Clark and Ledbetter, 1994). T cell proliferation is the result of IL-2 expression that is 
dependent on T cell activation. IL-2 triggers the activation of protein tyrosine kinases that 
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results in the expression of several DNA-binding proteins (including c-jun, c-fos and c­













Fig 2-1: Cellular interactions that form the anti-allograft response 





Cytotoxic T cell 
mediated cell death 
Abbreviations: TCR= T cell receptor; MHC= major histocompatibility complex 
Activated macrophages elaborate IL-I, which causes CD4+ T cells to produce a series of 
humoral mediators. Other macrophage-derived cytokines, important in graft destruction, 
include tumour necrosis factors (TNFP and TNFa). The ability of activated CD4+ T 
lymphocytes to elaborate lymphokines is critical in the early phases of acute rejection. 
CD+ 4 cells can be divided into 2 subclasses: T helper 1 (Th I) and T helper 2 (Th2). Th 1 
cells produce effector lymphokines, especially IL-2, which causes differentiation and 
proliferation of activated T lymphocytes and stimulates B cell maturation. Interferon 
(IFN) I derived from Th 1 cells, induces and intensifies class I and II MHC antigen 
expression on the graft, and stimulates B cells to increase antibody production. It may also 
increase lymphocyte adhesiveness to an antigenic surface by upregulating leucocyte 
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function-associated antigen-I (LF A-1) expression (Paineau et al., 1989; Patarroyo and 
Makgoba, 1989). Th 2 cells produce inhibitory products such as IL-4 and IL- I 0. 
The net result of cytokine production is the emergence of antigen-specific, graft-infiltrating 
and destructive T cells. Cytokines also activate macrophages and other inflammatory cells, 
and the production of antidonor antibodies by stimulated T cells. Cytokines can amplify the 
ongoing immune response by up-regulating the expression of HLA antigens and co­
stimulatory molecules (such as B7) on graft parenchymal cells and antigen-presenting cells. 
The co-stimulators direct T cell differentiation, for example into a CD4
+ 
Thl cell which 
secretes lymphokines, facilitating cytotoxic T lymphocyte killing of cells; or differentiates 
into a CD4
+ 
Th 2 cell which stimulates antibody production by B cells (Dallman, 1995). 
Cell killing may occur via specific T-cell products, such as granzyme B (a serine esterase 
protein) and perforin (a pore-forming lytic protein), which have been reported to correlate 
closely with acute rejection of grafts (Clement et al., 1994). The type of organ grafted, 
HLA matching between donor and host and the degree of pre-sensitisation influence the 
acute rejection process. CD4
+ 
T helper cells are the primary, initiating and organizing 
component of host immuno-responsiveness against grafts. CD 8
+ 
cells are recruited 
secondarily to the site to complete the acute rejection process (Tilney et al., 1984; Mason 
and Morris, 1986; Mason, 1987). 
With completion of the rejection episode and destruction of the graft, intrinsic control 
mechanisms return the host activated immune processes to baseline. There is progressive 
decrease in the expression of graft antigens, slowing of clonal expansion of lymphocyte 
subpopulations, with reversion to their resting state; elaboration of cell products and 
surface receptors gradually cease. Suppressor mechanisms may reverse the intense 
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inflammatory process. Th2 cells may produce cytokines (for example, IL-4 and IL-I 0) 
which may inhibit alloresponsiveness and counter the effector activity of Thi-derived 
IFNI, TNFa and IL-Ip. 
Long term graft survival rate has not improved despite major improvements in one year 
graft survival. The half-life of cadaveric renal allografts remains at approximately 7 years 
(Paul and Benediktsson, 1993). The major reason for graft loss is chronic rejection or 
chronic allograft nephropathy, which may be related to poor HLA matching, more frequent 
acute rejection episodes, cytomegalovirus infections, ischaemic and reperfusion injury to 
the graft, the initial amount of functioning renal mass and nephron number (Brenner and 
Milford, 1993). Periglomerular and perivascular macrophages secrete cytokines that are 
profibrogenic, including platelet-derived growth factor (PDGF) and transforming growth 
factor (TGF)-p. This is associated with upregulation of the ET-I gene expression in 
endothelial, vascular smooth muscle and renal mesangial and epithelial cells and results in 
ET-1 secretion (Kurihara et al., I 989; Watschinger and Sayegh, 1996). Increased 
intracellular adhesion molecule-I (ICAM-1) expression is found on the glomeruli of rat 
renal allografts undergoing acute rejection (Azuma et al., 1994). The gradual functional 
deterioration caused by the development of glomerulosclerosis and arterial obliteration may 
also cause systemic hypertension which causes the remaining functional glomeruli to 
hyperfilter before eventually fibrosing, thus resulting in progressive renal damage 
(Neuringer and Brenner, 1992). 
Summary: The primary cells involved in rejection are T lymphocytes and macrophages: T 
lymphocytes are important regulators and effectors in rejection; macrophages and dendritic 
cells are important in antigen presentation. Other cells involved are B cells, natural killer 
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cells, neutrophils, eosinophils and platelets. Soluble factors important in acute rejection 
include components of the complement system, coagulation factors, leukotrienes, kinins 
and inflammatory cytokines. Recipient T lymphocytes recognise foreign HLA class II 
molecules in the allograft, and are activated to proliferate, differentiate and secrete a variety 
of cytokines. Cytokines upregulate expression of HLA class II antigens, stimulate B 
lymphocytes to produce antibodies against the allograft and help cytotoxic T cells, 
macrophages and natural killers cells to develop cytotoxicity against the graft. 
1.2.1.2 Histopathology 
The early stage of acute cellular rejection in the renal allograft is characterized by a 
perivenular and periglomerular infiltrate of transformed lymphocytes and macrophages. 
This is followed by infiltration of the interstitium and tubular epithelium (Fig 2-2). The 
interstitial infiltrate is pleomorphic, consisting predominantly of variably sized 
lymphocytes as well as macrophages, eosinophils, plasma cells and neutrophils (Porter et 
al., 1964). The interstitial infiltrate is associated with oedema, and there may also be 
extravasation of erythrocytes. The tubular lumina become dilated, brush borders disappear 
and cell death occurs. With vascular involvement, arteries and arterioles undergo 
subendothelial infiltration by lymphocytes and macrophages. The endothelium is often 
lifted from its basement membrane and, in some cases, small deposits of fibrin and 
platelets are found in relation to the endothelial injury. The mononuclear cell inflammation 
uncommonly infiltrates transmurally, involving the blood vessel wall and resulting in an 
inflammatory necrotizing arteritis. The Banff classification standardized the criteria for the 
histologic diagnosis of renal allograft pathology internationally as depicted in Tables 1-4 
and 1-5 (Solez et al., 1993; Racusen et al., 1999). 
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Table 1-4. Banff Classification: Criteria for acute rejection in renal allograft biopsies 
Grade I, mild acute rejection 
Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci 
of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 
tubular cells) 
Grade II, moderate acute rejection 
Cases with (A) significant interstitial infiltration and foci of severe tubulitis > l 0 
mononuclear cells/tubular cross section) and/or (B) mild or moderate intimal 
arteritis 
Grade III, severe acute rejection 
Cases with severe intimal arteritis and/or "transmural" arteritis with fibrinoid 
change and necrosis of medial smooth muscle cells. Recent focal infarction and 
interstitial haemorrhage without other obvious cause are also regarded as 
evidence for Grade III rejection 
Table 1-5. Banff Classification of acute rejection. Numerical codes 
g 0,1,2,3 
0, I, 2, 3 
0, I, 2, 3 
V 0,1,2,3 
no, mild, moderate, severe glomerulitis (g3 = mononuclear cells in 
capillaries of all or nearly all glomeruli with endothelial enlargement 
and luminal occlusion) 
no, mild, moderate, severe interstitial mononuclear cell infiltration (In 
rejection oedema and lymphocyte activation usually accompany 
mononuclear cell infiltration; i3 = > 50% of parenchyma inflamed) 
no, mild, moderate, severe tubulitis (t3 = > IO mononuclear cells per 
tubule or per 10 tubular cell in several tubules) 
no, mild, moderate, severe intimal arteritis (v3 = severe intimal arteritis 
and/or transmural arteritis and/or hemorrhage and recent infarction 
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1.2.2 GLOMERULONEPHRITIS 
The severity of glomerular injury is determined by (1) the primary insult and secondary 
mediators involved (2) the site of injury and (3) the speed of onset, extent and intensity of 
disease. 
1.2.2.1 Immune glomerular injury 
Glomeruli are susceptible to a variety of inflammatory, metabolic, haemodynamic, toxic and 
infectious insults. Most human glomerular disease is triggered by immune attack, diabetes 
mellitus or hypertension. Similar clinicopathological presentations are provoked by different 
aetiologies. Infections and vasculitides can trigger acute proliferative glomerulonephritis; 
metabolic disorders such as diabetes mellitus and deposition diseases (for example, amyloid) 
can induce glomerulosclerosis with nephrotic syndrome. Glomerular injury at different sites 
results in characteristic disease patterns and clinicopathological presentations (Table 1-6). 
Table 1-6. Correlation between site of glomerular injury and clinicopathologic 
presentation 
Target of injury Physiologic role Response to injury Renal disease 
Endothelial cell Maintains glomerular Vasoconstriction acute renal failure 
perfusion 
prevents leucocyte leucocyte infiltration focal/ diffuse 
adhesion proliferative GN 
Prevents platelet Intra vascular Thrombotic 
aggregation microthrombi microangiopathies 
Mesangial cell controls glomerular Proliferation/tmatrix Mesangioproliferative 
filtration surface area GN/glomerulosclerosis 
Basement prevents filtration of Proteinuria membranous GN 
membrane plasma proteins 
Visceral prevents filtration of Proteinuria minimal change 
epithelial cell plasma proteins disease/FSGS 
Parietal epithelial maintains Bowman's crescent formation crescentic GN 
cell space 
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Endothelial and subendothelial injury results in (1) recruitment of leucocytes (2) abnormal 
haemostasis leading to thrombotic microangiopathies and (3) vasoconstriction and mesangial 
cell contraction leading to acute renal failure. Mesangial injury, usually immunological in 
origin, results usually in asymptomatic abnormalities of the urinary sediment and mild renal 
insufficiency. Proteinuria is the dominant presentation with injury to the subepithelial aspect 
of the glomerular basement membrane and visceral epithelial cells. 
Immune-mediated glomerulonephritis accounts for a large proportion of acquired renal 
disease. The majority are associated with deposition of antibodies within the glomerular tuft. 
indicating dysregulation of humoral immunity. Cellular immunity, by modulating antibody 
production also contributes to the pathogenesis of glomerulonephritis via antibody-dependent 
cytotoxicity. Formation of antigen-antibody complexes activates complement and leads to a 
significant inflammatory response. Localization of these complexes in the different structures 
of the glomerular capillary determines the presence and severity of the inflammatory response. 
The role of complement in immune-mediated renal injury has been clearly established in anti­
glomerular basement membrane (GBM) antibody glomerulonephritis, membranous 
nephropathy and mesangial proliferative nephritis. 
Secondary immune mechanisms involve the cascade of inflammatory mediators that may be 
recruited to propagate renal damage after the primary glomerular attack. These include 
cytokines, growth factors, reactive oxygen metabolites, platelet-activating factor and 
eicosanoids, proteases and vasoactive substances (ET and EDRF). The presence of an 
inflammatory infiltrate is associated with generation of multiple mediators that participate in 
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the decrease in glomerular filtration rate (GFR) associated with the different types of 
glomerulonephritis. Leukotrienes, especially leukotriene D4 (LTD4), generated by 
neutrophils, play a significant role in the glomerular haemodynamic changes associated with 
immune injury; LTD4 receptor blocker partially ameliorates the decrement in the 
ultrafiltration co-efficient in the anti-Thy-I antibody model (Bresnahan et al., 1992). 
Leukotriene generation is antagonised by 15-lipoxygenase products (lipoxin A4 and lipoxin 
B4) produced by macrophages (Badr, I 992). The glomerular response to immune injury 
therefore depends on the interaction between leukotrienes derived from neutrophils and 
lipoxins generated by macrophages, both cell types stimulated by the presence of antigen­
antibody complexes. 
Thromboxane A 2 (TXA2) and prostaglandin E2 (PGE2), generated by endothelial, mesangial 
and epithelial cells of the glomeruli, are involved in glomerular immune injury. TXA2 is 
associated with renal vasoconstriction and reduction in the ultrafiltration co-efficient in the 
early phases of immune injury; normalization of GFR and renal plasma flow in the later stages 
depends on the generation of PGE2 . The highest concentrations of PGE2 are present in the 
medullary collecting duct; its production is regulated by sodium chloride, molarity and 
bradykinin (Zusman and Keiser, 1977). Studies in humans and animals have shown that PGE2 
and PGii are natriuretic (Johnston et al., l 967; Bolger et al., 1978) and can stimulate renin 
release. PGE2 antagonizes arginine vasopressin (A VP)-induced water reabsorption (Grantham 
and Orloff, 1968). 
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Nitric oxide (NO) may contribute to immunologic renal disease by different and seemingly 
opposing mechanisms. Cytokines produced during renal injury stimulate nitric oxide synthase 
(NOS) to form NO in infiltrating macrophages as well as in glomerular endothelial and 
mesangial cells. In immune complex nephritis, isolated glomeruli and infiltrating 
macrophages produce large amounts of NO; cellular NO secretion and urinary NO excretion is 
augmented; inducible NOS (iNOS) mRNA expression is stimulated (Jansen et al., 1994). The 
L-arginine analogue, N°-monomethyl-L-arginine(L-NMMA) is able to prevent the onset of
glomerulonephritis in this model. Mesangial cells are stimulated by NO to increase capillary 
surface area and glomerular ultrafiltration coefficient, with consequent hyperfiltration and 
possible glomerular scamng (Zatz and DeNucci, 1991 ). Focal or segmental 
glomerulosclerosis occurs after reduction of renal mass due to the resulting hyperfiltration, 
and to increased intraglomerular hydraulic pressure. Inhibition of NO by N°-nitro-L-arginine 
methylester (L-NAME) and L-NMMA leads to increased intraglomerular hydraulic pressure, 
accompanied by renal vasoconstriction, proteinuria and glomerular sclerosis (Reyes et al., 
1993). Glomerular scarring can be prevented and renal vascular resistance ameliorated in renal 
mass-ablated animals that have been fed with L-arginine (Reyes et al., I 994), thus 
demonstrating the protective role of NO in glomerulosclerosis. NO also has anti-thrombotic 
and platelet-inhibitory effects in glomerular injury (Shultz and Raij, 1992). Thus, elevated NO 
levels in glomerulonephritis affect vascular tone, mesangial relaxation and tissue perfusion. 
The resulting glomerular hyperfiltration is thought to directly affect mesangial integrity and 
lead ultimately to glomerulosclerosis. 
A hallmark of proliferative glomerulonephritis is an increase in glomerular cell number, 
which initially is due predominantly to infiltration of the glomerular tuft by leucocytes. 
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Subsequently, resident glomerular cells proliferate in response to growth factors such as 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF) and thrombospondin. 
Glomerular inflammation can resolve with complete recovery of renal function or with a 
variable degree of scarring and chronic renal insufficiency. 
Transforming growth factorp (TGFP) stimulates production of extracellular matrix by most 
glomerular cells, inhibits synthesis of tissue proteases that normally degrade matrix proteins, 
and is a potent stimulus for scar formation following glomerular injury. Angiotensin II, PDGF 
and endothelins are other potential modulators of this process (Wilson, 1996). Moderate to 
severe glomerulonephritis is usually associated with tubulo-interstitial inflammation and 
scarring, which correlates closely with long term impairment of renal function. 
1.2.2.2 Non-immunological glomerular injury 
Nephropathy complicates approximately 30% of type I and 20% of type 2 diabetes mellitus. It 
is characterized clinically by proteinuria and progressive renal insufficiency and 
pathologically by glomerulosclerosis due to thickening of the glomerular basement membrane 
(GBM) and mesangial expansion with extracellular matrix. This may be triggered by 
glomerular hypertension, the direct effect of hyperglycaemia on mesangial cells, advanced 
glycosylation end products, growth factors such as growth hormone, insulin growth factor I 
(IGF 1 ) and angiotensin II, cytokines (such as TGFP), hyperlipidaemia and cell sorbitol 
accumulation and myoinositol deficiency (secondary to activation of the aldose reductase 
polyol pathway). Haemodynamic factors also play a central role. High intraglomerular 
pressure is a major cause of glomerular injury and can result from systemic hypertension or a 
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local change in glomerular haemodynamics. Nephron loss, from any cause, is followed by 
compensatory hyper-filtration in the remaining functional glomeruli in an effort to maintain 
GFR. Over years, the hyperfiltering remnant nephrons develop focal and segmental 
glomerulosclerosis and eventually, global sclerosis (Neuringer and Brenner, 1992). TGF� may 
be an important regulator of matrix accumulation in remnant nephrons. Other mediators are 
angiotensin II, PDGF and endothelins. 
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1.3. AIM OF STUDY 
Vasoactive substances, with directly opposing effects, are present and functional in the 
kidney. Previous reports in the literature are predominantly those of animal experiments or 
human studies of isolated peptides. The aims of this thesis have been: 
( 1) To examine the role of functionally opposing vasoactive peptides ( endothelin-1, atrial
natriuretic peptide and kinins) in a human model of renal inflammation, namely acute renal 
rejection and glomerulonephritis. Comparison was made with various glomerular disorders in 
an effort to assess the effect of immunosuppressive drugs on these peptides. 
(2) To study the localisation of ETA and ET 8 receptors in these renal disorders, as this has
not been previously elucidated in human renal disease. 
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CHAPTER 2 
MATERIALS AND METHODOLOGY 
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2.1 ETHICAL APPROVAL AND PATIENT/GUARDIAN CONSENT 
Ethical permission for the study was obtained from the Ethics Committee of the Medical 
School, University of Natal. Permission for the collection of post-mortem tissue samples had 
been obtained from Professor J B Botha, Head - Department of Forensic Medicine, University 
of Natal. Normal kidney tissue was collected at autopsy with the co-operation of the attending 
Forensic Surgeon. Consent was obtained from patients, normal subjects and the family of the 
deceased (Appendix 2.1.1 and 2.1.2). Pathological kidney tissue was collected at the Renal 
Unit, Addington Hospital, Durban. All patients were informed by myself that blood and urine 
samples and a small piece of kidney tissue that will be removed at biopsy will be used for 
research purposes. 
2.2 SAMPLE COLLECTION 
2.2.1 RENAL DISORDERS 
2.2.1.1 Acute renal allograft rejection 
Samples of blood, spot urine and kidney biopsy material were collected from renal transplant 
patients undergoing graft dysfunction. Renal biopsies were undertaken for routine diagnostic 
purposes, and those patients with a diagnosis of acute rejection were included in the study. All 
relevant personal and clinical details together with all medications that had been administered 
are recorded in Appendix 2.2.1. l 
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2.2.1.2 Renal parenchymal disease 
Blood, spot urine and renal biopsy material was collected from patients with haematuria, 
proteinuria, nephrotic syndrome or renal dysfunction who underwent routine diagnostic renal 
biopsies. The tissue was processed as in 2.3. I. I below. All relevant clinical details are 
recorded in Appendix 2.2.1.2. This group of patients served as disease controls. 
2.2.2 CONTROLS 
2.2.2.1 Kidney donors 
Blood and spot urine samples were collected from kidney donors prior to uni-nephrectomy; 
these served as controls and were compared with samples collected post-uninephrectomy. 
2.2.2.2 Post mortem kidney tissue 
Human kidney tissue was collected from individuals who had died in or soon after arrival at 
hospital, or were declared dead on arrival at hospitals in the Durban area, as a result of trauma 
not involving the abdomen or sudden unexplained death. The corpses were immediately 
refrigerated and maintained at 4°C in the hospital or state morgue. The age, sex, cause and 
time of injury and death was recorded, together with all medications that had been 
administered before death (Appendix 2.2.2). Kidney tissue was collected within 24h of death 
in 5% (v/v) formal saline and served as normal controls. 
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2.3 SAMPLE PROCESSING AND STORAGE 
2.3.1 KIDNEY TISSUE 
2.3.1.1 Tissue processing 
Kidney tissue was processed as follows: 
• 0.5cm3 of tissue in 5% formal saline (v/v) fixative for 24 h at room temperature (RT) to be
embedded in paraffin wax and used for light microscopy (Appendix 2.3.1. la)
• 0.25cm3 of tissue in 2% paraformaldehyde (PFA, w/v)/1 % gluteraldehyde (v/v; pH 7.2)
fixative for 2 h at 4°C to be embedded in resin and used for immuno-electron microscopy
• 0.25cm3 of tissue in 4% PFA (w/v)/2% gluteraldehyde (v/v; pH 7.4) a modified Karnovsky
fixative [Karnovsky, 1965], for 2 h at 4°C to be embedded in resin and used for
transmission electron microscopy (TEM); Appendix 2.3.1.1 b
2.3.1.2 Tissue fixation and wax embedding for light microscopy 
Sections (5mm thick) of kidney were placed in tissue cassettes. These tissue samples were 
dehydrated and embedded in paraffin wax using absolute ethanol, xylene and wax under 
sterile conditions in an automatic tissue processor (Shandon), and these samples were used for 
both light microscopy and in situ RT-PCR. The automated schedule of steps outlining the 
fixation, dehydration, clearing, infiltration and embedding carried out by the Department of 
Histopathology, University of Natal are listed in Appendix 2.3.1. la. Of these wax embedded 
tissue samples, three µm sections were adhered onto plain glass slides for histology, as well as 
poly-L-lysine (Sigma Chemicals, St. Louis) coated glass slides to be used for the localisation 
of endothelin and its receptors, TK and ANP by immunocytochemistry (ICC). Four micron 
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sections of these tissue samples were adhered onto glass slides coated with a 2% solution (v/v) 
of 3-aminopropyltriethoxysilane (Sigma Chemicals, St. Louis) in acetone for the 
demonstration of ET-1 expression by in situ RT-PCR. 
2.3.1.3 Tissue fixation and resin embedding for electron microscopy 
2.3.J.3.J Tissue fixation for transmission electron microscopy (TEM) 
Biopsy tissue for TEM was immediately immersed in Kamovsky's fixative for 90 min at 4°C. 
The specimen was then diced into lmm3 cubes and re-immersed in fresh Kamovsky's fixative 
for a further 30 min. Thereafter, the tissue was transferred to 0.2M sodium cacodylate (pH 
7.2) maintained at 4°C until embedded and polymerised in low viscosity embedding media 
(Electron Microscopy Services, Pennsylvania, USA) as outlined in Appendix 2.2.1. lb 
[Glauert, 1975]. 
2.3.1.3.2 Tissue fvcation for immuno-electron microscopy 
Biopsy tissue for immuno-electron microscopy was immediately immersed in 2% PF A 
(w/v)/1 % gluteraldehyde fixative (v/v, pH 7.2) for 2 h at 4°C, then transferred to 0.2 M 
sodium cacodylate buffer (pH 7.2) maintained at 4°C before resin embedding. 
2.3.1.3.3 Resin embedding for electron microscopy 
The fixed tissue was dissected into l rnm3 sections and placed in disposable baskets in a tissue 
processor (Reichert-Lynx). The machine was programmed to incubate the sections in a series 
of reagents as described in Appendix 2.3. l. lb. The tissue was then removed from the 
processor and polymerised in pure resin overnight at 40°C. 
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2.3.1.4 Sample storage 
2.3.1.4.J Wax embedded tissue 
The wax embedded tissue samples were stored at room temperature (RT) for future 
microscopic and immunohistochemical analysis. 
2.3.1.4.2 Resin embedded tissue 
The resin embedded tissue samples were stored at room temperature (RT) for future 
microscopic and immuno- histochemical analysis as outlined in section 2.6. 
2.3.2 URINE SAMPLES 
2.3.2.1 Endothelin-1 (ET-1) 
Spot urine samples (10 ml) were collected in 200 ul bacitracin [(bacteriostat); 2840 u/ml; 
Sigma, St Louis] and 200 ul Soyabean trypsin inhibtor [(SBTI, inhibitor of arginine 
proteases); 2720 u/ml, Sigma, St Louis] and centrifuged at 1400xg for 20 min at 4°C. One ml 
supernatant was aliquotted into microfuge tubes containing 200 ul mediator peptide inhibitor 
cocktail (see Appendix 2.3) and stored at -20°C until ET-1 measurements were made. 
2.3.2.2 Tissue kallikrein 
10 ml urine samples were decanted into corningware tubes containing 200 ul bacitracin and 
200 ul SBTI (inhibitor of arginine proteases other than TK). Urine was centrifuged at 1400xg 
for 20 min at 4 °C. Thereafter 1 ml of urine was aliquotted into eppendorf tubes containing 50 
ul 0.2M Tris-HCl (pH 8.2) and stored at -20°C until assayed. 
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2.3.2.3 Basal kinin generation 
Spot urine samples were collected in corningware tubes (Corning, USA) containing 200 ul 
kininase inhibitor mediator peptide cocktail (Appendix 2.3), excluding STB I and aprotinin 
(so that kinins could be generated from endogenous kininogen) and centrifuged at I 400xg for 
20 min at 4°C. One ml aliquots were stored in eppendorf tubes at -20°C until the kinin 
generation assay. 
2.3.2.4 ANP 
Spot urine samples were collected in 200 ul bacitracin/SBTI and centrifuged at 1400xg for 20 
min at 4°C. One ml supernatant was aliquotted into eppendorf tubes containing 200 ul 
mediator peptide inhibitor cocktail and stored at -20°C until assayed. 
2.3.3 BLOOD SAMPLES 
2.3.3.1. Endothelin-1 
Whole blood samples were collected from patients recumbent for 20 min in chilled sodium 
ethylenediamine tetraacetic acid (EDT A; 2mg/ml, w/v) tubes and centrifuged immediately at 
1400xg for 20 min at 4°C. One ml plasma was transferred into polypropylene tubes (Corning. 
USA) containing 200ul peptide inhibitor cocktail and stored at -20°C until assayed. 
2.3.3.2 ANP 
Whole blood samples were collected as reported in 2.3.3.1 above and stored at -20°C until the 
assay was done. 
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2.4 ANTIBODY PROFILES 
2.4.1 Endothelin-1 (ET-1) antibody 
The ET-1 antibody was supplied by Biomedica (Vienna, Austria). The immunogen was 
human ET-1 coupled to bovine serum albumin (BSA) and keyhole limped haemocyanine 
(KLH). The antibody was raised in the rabbit, and produced as an immuno-affinity purified 
IgG, lyophilized in 0.05 M borate buffer (pH 8.5). The antibody specificity was I 00% with 
ET-1, 142% with ET-2, 98% with ET-3, and less than 1% with Big ET 1-38 and Big ET­
fragment 22-38, Sarafotoxin and ANP. 
2.4.2 Endothelin receptor antibodies 
2.4.2.1 Endotlzelin A (ET A) receptor antibody 
ETA receptor antibodies (AS444) were kindly provided by Werner Mi.iller-Estcrl (Institute of 
Biochemistry, University Hospital Frankfurt, Theodore-Stern-Kai 7, D-60590, Frankfurt, 
Germany). AS444 raised in the rabbit against peptide sequences CON 25 (ED I- from the NH2 
terminal) and CTS 24 (ED4 -from the carboxy terminal) of the human ET A receptor. The 
whole antiserum was lyophilized and reconstituted with distilled water. 
2.4.2.2 Endotlzelin B (ET8) receptor antibody 
ET 8 receptor antibodies (AS445) were also provided by Werner Mtiller-Esterl. AS445 was 
raised in the rabbit against peptides CGL-26 (ED I-from the amino terminal) and CLK (ED4-
from the carboxy terminal) of the ET 8 receptor. The whole antiserum was lyophilized and 
reconstituted with distilled water. 
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2.4.3 ANP antibody 
ANP antibody, raised against human ANP 1-28, was supplied by the Peptide Institute (Osaka, 
Japan). The antiserum was lyophilized with 0.001 M PBS (pH 7.0). The immunogen was 
ANP (human, 1-28)-TG (bovine thyroglobulin). The specificity of ANP (human, 1-28) was 
reported to be 100 %, ANP (human, 7-28) 100 %, [Met (0) 12]-ANP (human, 1-28) 150%, 
ANP (rat, 1-28) 55 % and 13-ANP (human, 1-28 dimer) 100 %. The sensitivity (IC50) was 0.28 
pmol/ml. There was no cross-reactivity against Oxytocin, (Arg8)-Vasopressin, Somatostatin, 
(Met5)-Enkephalin and 13-Endorphin (human). 
2.4.4. Tissue kallikrein antibody 
2.4.4.J Generation of anti-human rTK antibody 
Anti tissue kallikrein antibody directed against recombinant tissue kallikrein (rTK) generated 
in E. Coli transfected with human tissue cDNA was raised in the goat. The recombinant TK 
(rTK) was supplied by Dr Michael Kemme (Institute for Technical University of Darmstadt, 
Darmstadt, Germany). 
2.4.4.2 Antibody Production 
A healthy goat was initially immunised by a single intramuscular injection of recombinant 
tissue kallikrein (rTK), conjugated in 125 µl Titermax® adjuvant. Thereafter, a booster 
programme using similar doses of conjugated antigen was initiated over a 4 month period. 
Serum from pre-booster (non-immune) and fortnightly venous bleeds was used to determine 
cross-reactivity, specificity and antibody titre. The titre was determined by a standard single 
site enzyme-linked immunosorbant assay (ELISA) using human urinary kallikrein (Protogen, 
Sweden) as the antigen. The titre increased from 1: 50 to an optimum of I :800. 
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2.4.4.3 Antibody isolation and purification 
The isolation and characterization of the IgG was performed according to the method 
described by Johnstone and Thorpe ( 1982). The serum proteins were double precipitated with 
14 % NaSO4 (w/v), and centrifuged at 3000xg. The precipitate was reconstituted up to 30 % of 
the original volume with distilled H2O, and dialysed against 0.07 M sodium phosphate buffer 
(pH 6.3) for 24 h at 4°C. Isolation of the IgG was performed using a diethylaminoethyl 
sephadex (DEAE), a-25 ion exchange column (Sigma) with 0.02 M sodium phosphate buffer 
(pH 8.0). One ml fractions were collected. Those fractions showing the highest absorbance 
(0.311 - 0.827) at 280 nm were pooled. The protein concentration of this pooled fraction was 
1.11 mg/ml. The IgG was then characterized on 7 % sodium dodecyl-sulphate polyacrylamide 
gel (SDS-PAGE) against IgG molecular weight markers (Sigma MW SOS 70) to determine 
purity. The purity, specificity and sensitivity of the antibodies were verified by a single site 
ELISA using human urinary kallikrein (HUK, which also determined the antibody titre), 
Western blot (immunoblotting), positive control tissue and preabsorption with rTK in 
immunocytochemical studies, as well as the use of control human urine (TK is present in 
human urine in readily measurable concentrations), in an ELISA which demonstrated the 
reproducibility of the results produced with these antibodies. The optimal rTK concentration 
detected was 7.5 ug and the optimal antibody dilution was 1: 2000; 30 µl aliquots were stored 
at -20°C.The methodology is described in Appendix 2.4.4.3 a-c. 
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2.5 MEASUREMENTS 
2.5.1 ENDOTHELIN-1 ELISA 
ET-1 was measured in plasma and urine by a sandwich-type enzyme immunoassay, based on 
the method of Suzuki et al. (1989), using a commercial kit supplied by Wako Chemical 
Industries, Osaka (Japan). A sandwich-type antigen-antibody complex < anti ET-I 
monoclonal antibody: ET-I: enzyme-labelled anti ET-I polyclonal antibody > was formed. 
Microplates coated with anti ET-I monoclonal antibody were incubated with the samples and 
enzyme-labelled antibody (peroxidase-labelled anti ET-I polyclonal antibody). After washing 
the plates with PBS and removing unbound material, the amount of enzyme (peroxidase) 
bound to the plate is directly proportional to the amount of ET-I in the sample, and was 
determined by a colour reaction using 0-phenylenediamine and hydrogen peroxide as 
substrates measured at 492 nm. All measurements were made in duplicate. When I ml of 
plasma was spiked with a known concentration of ET-1, recovery rates of 97.3% and 98% 
were achieved. Repeated assays yielded an inter-assay co-efficient of variation of 6.1 %. Data 
report included with the kit indicated that cross-reactivities with ET-3 and Big ET-1 were 
below 0.4%, and a measurable range of 2-200 pg/ml (corresponding to 0.5-50 pg/ml when I 
ml of plasma is pre-treated). The detailed methodology is tabulated in Appendix 2.5.1 a. The 
standard curve is shown in Appendix 2.5.1 b. 
2.5.2 ATRIAL NA TRIURETIC PEPTIDE RIA 
Blood samples collected in chilled sodium EDTA (2 mg/ml, w/v) tubes was centrifuged at 
1400xg for 20 min at 4 °C. One ml plasma was aliquotted into microfuge tubes containing 200 
µI peptide inhibitor cocktail and stored at -20° until the assay. Urine samples were collected in 
95 
chilled tubes containing 200 ul thiomersal (Sigma, St Louis) and 200 ul SBTI (4mg/ml) and 
centrifuged at 1400xg for 20 min at 4°C. One ml supernatant was aliquotted into microfuge 
tubes containing 100 ul 0.2 M Tris buffer (pH 8.2). ANP was extracted from plasma and urine 
samples using Sep-Pak C18 cartridges. The cartridges were activated with 1ml 60 % 
acetonitrile in I % trifluoroacetic acid (TF A). The plasma sample was acidified with 0.1 % 
TF A and loaded onto Sep-Pak cartridges. After washing, ANP was eluted with 60 % 
acetonitrile in 1 % TF A. The eluant was evaporated to dryness under a nitrogen stream at 
37°C in a water bath. The residues were reconstituted with a buffer solution and subjected to 
RIA using a commercial kit (Peninsula Laboratories, Belmont, Ca). Standard curve was 
generated on semi-log graph paper. To calculate the amount of peptide in the original sample, 
the concentration of the assayed sample was multiplied by the dilution factor used to prepare 
the sample. Measurements were expressed in pg/ml. Detailed methodology is outlined in 
Appendix 2.5.2a. The standard curve is shown in Appendix 2.5.2b. 
2.5.3 ASSAYS FOR TISSUE KALLIKREIN (TK) 
The presence of active TK in urine samples was determined by an amidolytic assay whereas 
total immunoreactive TK was measured by ELISA. Purified human urinary tissue kallikrein 
(HUK, Calbiochem, Lucerne) was used to validate both the amidolytic assay and ELISA, and 
these results were used to calculate both the intra- and inter-assay coeffficients of variation. 
2.5.3.1 Controls for Amidase assay, TK ELISA and Kinin generation ELISA 
A large volume of pooled human urine (from normal volunteers), a fairly good source of TK, 
was collected in thiomersal. Aliquots (1ml) were mixed with 50 ul of 40 mM Tris (pH 8.0) 
per ml of urine and stored at -20°C. Serial dilutions of this urine were included as controls for 
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both the amidolytic assay and TK ELISA. These values were used to calculate both the intra­
and inter-assay coefficients of variation. For basal kinin values, aliquots were mixed with 100 
ul of inhibitor cocktail (refer to Appendix 2.3) per ml of urine, and for the kinin generation 
assay, 100 ul kinin generating cocktail (Appendix 2.3) per ml of urine and stored at -20°C. 
These were used as controls for the kinin generation ELISA. One set of plain urine samples 
stored at -20°C, without any buffer, was used to measure total protein. 
2.5.3.2 Enzymic assay (amidolytic microassay) 
This is a colorimetric, end-point microassay using a microtitre plate for the measurement of 
the enzymic activity of TK in biological samples. The amount of TK is measured by assessing 
the activity of the enzyme on the selective, synthetic substrate, H-D-Val-Leu-Arg-pNA 
[(S2266, Kabivitrum, Sweden); Amundson, 1979] in the presence of soya bean trypsin 
inhibitor (SBTT) as modified by Lauar et al. (1982), and further developed as an end-point 
assay in a microtitre plate by Rahman et al. (19946). The enzymic activity of TK is 
proportional to the release of para-nitroaniline (pNA) from H-D-Val-LeuArg-pNA, which has 
a peak absorbance at 405 nm. A microassay standard curve was constructed using human 
urinary kallikrein (HUK, Calbiochem, Lucerne) from which the concentration of TK in urine 
samples were measured in ng/ml (Appendix 2.5.3.2b). Control urine was included in each run 
to determine inter-assay coefficient of variation. During each assay, 2 sets of plates were 
processed simultaneously, ohe being the measurement of TK activity at zero time (blank), and 
the other the enzymic activity of TK after a 3 h incubation. All determinations were performed 
in triplicate as tabulated in Appendix 2.5.3.2a. 
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2.5.3.3 TK ELISA 
Aliquots of urine were used to measure total TK (in triplicate) by a sandwich ELISA using 
goat anti-human rTK IgG and rabbit anti-human rTK IgG. The anti-species antibody, anti­
rabbit IgG raised in sheep (Sigma, St Louis), was conjugated with the enzyme alkaline 
phosphatase, that hydrolyses the chromogenic substrate disodium p-nitrophenyl phosphate 
(pNPP). The stepwise procedure is described in Appendix 2.5.3.Ja. The standard curve is 
depicted in Appendix 2.5.3.Jb. 
2.5.4 MEASUREMENT OF BASAL KININ LEVELS AND KININOGENASE 
ACTIVITY OF TK BY KININ GENERATION ELISA 
The capacity to form kinins by TK from the kininogen in urine was determined by initially 
generating the release of its kinin moiety with endogenous TK followed by the quantitative 
analysis of the released kinin by ELISA. An important aspect of this assay is the use of two 
separate kininase/protease inhibitor cocktails (Appendix 2.3). Firstly, one set of aliquots of all 
samples and control urine were stored in inhibitor cocktail that contained proteins that 
inhibited the enzymic activities of TK, PK and other trypsin-like proteases ( l O uM aprotonin, 
w/v, l O uM SBTI, w/v), thereby preventing the release of kinin from endogenous kininogen. It 
also contained IO uM captopril, an inhibitor of the KIi family of kininases, and 10 uM 
phosphoramidon, another kininase inhibitor, to ensure that the basal kinins present in the 
samples were not destroyed. A second set of aliquots of all samples and control urine 
contained peptidases that prevented the destruction of kinins but permitted its formation. The 
second aliquot of each sample and control urine was stored in kinin generating cocktail, which 
was similar to the inhibitor cocktail except that it lacked aprotonin and SBTI. The absence of 
these protease inhibitors ensured that kinin could be released from endogenous kininogen and 
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protected by inhibitors of the peptidases. Activation of endogenous TK was achieved by 
incubating equal volumes of urine and generating cocktail for 60 min at 3 7°C in the presence 
of kininase inhibitors to limit the degradation of the generated kinin (Appendix 2.5.4). The 
released kinin was then extracted with acid-alcohol (absolute alcohol/3 mM HCI, v/v) and 
measured by a competitive ELISA following overnight incubation with a standard amount of 
monoclonal mouse anti-BK IgG (SBKl) at 4°C, to bind the released kinin. Known amounts of 
standard BK (1.25 - 150 ng BK/ml, Sigma, St. Louis) were also allowed to react overnight 
with standard amounts of SBKI. The wells of a Nunc Immulon Maxisorp™ ELISA plate 
(Nunc, UK) were coated with a standard amount of BK conjugated to cytochrome C using the 
linker N-succimidyl 3- (2-pyridyldithio) propionate (SPDP). The kinin-SBK 1 reaction 
mixtures were then added to each well and incubated for 3 h at 37°C so that any remaining 
free antibody could react with the BK-SPDP-cytochrome C conjugate bound to the ELISA 
plate. The secondary antibody wa!> an anti-mouse IgG labelled with the enzyme alkaline 
phosphatase, which converted the colourless disodium p-nitrophenyl phosphate (pNPP) to a 
yellow chromogen that has a maximal absorbance at 405 nm. The absorbance values obtained 
for the standard BK was used to plot a standard curve of absorbance versus log concentration 
from which the basal and generated kinin contents of the tissue extracts were determined 
(Appendix 2.5.4b). The basal and generated kinin contents of control urine were also 
measured during each run to determine the inter- and intra-assay coefficients of variation. The 
detailed stepwise method for the competitive ELISA is tabulated in Appendix 2.5.4a. 
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2.6 IMMUNOLOCALISATION OF ET-1 AND ETA AND ET8 RECEPTORS, ANP 
AND THE KININ FORMING ENZYME TISSUE KALLIKREIN 
2.6.1 LIGHT MICROSCOPY: PEROXIDASE-ANTIPEROXIDASE (PAP) 
IMMUNOLABELLING METHOD 
Three um thick sections of wax-embedded tissue were adhered onto adhesive coated (poly-L­
lysine, Sigma Chemicals) slides. The technique used was adapted from that described by 
Robinson et al. (1990), MacLennan et al. (1990) and Marriott and Carlton (1990). The kidney 
sections were placed on a heating mantle at 60°C until the wax melted. The PAP method 
required dewaxing the tissue sections using xylene and rehydration with increasingly dilute 
alcohol solutions ( 100%, 90%, 70% ethanol) and distilled water as the final rehydrant. When 
the tissue was partially rehydrated, it was immersed in absolute methanol (99.9%; Saarchem, 
S Africa) for 20 min to quench endogenous peroxidases. The tissue was then heated in 0.1 M 
sodium citrate buffer (pH 6.0) at 80°C for 8 min for antigen retrieved in a Sharp R-4A52 
microwave oven (Sharp Electronics, Japan). The tissue was further blocked with 5% H202/ 
95% MeOH for 5 min to quench endogenous peroxidases. Immunolabelling for ET A and ET 8
receptors, ANP and TK was carried out similarly at the following dilutions: ET-I 1 :50; ET A 1: 
650; ET 8 I: 500; ANP I: I 00. Incubation with the specific primary antibody in 0.1 M 
phosphate buffer (pH 7.4)/1 % BSA (v/v)] was carried out for 2 min. Next the tissue was 
incubated with biotin link (DAKO K0690) for 2 min, and then treated with Strepavidin 
(DAKO K0690) for 2 min. The sections were washed between incubations by submerging the 
slides for 5 min in 0.01 M PBS (pH 7.4) containing 27 mM potassium chloride, 0.137 M 
sodium chloride (w/w) (Sigma) for 5 min and the tissue sections were not allowed to dry out. 
All dilutions were made up in 0.01 M PBS/I% BSA (pH 7.4, v/v). Labelled slides were stored 
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in the dark to preserve the immunoprecipitant label. The labelling antibody, containing the 
PAP immunoenzyme complex, was visualised by incubating the sections for 2-5 min with 
liquid 3,3' diaminobenzidine (DAB) precipitant (DAKO, K3465). The sections were 
counterstained with Mayers' haematoxylin (Sigma, St Louis) for 3-5 min. Sections were then 
dehydrated and mounted with a permanent medium (Entellen, Merck Gmbh) and 
immunovisualised by conventional light microscopy under a Nikon photomicroscope (Nikon 
Optiphot, Japan). The detailed methodology is described in Appendix 2.6.2. 
2.6.2 CONFOCAL MICROSCOPY: FLUORESCENT IMMUNOLABELLING 
METHOD 
This process required melting the wax on a heating mantle, dewaxing in xylene and 
rehydrating the 3 micron sections with increasingly dilute alcohol solutions ( I 00 %, 90 %, 70 
%) and distilled H20 as the final rehydrant. Endogenous peroxidases were quenched by 
immersing the sections in I 00% MeOH for 20 min. Antigen retrieval was carried out by 
heating the tissue in 0.1 M sodium citrate buffer (pH 6.0) at 80°C for 3 min in a microwave 
oven (Sharp R-4A52), and nonspecific sites blocked with human IgG (Sigma) for 2 min. 
Immunolabelling for ET-I, ETA and ETB receptors, ANP, and TK was carried out similarly 
at the following dilutions: ET-I I: 50; ETA I: 650; ET 8 I: 500; TK I: 1000. The tissue 
sections were incubated with the specific primary antibody diluted in 0.1 M PBS (pH 7.4) for 
18h at 4°C. The bound primary antibody complex was conjugated to a fluorescein labelled 
[fluorescein isothiocyanate (FITC), 525 nm, Sigma] anti-rabbit lgG for 30 min at RT. All 
washing steps were carried out in 0.0lM PBS (Sigma; pH 7.4). Fluorescent labelling was 
analysed using the Leica TD4 confocal microscopy system (Leica, Germany). All dilutions 
were made up in 0.0IM PBS/0.1% BSA (v/v, pH 7.4) and tissue sections were not allowed to 
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dry out between incubations. Labelled slides were stored in the dark at 4°C to limit bleaching 
of the fluorescent tag. The detailed method is outlined in Appendix 2.6.3. 
2.6.3 ELECTRON MICROSCOPY: IMMUNOLOCALISATION OF ENDOTHELIN-1 
AND ITS RECEPTORS IN THE HUMAN KIDNEY 
Fresh tissue was immersed in 1 % glutaraldehyde (v/v) and 4% paraformaldehyde (w/v) 
fixative in a 0.2 M cacodylate buffer (pH 7.2) for 4 h at 4°C, then transferred to sodium 
cacodylate buffer (0.2 M, pH 7.2) until processed. The fixed tissue was divided into 1 mm 
cubes, and processed in an automatic Reichert-Lynx tissue processor. The specimens were 
then rotated through a pre-programmed sequence of dehydration in graded alcohol solutions 
(70%, 90% and absolute alcohol) for 15 min each, immersed in an intermediate solvent 
(propylene oxide) for 30 min and then in spurr-epoxy resin for 120 min (2 changes of 60 min 
each). The sections were then embedded in pure resin overnight at 60°C and I µm sections cut 
with a Reichert Ultra cut ultramicrotome (Jung, Germany). Sections were collected onto glass 
slides, heat fixed, stained with 1 % alkaline toluidine blue (Sigma) and examined with a Nikon 
microscope. Fields of interest were selected, 50 nm sections cut and collected onto uncoated 
Nickel grids prior to immunostaining. The sections were incubated with rabbit anti ETl ,  ETA 
and ETB antibodies ( dilutions of 1: I 00, I: 1000 and I: I 000 respectively) and goat anti-rabbit 
IgG (1: 100 dilution) conjugated with a 10 nm Aurogold probe. Sections were counterstained 
with 2% uranyl acetate and 1 % Reynold's lead citrate (Pelco International, California, USA) 
and examined under a Jeol 1010 transmission electron microscope. The detailed methodology 
is outlined in Appendix 2.6.4. 
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2.6.4 CONTROLS FOR ICC 
2.6.4.1 Negative controls for ICC 
Loss of immunolabelling following preabsorption of the primary antibody with an excess of 
rTK demonstrated the specificity of the antibody. The goat anti-human rTK antibody was 
diluted 1:500 with 0.01 M phosphate buffer (pH 7.2) and an equal volume added to 500 ul of a 
2 mg/ml stock solution of rTK to yield a final concentration of I mg antigen (rTK) per ml. 
This was mixed and incubated overnight at 4°C to allow formation of antigen antibody 
complexes. Following centrifugation (2200 x g, 4°C, Biofuge 13R), the preabsorbed antibody 
was used to replace the primary antibody. An additional control was the replacement of the 
primary antibody by I 00 ul PBS. The immunolocalisation procedure is described in section 
2.6.1. 
2.6.4.2 Positive tissue controls for Immunocytochemistry 
Since TK is abundant in the duct cells of the human salivary glands, samples of fresh human 
salivary gland were collected at post-mortem, fixed in 5% formal saline and embedded in 
paraffin wax. During each labelling run, this appropriate positive control tissue demonstrated 
the presence of TK in the apical region of duct cells in human salivary glands (Schachter, 
1980; Orstavic, 1980). Placental tissue and cardiac atria were used as positive control tissue 
for ET-1 and ANP respectively. 
2.7 EXPRESSION OF ENDOTHELIN-1 mRNA IN THE HUMAN KIDNEY 
2.7.1 In situ reverse transcriptase polymerase chain reaction (RT-PCR) 
Four µm thick wax impregnated tissue sections, placed on pre-treated glass slides, were 
dewaxed in xylene and rehydrated in ethanol into water. The tissue was then treated with 
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20µg/ml Proteinase K [in 100 mM Tris HCl (pH 8.0), 50m M EDT A v/v] for 25 min at 37°C 
to permeabilise the cell membranes. This was followed by a DNAse treatment overnight to 
destroy all DNA present. cDNA synthesis using the Moloney murine leukaemia virus (M­
MuL V) reverse transcriptase and the First Strand Synthesis Kit (Pharmacia, Sweden) was then 
carried out at 37°C for 1 h. The PCR reaction was followed in the presence of the appropriate 
primers and a freshly prepared colour substrate (1 :50 dilution of nitroblue tetrazolium/ 5-
bromo-4-chloro-3-indoyl-phosphate (Roche) and incubated at RT in the dark until a reddish­
purple colour precipitate was visible. The detailed methodology is outlined in Appendix 2. 7. 
2.8 MEASUREMENT OF RENAL PLASMA FLOW 
Effective renal plasma flow (ERPF) was measured in 6 stable renal transplant patients ( on day 
3 post transplant) and one control subject in the Medical Physics Department at Addington 
Hospital, Durban, using sodium 131 iodohippurate. Simultaneous measurement of GFR was 
made using 99M Technetium-diethelene triamine penta acetate (Tc-DTPA). ERPF was 
repeated in 3 of the patients, 2 during an episode of acute rejection. 
2.9 MEASUREMENT OF TOTAL BODY WATER 
Assessment of excess fluid distribution by total body water (TBW) was made by bioelectrical 
impedance analysis (BIA) using the Biostat body composition analyser (BodyTrak, Cape 
Town) in 5 transplant patients, 4 patients with renal disease and 3 controls. Electrodes are 
placed on the right hand and right foot with the subject relaxed in the supine position. A high 
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frequency electrical current discriminates between the different impedances ( or resistances) of 
muscle and fat. A comprehensive body composition analysis is given which calculates data on 
ideal body weight, fat weight, lean weight, TBW, BMR and estimated average energy 
requirement and corresponding normal ranges. BIA correlations against densitometry and 
dilution techniques such as D20 and H20 have enabled accurate determinations of TB W to be 
simply and rapidly made. 
2.10 PHOTOMICROGRAPHY 
Initially for light microscopy, tissue sections processed by the PAP method and stained with 
DAB were examined, and areas of interest photographed, with a Nikon binocular Optiphot 
photomicroscope (Nikon, Japan) with objective magnifications ranging from 1 Ox to I 00x 
using Kodak 160 ASA (Eastman-Kodak, USA) colour film. For tissue sections labelled with a 
fluorescent tag, immunofluorescence was observed with a Leitz DM IRB confocal microscope 
(Leica, Gem1any) attached to Diamond Pro 17 (Mitsubishi) and Diamond Pro 21 T 
(Mitsubishi) monitors. Confocal images were recorded at a pixel density of 225 x 225 pixels 
in 8 bit tagged image file (tit) format. Subsequently, PAP and fluorescent-labelled tissue 
sections were viewed under a Leica DMLB microscope and the images captured with a Leica 
DC 100 digital camera (Leica, Germany). These 24 bit images were also recorded in tagged 
image file (tit) format. 
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2.11 IMAGE ANALYSIS 
2.11.1 Analysis of PAP images 
PAP immuno-stained tissue slides were viewed by a Nikon Optiphot microscope (Nikon, 
Japan) which was interphased to a 3 CCD digital camera system (Sony Corp., Japan). The 
quantitative image analyser used to determine the labeling intensity of the PAP immuno­
localisation was the Kontron Elektronic KS 300 (Zeiss GmbH, Germany), runnmg on 
Windows 95™ , (Microsoft Corp., USA). The digital images captured were processed and 
converted to grey image ranging in grey density from O to 255. The areas of PAP labelling 
were segmented. This involved the immuno-positive areas being separated from their 
environments on the basis of their grey values (set up threshold factor), thereby creating a 
binary image for quantification. The grey values in the image represent the intensity of the 
label over the entire area of possible x-y co-ordinates. A coloured contour was superimposed 
on the binary image to complement previous threshold areas. This image was then masked 
onto the original image of the chosen areas. The median maximal density of immuno-labelling 
was then calculated as pixels per unit area. Figure 2.11.1 is a photomicrographic 
representation of this procedure. 
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2.11.2 Analysis of immunofluorescent images 
Determination of the amount of ET-1, ETA and ETa receptors and TK were computed by 
image analysis. Confocal scanning laser microscopy is a powerful imaging technique in which 
the staining intensity of fluorescently labelled tissue section could be viewed. An important 
capability of the confocal microscope is that it can optically cut sections through tissue. This 
feature was used to determine the middle plane of the cell or tissue section, and an image 
representative of the whole cell was then generated. 
Confocal images were typically recorded at a pixel density of 225x225 pixels. The grey scale 
ranged from Oto 256, and was divided into 8 equal phases (POLI Look-Up-Table), with each 
phase having a lower and upper threshold value on the grey scale. All the pixels in each phase 
were attributed with a colour for easy visible distinguishing between the phases. The 
breakdown of the phases is as follows: 
PHASE Lower and upper Fluorescence intensity 
threshold 
1 purple 0-56 No fluorescence 
2 blue 
3 cyan 56-88 Low fluorescence 
4 green 89- 154 Medium fluorescence 
5 yellow 
6 orange 155 -256 High fluorescence 
7 red 
8 white 
The analysis performed in this study was based on a breakdown of the number of pixels per 
phase of the grey scale in the cytoplasm of various structures in the normal and diseased 
kidney. The amount of antigen was estimated by analysis of the computer generated confocal 
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images using the Analysis 2.1 Pro system (Soft-Imaging Software GmbH, 1996, Germany). In 
order to analyse the cytoplasm only of each structure of interest (proximal-, distal-, collecting 
tubules and glomerulus), a mask had to be generated for each type of structure. The regions of 
interest (ROI) - first the whole tubule, then the tubule duct and nuclei - are encircled. These 
images are then turned into black and white images and the one deducted from the other to 
generate the cytoplasm-only mask. A histogram was generated showing the pixel-breakdown 
in the cytoplasm of the different structures. This information was used to calculate the number 
of pixels falling within each phase, as well as the area analysed. This data, exported to 
Microsoft Excel was computed to calculate the mean intensity of immunolabelling per phase 
in (n) number of cells applying the unit pixel/µm2• 
2.12 STATISTICAL ANAL YIS 
Statistical analysis was carried out by the Instat 2 computer programme and reviewed by a 
statistician. Results are presented as the mean and standard error of mean (SEM). Significance 
was calculated by a two-tailed, unpaired Student's t-test, the Mann-Whitney test and the 
Kruskal-Wallis test. Levels of significance were determined using a 95 % confidence interval; 
a p-value < 0.05 was taken to be statistically significant. 
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APPENDIX (A) OF BUFFERS, REAGENTS 
AND METHODS 
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Appendix A 2.1.1 Consent form for Controls 
A 2.1.1.1 Normal subjects 
We plan to study hormones produced by patients with kidney disease and to compare this with 
normal subjects as yourself. You will be required to bring a 24-hour collection of urine and 
have blood taken from a vein in your arm. 
You are free to agree or refuse to participate in this study. 
Sicabanga ukwenza ucwaningo ngo'ju olukhiqizwa zindlala (hormones) emzimbeni Kololu 
cwaningo sizo qhathanisa ama hormones abantu abaguliswa yi zinso - na bantu abangaguli 
ndawo. Kuzo dingeka umchamo oqongelelwe ilanga lonke nobusuku bonke- uma useletha -
kuzo thathwa igazi engalweni nje ngoku jwayelekile. 
Ukhululekile ukwala uma ungathandi uku zibandakanya na lolu cwaningo. 
Name/ Igama Date 
A 2.1.1.2 Informed Consent for the Collection of Autopsy tissue 
To the guardian 
I wish to determine the role of peptides in kidney disease and compare the changes in disease 
with normal human tissue. To accomplish the above objective I need small samples of normal 
human tissue, which is most easily obtained from the post- mortem procedure. 
Please consent to the above so that I may be able to accomplish this investigation. 
Ngifisa ukubheka iqhaza elibanjwa ngama-enzyme ezifeni zezinso. Bese ngiziqhathanisa 
nalezo zabantu abangaka ngenwa yilezozifo. Ukuze lolocwaningo luphumelele ngingatho 
koza ukuthola isicutshana sense engenasifo. Lesosicutshana singatholakala kalula uma 
udokotela enza uqhaqho lokuthola imbangela yokufa komuntu, obengaphethwe yisifo sezinso. 
Ngicela usayine; usinike imvume yokukwenza lokhu, ngoba ngayo ngiyethemba lolucwaningo 
luyoba yimpumelelo. 
Igama Lomzali/ Umbheki kamufi 
Name of guardian 
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Date 
Appendix A 2.1.2 Consent form for patients 
As you know, your kidney is not functioning normally. It is essential that you have a 
procedure called "kidney biopsy" so that the cause of the kidney failure can be determined, in 
order that you may be treated correctly. A scan of the kidney will be done in the Ultrasound 
Department, and a fine needle will be passed into the kidney tissue (which will be made pain­
free by an injection of local anaesthetic) and a small amount of kidney tissue will be removed 
and will be sent to the Laboratory for diagnosis of your condition. A portion will be used for 
research to study localisation of peptides in kidney disease. After the biopsy, you may find 
blood in the urine, this usually settles in about 2 days. If it does not settle (which is rare), 
various treatments (including surgery) may be undertaken to stop the bleeding. 
Blood will be taken from a vein in the arm and urine will be collected on the day of the biopsy 
to study hormones produced by your kidney. 
You are free to agree or refuse permission for any of these procedures. 
Njengoba wazi ukuthi izinso zakho azisebenzi ngendlela efanele; kubalulekile ukuba 
kuthathwe isicutshana ensweni yakho; sihlolwe, ukuze kutholakale ukuthi kungani 
ingasebenzi ukuhlanza igazi nokwenza umchamo ngendlela efaneleyo. Lokhu kuyosiza 
kakhulu ekwelashweni kwakho. Uyoyiswa emafutheni (Ultrasound Department) lapho 
okuyofike kuthathwe khena isithombe sezinso. Kuyobe sekufakwa inalithi encane kwenye 
yesinzo zakho, kuthathwe isicutshana esincane senso. Yisona-ke esizoya kohlolwa ukuze 
kutholakale imbangela yokungasebenzi kwezinso zakho. Uyoqale unikwe umjovo, oyokwenza 
ukuba kube ndikindiki; ukuze kungabibuhlungu. 
Kuyobe sekuthathwa igazi engalweni yakho, kanye nomchamo ukuze kuyohlolwa kubhekwe 
izinjengezi (hormones) ezibalulekile empilweni yomuntu; ezikhiqizwa yizinso. 
Emva kokuthathwa kwesicutshana ensweni, kunokwenzeka umchamo wakho ube negazi. 
Ngokujwayelekile lokhu kuyaphela ezinsukwini mhlawumbe ezimbili. Uma kungapheli 
zikhona izindlela zokunqamula lokho kopha. Kungenzeka-ke nokho ugcine usuhlingwa ukuze 
kunqanyulwe ukopha, kodwa yinto engajwayelekile leyo neze neze. 
Imiphumela yalolucwaningo iyosiza impilo yakho; kodwa-ke ukhululekile ukwala uma 
ungathandi ukuzibandakanya nalolucwaningo. 
Name (Igama) Date 
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Appendix A 2.3: Reagents for Sample Collection (2.2), Processing and Storage (2.3) 
1. Sterile normal saline (NS) (0.9% NaCl, w/v, pH 7, Sabax)
2. SBTI (2720 rn1its/ml in 0.2 M Tris, Sigma)
3. Bacitracin (2840 units/ml in 0.2 M Tris, Sigma); 0.0147g in 10 ml
4. PBS (0.2 M; pH 7.4). NaH2PO4 3.12g; NaH2HPO4 11.32g; NaCl 8.5g
5. 5% formal saline (41 % formaldehyde / 0.9% NaCl, I :8 v/v) - dilute formaldehyde (35%,
Saarchem, SA) I :7 in 0.9% NaCl
6. 2% (w/v) paraformaldehyde (PF A) and I% (v/v) gluteraldehyde - dissolve 2 g PF A
(Saarchem, SA) in I 00 ml sodium cacodylate buffer (0.2 M, pH 7.2) at 60°C, and add 4 ml
of a 25% Gluteraldehyde solution (Saarchem, SA). Store at 4°C
7. Karnovsky's fixative ( 4% PF A, w/v and 2% gluteraldehyde v/v, pH 7.4) - dissolve 4 g PF A
in 100 ml sodium cacodylate buffer (0.2 M, pH 7.2) at 60
°
C, and add 8 ml of a 25%
Gluteraldehyde solution (Saarchem, SA). Store at 4°C
8. Sodium cacodylate buffer (0.2 M, pH 7.2) - dissolve 4.28g Cacodylic acid Na salt (Acros
Organics, USA) in I 00 ml dH2O. To 25 ml of this stock add 2.1 ml 0.2 M HCI { 1.7 ml
cone HCI (Saarchem, SA) made up to 100 ml with dH2O} and make up to 100 ml to
adjust to pH 7.2.
9. TK cocktail 40 mM Tris, pH 8 - dissolve 4.8 g Trizma base (Sigma Chemicals, St. Louis) in 
800 ml dH2O, adjust pH to 8.0 with HCI and adjust volume to 1 L.
10. Kinin generating cocktail: (60 mM EDTA, 6 mM phenanthraline, 10 uM captopril and 10
uM phosphoramidon) - all w/v and dry reagents purchased from Sigma Chemicals, St. Louis
11. Basal kinin and kinin inhibitor cocktail : (60 mM EDTA, 6 mM phenanthraline, 10 uM
captopril, IO uM phosphoramidon, IO uM SBTI and l 0 uM aprotonin) - all w/v and dry
reagents purchased from Sigma Chemicals, St. Louis.
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Appendix A 2.3.1.2 Fixation, Dehydration and Embedding schedule for light microscopy 
Reagents 
1. 5% formal saline ( 41 % formaldehyde / 0.9% NaCl, 1 :8 v/v) - dilute formaldehyde (35%,
Saarchem, SA) 1 :7 in 0.9% NaCl
2. Absolute ethanol (99% ethanol, Saarchem, SA)
3. Xylene (AR, Saarchem, SA)
4. Paraffin wax (Paraplast plus, Sherwood Medical, St. Louis, USA)
Procedure 
STEP SOLUTION 
1. Fixation - 5% formal saline
2. Fixation - 5% formal saline
3. Dehydration - absolute ethanol
4. Dehydration - absolute ethanol 
5. Dehydration - absolute ethanol 
6. Dehydration - absolute ethanol 
7. Dehydration - absolute ethanol 
8. Dehydration - absolute ethanol
9. Dehydration - absolute ethanol
10. Clearing - xylene
11. Clearing - xylene 
12. Vacuum infiltration I - paraffin wax 
13. Vacuum infiltration 2 - paraffin wax 
14. Embedding - paraffin wax 
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TEMP TIME 
24°C 1 h 
24°C I h 
24
°
C I h 
24°C I h 
24°C I h 
3s
0
c I h 
3s
0
c I h 
3s
0
c I h 
35
°
c 1 h 
3s
0
c I h 
3s
0
c I h 
60°C I h 
60
°
C I h 
20°c 20 min 
Appendix A 2.3.1.3 Fixation, Dehydration and Embedding schedule for electron 
microscopy 
Reagents 
1. 2% (w/v) paraformaldehyde (PF A) and 1 % (v/v) gluteraldehyde - dissolve 2 g PF A in I 00
ml sodium cacodylate buffer (0.2 M, pH 7.2) at 60°c, and add 4 ml of a 25%
Gluteraldehyde solution (Saarchem, SA). Store at 4°C
2. Karnovsky's fixative (4% PFA, w/v and 2% gluteraldehyde v/v, pH 7.4) - dissolve 4 g PFA
in 100 ml sodium cacodylate buffer (0.2 M, pH 7.2) at 60°c, and add 8 ml of a 25%
Gluteraldehyde solution (Saarchem, SA). Store at 4°C
3. Sodium cacodylate buffer (0.2 M, pH 7.2) - dissolve 4.28 g Cacodylic acid Na salt (Acros
Organics, USA) in 100 ml dH20. To 25 ml of this stock add 2.1 ml 0.2 M HCl {1.7 ml
cone HCl (Saarchem, SA) made up to 100 ml with dH20} and make up to I 00 ml to
adjust to pH 7.2.
4. Absolute ethanol (99% ethanol, Saarchem, SA)
5. Propylene oxide (Sigma Chemicals, St. Louis)
6. Araldite epoxy resin (Spurr, Electron Microscopy Sciences, Pennsylvania, USA)
Procedure 
STEP SOLUTION TEMP 
1. Fixation for TEM - Karnovsky's fixative RT 
2. Fixation for Immuno-electron microscopy - 2% PFA/1% 4°c
gluteraldehyde
-, 
_,. Second fixation for TEM - Karnovsky's fixative RT 
4. Store fixed tissue from 2 and 3 above in Sodium cacodylate 4°c 
buffer (0.2 M, pH 7.2) before embedding 
5. Sodium cacodylate buffer (0.2 M, pH 7.2) RT 
6. Dehydration - 70% ethanol RT 
7. Dehydration - 90% ethanol RT 
8. Dehydration - absolute ethanol RT 
9. Dehydration - absolute ethanol RT 
10. Dehydration - absolute ethanol RT 
11. Dehydration - absolute ethanol RT 
12. Clearing - Propylene oxide RT 
13. Infiltration - 50/50 propylene oxide and resin RT 
14. Infiltration - Pure resin RT 


















Appendix A 2.4.4.3a Isolation of IgG from serum 
Reagents 
I. Diethylaminoethyl sephadex (DEAE A-25, Sigma Chemicals, St. Louis) - in 50 ml wet
settled volume of 0.07 M phosphate buffer.
2. 14% Sodium sulphate - dissolve 0.14 g anhydrous Na2SO4 (Saarchem, SA) in I ml serum
3. 0.07 M Sodium phosphate pH 6.3 - dissolve 54.6 g NaH2PO4 (Saarchem, SA) in 5 1 dH2O
Method 
STEP SOLUTION TEMP. TIME 
I. Warm serum in water bath 25°C 15 min 
2. Add anhydrous sodium sulphate to make a 18% (w/v) 25
°
C 30 min 
solution, stir to dissolve and incubate
3. Centrifuge at 3000xg 25°C 30 min 
4. Discard supernatant, note volume of protein precipitate and 25°C 
redissolve in warm H2O up to half the original volume 
5. Add anhydrous sodium sulphate to make a 14% (w/v) 25°C 30 min 
solution, stir and incubate 
6. Centrifuge at 3000xg 25
°C 30 min 
7. Discard supernatant, redissolve precipitate in warm water up 4
°c ON 
to one third of starting volume and dialyse against 0.07M
phosphate buffer




9. Pack hydrated ion exchanger into a polypropylene column RT 
and wash with 3 column volumes 0.07 M phosphate buffer at
a flow rate 1 ml/min
10. Load - dialysate RT 
11. Elute - with 0.07 M phosphate buffer, collect 1 ml fractions RT 
12. Measure absorbance at 280 nm RT 
13. Pool fractions with highest absorbance 
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Appendix A 2.4.4.Jb Titre determination for anti-rTK antibody in rabbit and goat serum 
Reagents 
1. Human Urinary Kallikrein (HUK, Calbiochem, USA)
2. Coating buffer (Na2CO3/NaHCO3, pH 9.6) - dissolve 1.59 g Na2CO3 (Saarchem, SA) and
2.93 g NaHCO3 (Saarchem, SA) in 1 1 dH2O
3. 0.01 M PBS/ 0.5% (v/v) Tween - dilute 100 ul Tween 20 (Sigma Chemicals, St. Louis) in
200 ml 0.01 M PBS { 1 PBS tablet (Sigma Chemicals, St. Louis) dissolved in 200 ml
dH2O}
4. 5% (w/v) Milk protein blocker - dissolve 5g Country Pasteur fat free milk powder
(Nutritional Foods, SA) in 100 ml PBS. Make fresh.
5. Rabbit anti-goat (Sigma Chemicals, St. Louis) or sheep anti-rabbit (Boehringer
Mannheim, Germany) IgG conjugated to alkaline phosphatase
6. 0.1 M PBS/0.1 % BSA (w/v) - dissolve 1.56 g NaH2PO4 (Saarchem, SA), 5.66 g Na2HPO4
(Saarchem, SA) and 4.25 g NaCl (Saarchem, SA) in 800 ml dH2O, adjust to pH 7 with
HCl, add 1 g BSA (Fraction V, Boehringer mannheim) and make up to 1 I. Store at 4°C.
7. Phosphatase substrate (pNPP, Sigma Chemicals, St. Louis)
Procedure 
STEP SOLUTION 
1. Dilute HUK (stored at -20°C in aliquots of 1200 ng/400 ul
NS) in 4ml coating buffer (Na2CO3/NaHCO3 , pH 9.6) to
obtain 5 ug HUK/ml coating buffer
2. Coat ELISA plate (Corning) by adding 1 00ul of diluted
HUK to each well
3. Wash plate with 0.1 M PBS/Tween 
4. Block plate twice with 5%Elite/5%BSA 
5. Dilute serum 1/200; 1 /400; 1/800; 1/1600 and 1/3200 
with 0.1 M PBS/0.1 % BSA 
6. Load 1 00ul of diluted serum (triplicate). Blanks are wells 
filled with 100 ul 0.1 M PBS/0.1 % BSA 
7. Wash plate with 0.1 M PBS/Tween 
8. Load 1 00ul of alkaline phosphatase conjugated anti-goat 
or anti-rabbit IgG diluted 1/250 in 0.1 M PBS/0.1 % BSA 
9. Wash plate with 0.1 M PBS/Tween
10. Load plate with 100 ul 1 mg/ml phosphatase substrate and









37°c 60 min 
RT 3X3min 
37°c 60 min 
RT 3X3min 
RT 
Appendix A 2.4.4.3c Western Blot Analysis for Rabbit and Goat anti- human rTK IgG 
Reagents 
1. Recombinant tissue kallikrein (rTK, 750 ug/ml, supplied by Dr. Michael Kemme,
Institute for Biochemistry, Technical University of Darmstadt, Germany).
2. PBS pH 7.2 - dissolve 1 PBS tablet (Sigma Chemicals, St. Louis) in 200 ml dH20
3. 22 µm Nitrocellulose paper (Amersham, England)
4. 3 µm Whatman paper (Whatman, England)
5. Blocking solution (Boehringer Mannheim, Catalogue No. 258576)
6. Rabbit and goat anti-human rTK IgG isolated in 2.4.3
7. TBST {10 mm Tris pH 9.5, 150 mM NaCl, 0.05% (v/v) Tween 20}
8. 3% (w/v) BSA in TBST - dissolve 3 g BSA (Fraction V, Boehringer Mannheim)
9. Secondary antibodies:
9.1 Alkaline phosphatase conjugated rabbit anti-goat IgG (Sigma chemicals, St. Louis)
diluted 1: 10000 with TBST 
9.2 Sheep anti-rabbit IgG conjugated to alkaline phosphatase (Boehringer Mannheim, 
Germany) diluted 1 :3000 with TBST 
10. Detection buffer (0.1 M Tris-HCI, 0.05M MgC]z, 0.1 M NaCl, pH 9.5)
11. Chromogen 0.375 mg/ml NBT (nitro blue tetrazolium chloride)/0.188 mg/ml BCIP (5-
bromo-4-chloro-3-indoyl-phosphate)
12. 0.05M EDTA ( ethylenediamine-tetra-acetic acid) (Sigma, St. Louis) pH 8
13. 40% Acrylamide Stock solution (w/v) - dissolve 40 g acrylamide (Sigma Chemicals, St.
Louis) and 1.07 g N,N'-Bisacrylamide (BDH, UK) in 100 ml dH20 by stirring in the dark
with a bit of Amberlite mixed bed ion exchange resin (Sigma chemicals, St. Louis). Filter
through 0.45 um millipore filter and store at 4°C
14. 1.125 M Tris, pH 8.8 (w/v)-dissolve 136.12 g Trizma base (Sigma Chemicals, St. Louis)
in 800 ml DEPC treated H20, adjust to pH 8.8 with HCl and make up to I L.
15. 10% Sodium dodecyl sulphate (SDS, w/v) - dissolve 10 g SDS (Amresco, Ohio, USA) in
100 ml DEPC treated H20
16. TEMED (BDH, UK)
17. 10% Ammonium peroxodisulphate (APS, w/v)- dissolve 10 g APS (BDH, UK) in 100
ml dH20.
18. 0.5 M Tris, pH 6.8 - dissolve 61.5 g Trizma base (Sigma Chemicals, St. Louis) in 800 ml
DEPC treated H20, adjust to pH 6.8 with HCI and make up to 1 L.
19. Loading buffer (10% SDS, 1 % bromophenol blue, 5% 13-mercaptoethanol, 1 % glycerol,
0.5M tris-HCl pH 6.8)
20. Prestained low range standards - Ovalbumin 43 kDa, Carbonic anhydrase 29 kDa,
Lactoglobulin 18.4 kDa, Lysozyme 14.3 kDa, Bovine Trypsin Inhibitor 6.3 kDa, Insulin
2.9 kDa (Life Technologies former Gibco/BRL, Germany)
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21. Low range molecular weight markers - lysozyme 14.4 kDa, trypsin inhibitor 21.5 kDa,
carbonic anhydrase 31 kDa, ovalbumin 45 kDa, serum albumin 66.2 kDa and
phosphorylase B 97.4 kDa ( Biorad, USA)
22. Running Buffer (0.4M glycine, 0.02M SDS, 0.12M Tris-HCI, pH 8.3 )
23. Transfer buffer (10% methanol, 0.025M Tris-HCI, 0.192M glycine, pH 8.3 )
24. 0.4% Tween 20/PBS (200 µl Tween 20 in 50 ml PBS)
25. India ink solution {50 µl India ink ( Pelikan drawing ink A, Pelikan, Germany) in 50 ml
0.3% Tween 20/PBS}
26. Composition of Running and Stacking gels
15% Running gel 5% Stacking Gel 
40% Acrylamide Stock 18 ml 2.5 ml 
1.125 M Tris, pH 8.8 16 ml 5 ml 
dH2O 14 ml 12.5 ml 
10% SDS 480 ul 200 ul 
TEMED 20 ul 25 ul 
10% APS 200 ul 150 ul 
Procedure 
CHECKERBOARD TEST FOR ANTIGEN AND ANTIBODY DILUTION 
STEP PROCEDURE TEMP TIME 
1. Serially dilute rTK stock (250 to 0.9 ng/ml) with PBS
2. Cut Nitrocellulose paper into 8 mm x 8 cm strips
3. Spot 1µ1 of each dilution of rTK l cm apart on each of the RT lh
nitrocellulose strips and dry on Whatman paper 
4. Block non-specific binding sites with 1 x blocking solution RT 2xl0 min 
with shaking 
5. Prepare serial dilutions of rabbit & goat anti-human rTK fgG 4
°
C ON 
with 3% BSA in TBST and incubate with shaking 
6. Wash in TBST RT 3Xl0min 
7. Incubate with secondary antibody RT 3 h 
8. Wash in detection buffer RT 3Xl0min 
9. Incubate with chromogen solution in the dark RT few min 
10. Stop reaction with 0.05M EDT A RT 5-10 min 
11. Wash with dH2O RT 30 min 
12. Press dry between Whatman paper, mount, seal in cellophane
& determine optimal rTK cone.& Ab dilution
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SOS-PAGE 
I. Clean Mini Protean® II Electrophoretic cell (Biorad, USA) 
with 70% alcohol and dH20 and assemble 
2. Prepare 15% running gel and pour into gel tank RT 1 h 
3. Mix 20 ul of 1 mg /ml concentrations of MWM, antigens and 95 OC 5 min 
control proteins with 14 ul loading buffer Ice Until use 
4. Prepare 5% stacking gel and pour into gel tanks RT I h 
5. Load wells with 10 ul of each protein from 3 in duplicate
6. Assemble apparatus and electrophoresis at 160 m V l h
ELECTROPHORETIC TRANSFER 
I. Cut Whatman paper & nitrocellulose membrane
2. Equlibrate gel, Whatman paper, nitrocellulose membrane and RT 2-3 min
Biorad fibre pads in transfer buffer
3. Assemble Mini Transblot® Electrophoretic transfer cell
(Biorad, USA) with gel (reversed left to right) closer to
negative electrode & nitrocellulose near +ve eloctrode
4. Perform protein transfer at 90 Ma 2h 
5. Remove and cut nitrocellulose membrane
IMMUNOBLOTTING 
I. Block non -specific binding sites with 1 x blocking solution RT 30 min 
2. Wash in PBS RT 3XI0min 
" 
.) . Incubate with 1 ° Ab diluted in in 1 x blocking solution 4°c overnight 
4. Wash in TBST RT 3Xl O min 
5. Incubate with 2° Ab diluted in TBST RT 3 h 
6. Wash in detection buffer RT 3Xl0 min 
7. Incubate with chromogen solution in the dark RT few min 
8. Stop reaction with 0.05M EDT A RT 5-10 min
9. Wash with dH20 RT 30 min 
10. Press dry between Whatman paper, mount, seal in cellophane 
& determine optimal rTK cone.& Ab dilution 
PROTEIN STAINING 
I. Wash with 0.4% Tween 20/PBS RT 2x 5 min 
2. Place in ink solution RT 15 min 
3. Destain with multiple washes of PBS RT Few min 
4. Dry on Whatman paper, mount and seal in cellophane 
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A-2.5.1 ENDOTHELIN-1 ELISA (PLASMA AND URINE)
(A) SAMPLE COLLECTION AND PRE TREATMENT
1) Collect whole blood from recumbent patients in chilled sodium EDTA (2 mg/ml) tubes and
centrifuge immediately at 1400xg for 20 min at 4°C. 
2) Transfer plasma into polypropylene tubes with 200 ul kinin cocktail and store at> -20°C.
3) Collect urine in 200 ul/ Bacitracin/SBTl solution; centrifuge at 3000 rpm for 20 min at
40c.
4) 1 ml of supernatant is placed into polypropylene tubes with 200ul of kinin cocktail and
stored at -20°C. 
(B) SAMPLE PREPARATION
1) Holding the Sep-Pak C-18 column (Waters, Milford, USA) vertically, wash it by injecting
5ml of the following solutions, in the order shown : eluent, methanol, distilled water, 4% 
acetic acid. The eluant comprised 10ml dH2O, 4ml acetic acid and 86ml ethanol. 
2) Fix a I Om! syringe (without the plunger) to the activated Sep-Pak column and add a small
amount of 4% acetic acid with a micropipette to remove air bubbles in the connection between 
the column and the syringe. 
3) Add 3ml 4% acetic acid into a polypropylene tube containing I ml plasma and mix well.
4) Transfer this mixture of plasma and 4% acetic acid into the syringe and let the specimen
pass through the Sep-Pak column by gravitation. 
5) Wash the wall of the polypropylene tube with I ml 4% acetic acid and transfer this into the
syringe and let it pass through the column. 
6) Wash the column with 10 ml of distilled water.
7) After all the water has passed through the column, remove the column from the IO ml
syringe and fix it to a 5ml syringe and elute the absorbed fraction with 4ml of eluent into a 
polypropylene tube. 
8) The eluate is then evaporated to dryness under a stream of nitrogen at 3 7°C.
9) Add I ml ethanol to the dry residues thus obtained, mix well with a vortex mixer to obtain a
suspension of the residues. 
10) Evaporate the suspension to dryness under a stream of nitrogen at 3 7°C.
11) The dry residues are reconstituted with 250ul of buffer solution (50mM Good's buffer, pH
8.0) mixed with a vortex mixer and sonicated for IO min. 
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12) The suspension is transferred to a microfuge tube and centrifuged ( 12000 rpm r 5 min.
13) The supernatant obtained is used for Endothelin-1 assay.
(C) ENDOTHELIN-1 MEASUREMENT
The solution from the microplate wells (Wako Chemical Industries, Osaka, Japan) is removed 
before use and the plate washed three times with washing solution (PBS). 
1) Prepare Endothelin-1 standards by adding 1 ml of buffer solution to one bottle of standard
Endothelin-1 (I ng/ml), dissolve and transfer the solution to a polypropylene tube. 
3) Serial dilutions with Good's buffer were made using five polypropylene tubes to obtain
standards of 200, 40, 8,2, and 0 pg/ml. 
4) Add 50ul of buffer solution to all wells and add I 00ul of standard solutions prepared above
and samples in duplicate. 
5) Mix gently, seal the plates with parafilm and incubate for 24 hours at 4°C.
6) Wash the plate 4 times with PBS using an automated plate washer (BioTek Instruments
Inc. Model ELP-40). 
7) Add IO0ul of the peroxidase labelled anti-ET 1 polyclonal antibody (1.5 µg/ml; raised in the
rabbit) solution to all wells except those containing the reagent blanks. 
8) Add I 00ul buffer solution to wells with reagent blanks.
9) Mix gently, seal the plate with parafilm and incubate at 4°C for 24 h.
10) Remove the reaction mixture and wash the plate 4 times with PBS.
11) Add 100 ul colouring reagent (O-phenylenediamine 14.4mmol/l) to all wells, mix gently
and allow it to stand for 60 min at room temperature in the dark. 
12) Stop the reaction by adding 100 ul reaction terminator (sulphuric acid 49mg/ml) to all
wells. 
13) Measure the absorbances of the samples and standards against the reagent blank by a
microplate reader (Bio-tek Model ELX800) at 492 nm. 
14) A graph is plotted on logarithmic graph paper using the absorbance of each standard
(ordinate) against its Endothelin-1 concentration (abscissa). 
15) Endothelin-1 concentration of the samples can be read directly from this curve by plotting
the measured absorbance and dividing by 4, as the actual specimens used for endothelin-1 are 
concentrated 4 times. 
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A-2.5.2 ANP RIA PROCEDURE
MATERIALS 
• RIA Buffer Concentrate ( 4x), 50ml
• Standard Peptide; 12.8 g lyophilized powder
• Rabbit antiserum specific for the peptide; lyophilized powder for 13 ml
• 1251-Peptide; lyophilized powder (1.5 µCi)
• Goat Anti-Rabbit IgG serum (GARGG); lyophilized powder for 13 ml
• Normal Rabbit Serum (NRS); lyophilised powder for 13 ml
• Instructions/flow sheet of RIA protocol and guidelines for the calculation results
• Data sheet
DAY 1: 
1. With distilled water, dilute the RIA Buffer Concentrate to a final volume of 200ml. Vortex
at room temperature. This buffer will be used to reconstitute all of the other components in 
this kit and should be used for dilution of samples, if needed. 
2. Reconstitute the standard peptide with I ml of RIA buffer.
3. Reconstitute the rabbit anti-peptide serum with 13 ml of RIA buffer.
4. Reconstitute the samples with the RIA buffer. Prepare a dilution series of the standard
ranging from 0.1 pg- 64 pg/tube.
5. Set up the initial RIA reactions in 12x75 mm polystyrene tubes.
a) Label tubes : TC-I, TC-2, NSB-1, NSB-2, TB-I, TB-2 and #7-22 for the standards
(where TC is total counts, NSB is non-specific binding and TB is total binding).
b) Label tubes #23-125 for the unknown samples.
c) Pipette 200 µl of RIA Buffer into the TC and NSB tubes.
d) Pipette 100 µl of RIA Buffer into the TB tubes.
e) Pipette 100 µl of the standards I through B into duplicate tubes #7-22.
f) Pipette 100 µl of primary antibody (rabbit anti-peptide serum) into TB-1, TB-2 tubes,
#7-22 tubes, and tubes #23 and higher. DO NOT ADD ANTIBODY TO THE TC
AND NSB TUBES.
g) Vortex the contents of each tube.
h) Cover and incubate overnight (16-24 h) at 4°C.
6. Cover and store all rehydrated solutions at 4°C, except for the standard peptide solution
which should be kept frozen at -20°C, or lower, for maximum stability.
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DAY2: 
7. Reconstitute the 1251-Peptide with l ml of RIA buffer. Mix thoroughly (this is your stock
solution). After rehydration, cover and store the tracer solution at -20°C, or lower, for
maximjum stability.
8. Combine X µI of 125 I-Peptide with X ml of RIA buffer and mix well. Measure with a
gamma counter to achieve between l 0000-15000 cpm. 
9. Add 100µ1 of the tracer to each solution test tube in the assay.
10. Vortex each test tube.
11. Cover and incubate overnight (16-24 h) at 4°C.
DAY3: 
12. Reconstitute the Goat Anti-rabbit IgG serum (GARGG) with 13ml of RIA buffer.
13. Reconstitute the Normal Rabbit Serum (NRS) with 13 ml of RIA buffer.
14. Add 100 µl of GARGG to every test tube.
15.Add 100 µI ofNRS to every test tube.
16. Vortex each tube and incubate at room temperature for 90 minutes.
17. Add 500 µl of RIA Buffer to each tube and vortex.
18. Centrifuged the samples at 3,000 rpm (approx. l 700xg) for 20 minutes at 4°C.
19. Set aside the TC tubes. DO NOT ASPIRATE THE TC TUBES.
20. For the remaining tubes, carefully aspirate the supernatant (do not decant since the pellet
may be lost or excess liquid may be left in the test tube).
SUMMARY OF ASSAY PROTOCOL 
1. Add sample or standard and antiserum.
2. Vortex and incubate overnight (16-24 h) at 4°C.
3. Add 1251-Peptide.
4. Vortex and incubate overnight (16-24 h) at 4°C.
5. Add GARGG and NRS.
6. Vortex at room temperature for 90 min.
7. Add RIA buff er.
8. Vortex and centrifuge for 20 minutes at l 700xg.
9. Aspirate off the supernatant (except TC tubes).
10. Count assay tubes.
11. On semilog graph paper, determine the concentration of samples against known standards.
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Appendix A 2.5.3.la T K Functional Microassay (Amidase) 








0.2 M Tris-HCl, pH 8.2 
300 ug/ml SBTI and 375 ug/ml EDTA in 0.2 M Tris-HCI pH8.2 
1.5 M in deionised water, (Chromogenix, Sweden) 
1.47 g/ml of SBTI (Sigma); 2720units/mg, 40 mg/ml Bacitracin 
(Sigma) in 0.2 M Tris-HCl, pH 8.2 
1. Urine samples (approx 15ml) collected immediately in 200 ul SBTI/Bacitracin /Tris-HCl
buffer at 4°c, and thereafter stored in 200 ul 0.2 M Tris-HCI pH 8.2 per l 000 ul sample, in
l ml aliquots, at -20°c.
2. One set of plain urine samples collected and stored, without any buffer, for total protein
determination, at -20°c
Method: 
1. On two sets of plates, 50 ul HUK (Protogen) of each standard human urinary kallikrein
(400 ng/ml - 12.5 ng/ml, in 0.2 M Tris-HCl pH8.2) is to be added to 50 ul Assay buffer
containing SBTI and EDT A. One plate is incubated at 3 7°c for 30 min. ( on tissue culture
plates, Corning Cell Wells™, 25860, Corning, New York). To the other plate, 50 ul dH2O
is added to each of the wells and the plate is read at 405 nm on Biorad Microplate Reader
(model 3550). This would determine the zero activity blank.
2. To the incubated plate, add 50 ul of the substrate S2266 and incubate again for 3 h at 37°c.
3. Read at 405 run on microplate reader.
4. 50 ul Standard/samples done in triplicate
5. Blanks will only contain assay buffer.
6. Total protein measurement done according to Bradford determination.
(300 ul Biorad bradford reagent, diluted 1/5 in dH2O, added to 30 ul of sample/Std. and
read at 595 run. Blanks are dH2O.)
7. Activity expressed as ngTK/ ug protein
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Appendix A 2.5.3.2b Measurement of Total protein [Bradford, 1976/ 
Reagents 
I. Bovine Serum Albumin (BSA, Fraction V, Boehringer Mannheim)
2. Biorad Protein Assay Reagent (Biorad, UK)
Procedure 
STEP SOLUTION 
1. Protein standard - 100 ml of 1 mg/ml BSA was prepared and stored in 1 ml
aliquots at -20C. A single I ml aliquot of this standard was serially diluted with
dH20 from 1000 to 16 ug/ml. 30 ul of each dilution was added to a microassay
plate in triplicate.
2. Blank - 30 ul dH20 was added to 3 wells of the plate
3. Samples - were added in triplicate to the plate
4. Biorad Protein Assay Reagent - was diluted 1/5 in dH20 and 300 ul was added to
each well of the plate
5. Read absorbance at 595 nm immediately
6. Calculation - subtract the absorbance of the blanks from the absorbance of the 
standards and samples. 
Plot absorbance vs concentration of BSA standards. 
Read protein concentration of samples from this graph. 
7. TK enzymic activity is expressed as ng TK / ug protein 
All stages are performed at RT 
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Appendix A 2.5.3.3 TK ELISA 
Reagents and Immunochemicals: 
1. Coating buffer (Na2CO3/NaHCO3 , pH 9.6)
2. Substrate buffer (5 mM MgCli/10% Diethanolamine, pH 9.8)
3. Milk protein blocker (5% Elite)
4. PBS/Tween (0.01M phosphate buffered saline/0.5% Tween 20)
5. Human Urinary Kallikrein
6. Goat anti-human TK IgG (30 ng/ml)
7. Rabbit anti-human TK IgG (25 ng/ml)
8. Anti-rabbit alkaline phosphatase (Sigma)
9. diphenylparanitroalaninephosphate substrate tablets (pNPP, Sigma)
Procedure: 
1. Coat the ELISA plate (Corning) with 100 ul, 30 ng/ml Goat anti- human TK in coating
buffer and incubate overnight at 4°c. (Make one vial up to 10ml)
2. Wash the plate 3x3min with PBS/Tween. Block with 200 ul of milk blo(.;ker for 30 min at
room temperature (RT). Wash again. Repeat blocking step. Wash.
3. Load the plate with 100 ul of sample or standard and incubate for 1 hr at 37°c (water bath).
Wash.
4. Load the plate with 100 ul, 25 ng/ml of rabbit anti- human TK and incubate for 1 hr at 37°c
(water bath). (Make one vial up to 12ml). Wash.
5. Incubate with 100 ul of anti-rabbit alkaline phosphatase (1:250 dilution in 0.0IM PBS).
Wash
6. Add 100 ul of I mg/ml pNPP substrate to the wells (1 tablet in 5 ml of substrate buffer) and
allow colour to develop for 1 hr.
Controls: Urine pool controls double-diluted from 1/8 to 1/512 in 0.0 I M PBS. 
Also, known samples are rerun to test for interassay variation 
Blanks: Use 0.01 M PBS instead of samples or standards. 
Standard Curve: Different concentrations of Human Urinary Kallikrein were run and a 
linear-linear relationship was obtained -200 ng/ml double diluted down 6X . 
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Appendix A 2.5.4 KININ ELISA 
Conjugation 
Reagents: 
1. SDP- 13 uM in 0. lM Phosphate buffer pH 8.6, 20% Ethanol
5 mg SPDP (Sigma P3415) + 500 ul phosphate buffer+ 200 ul ethanol
first dissolve SPDP in EtOH, and then add buffer
2. Cytochrome C- 10 uM in 0.1 M phosphate buffer pH 8.6
1 mg cytochrome C (Sigma C6913) + 833.33 ul phosphate buffer.
3. Bradykinin lmM
1 mg BK (Sigma)+ 943 2 ul O.OJM PBS pH 7.4
Method: 
1. Mix 1 volume SPDP with 1 volume Cytochrome C, and incubate at 22°c for 60 min.
2. Filter solution through ultra-free (Millipore) 10 000 nominal weight cut off filters to
remove any unconjugated SPDP ( may require 2-3 h).
3. Resuspend top part in two volumes of 0.3 M phosphate buffer pH 6 ( i.e. to give
original volume)
4. Add one volume of BK and incubate at 22°c for 60 min. Each batch of conjugate has to be 
tested for optimal concentration before use in ELISA (usually this is between 3-4 ug/ml
protein or approx. 1: 160 dilution).
5. Store at -200c in aliquots after testing for optimum concentration.
ELISA procedure: 
1. Coat Nunc Immulon Maxisorp™ microtitre plate overnight with 100 ul/well of
cytochrome-SPDP-BK conjugate (optimal concentration determined for each batch: ± 3-4
ug/ml) in sodium carbonate/coating buffer, pH 9.6 at 4°c.
2. Also overnight at 4°c, incubate sample or standard with equal volume of SBKl a-BK
antibody (1: 1000 in PBS)
3. The next day, wash plate with 0.0lM PBS/ 0.5% Tween, 3X3min; and then block plate
with 200 ul of 5% Milk blocker.
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4. Incubate for 30 min at room temperature (RT). Wash with PBS/Tween 3X3min and repeat
blocking step. Wash again.
5. Incubate 100 ul/well of preincubated sample or standard for 3 hrs/ 37°c. Wash.
6. Incubate l 00 ul/well with alkaline phosphatase labelled a-mouse lgG (1 :250 in PBS) for 2
hrs at 37°c. Wash.
8. Finally add l 00 ul of the substrate pNPP ( l  mg/ml in coating buffer) to the plate and
incubate at RT for approx. l hr, or until sufficient maximum absorbance values obtained at
405 nm (±1.8 AU) on Biorad microplate reader
Blanks: 
Non-specific binding to the plate was determined by incubating only SBKl a-BK (l/1000 in 
PBS (preincubated with equal volume of PBS buffer). 
The wells used for the blanks were coated with coating buffer only, and no conjugate. 
Endogenous (basal) kinins and Kinin Generation for ELISA measurement. 
Urine 
Reagents: 
1. Kininase inhibitor cocktail: kinin cocktail excluding SBTI and Aprotinin
2. Acid-Alcohol: absolute Ethanol/ 0.1 % cone. HCI
Methods: 
A: Endogenous (basal) kinins 
1. Thaw urine and centrifuge at 5000xg/10 min/4°c (stored in KI cocktail wth SBTI
and Aprotinin)
2. Remove 500 ul and add to 500 ul acid-alcohol and place at -20°c for 90 min.
3. Centrifuge (5000xg/10 min/4°c) and keep supernatant.
4. Wash pellet with 500 ul of acid-alcohol (I :2 in dH2O) and centrifuge (5000xg/l 0
min/4°c).
5. Pool supernatants and place in 24-well cell culture plate and evaporate to dryness at 55°c
overnight.
6. Resuspend dry residue in 500 ul ( original volume) of assay buffer and
centrifuge(S000xg/10 min/4°c). Use clear supernatant for ELISA measurements.
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B: Kinin Generation 
1. Thaw urine and centrifuge at 5000xg/10 min/4
°c (stored in KI cocktail without SBTI
and Aprotinin)
2. Mix 500 ul of urine with 500 ul kinin cocktail and incubate for 60 min at 3 7°c.
3. Remove 500 ul and add to 500 ul acid-alcohol and place at -20°C for 90 min.
4. Centrifuge(5000xg/10 min/4°c) and keep supernatant.
5. Wash pellet with 500 ul of acid-alcohol (1 :2 in dH20) and centrifuge (5000xg/l 0
min/4°C).
6. Pool supernatants and place in 24-well cell culture plate and evaporate to dryness at 55°c
overnight.
7. Resuspend dry residue in 500 ul (original volume) of assay buffer and centrifuge
(5000xg/10 min/4°c). Use clear supernatant for ELISA measurements.
C: Controls 
I. BK STD. CURVE: Bradykinin diluted to give concentrations of 150 ng/ml double-diluted
down to 2.34 ng/ml in PBS buffer.
2. CONTROLS: Urine pool, spiked at 2 concentrations of BK ( I 00 & 50 ng/ml) Acid-alcohol
extraction. Gives the variation for the extraction procedure and ELISA at two
concentrations of BK.
Urine pool samples are spiked with BK and the double-diluted to determine whether
concentrations of BK linearly diluted out with dilutions of urine
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Appendix A 2.6.2 IMMUNOCYTOCHEMISTRY: PAP METHOD 




100 % EtOH 




3. Boil (80°c) in 0. lM Na-citrate pH 6.0 ( microwave)
Allow to cool to room temp
place in dH2O
4. Use Dako PAP marker and wash in 0.0lM PBS/1 %BSA.
5. Incubate in 10% H2O2/ 95 % MeOH
Wash in 0.01M PBS. 
..... 2 xl0 min/ RT 
.... .2 x 5 min/ RT 
..... 1 x 20min/R T 
..... 2 x 4 min/ RT 
..... 1 x 3 min/ RT 
..... 1 x 5 min/ RT 
..... ± 3min HIGH 
..... 5min LOW 
..... ± 20min 
.... ±5min 
..... 2 x l 5min/RT 
6. Incubate with l O antibody ( diluted in Maleic acid/ milk blocker)
Incubate overnight at 4°c under humid conditions. 
Wash in 0.0lM PBS 
7. Incubate with Biotin link (DAKO K0690)
Wash in 0.0lM PBS . 
20 min/RT 
8. Incubate with Strepavidin 2° antibody (DAKO K0690) ..... 20 min/RT 
Wash in 0.0lM PBS. 
9. Incubate with liquid DAB (Dako)
10. Counterstain in Mayers' Hemotoxylin
Wash in tap H2O
11. Dehydrate tissue through EtOH into Xylene




* Method controls are l O antibody replaced with buffer or non-immune serum.
* All dilutions made up in 0.01M PBS/ 1 %BSA.
* Do not allow tissue sections to dry out.
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Appendix A 2.6.3 IMMUNOFLUORESCENCE 









.... 2 x 10 min/ RT. 
.... 2 x 5 min/ RT. 
..... 1 X 20 min/RT. 
..... 2 x 4 min/ RT. 
.... 1 x 3 min/ RT. 
.... 1 x 5 min/ RT. 
3. Boil (80°c) in 0. lM Na-citrate pH 6.0 ( Ag retrieval) ±3. min HIGH 
Allow to cool to room temp
place in dH2O 
4. Use Dako marker and wash in 0.0 l M PBS/0.1 %BSA
Incubate with 1 % Human IgG
Wash in 0.0IM PBS.
.... 5 min MED LOW 
.... ±20 min 
.... 15 min/RT. 
5. Incubate with 1° antibody (diluted in 0.0lM PBS/I %BSA)
Incubate overnight at 4°c under humid conditions. 
Wash in 0.0IM PBS. 
6. Incubate with anti-species Fluorescent conjugate
Wash in 0.0 lM PBS. 
7. Mount with 10 % PBS/90 % glycerol.
*Method controls are 1 ° antibody replaced with buffer
* All dilutions made up in 0.1 M PBS/0.1 %BSA.
* Do not allow tissue sections to dry out.
* Store labelled slides in the dark.
* Only antigen retrieval done in microwave.
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.... .30 min/RT. 
Appendix A 2.6.4 IMMUNO-ELECTRON MICROSCOPY 
Tissue fixation and processing for Immunoelectron microscopy. 
Biopsy tissue for immuno-electron microscopy was immediately immersed in 4 % PF A/ 1 % 
gluteraldehyde fixative for 2 h at 4°C, then transferred to 0.2 M sodium cacodylate buffer, pH 
7.2, maintained at 4°C. The fixed tissue was dissected into lmm3 sections and processed in an 
automatic Reichert-Lynx em tissue processor. During processing the specimens were retained 
in baskets at a fixed processing station and agitated. The specimens rotated through a 
preprogrammed sequence as outlined in Table l. 
TABLE 1. Dehydration and Embedding schedule for immunoelectron microscopy 
STEP SOLUTIONS TEMP TIME 
1 Sodium cacodylate buffer (0.2M, pH 7.2) 4°c 10 min 
2 Sodium cacodylate buffer (0.2M, pH 7.2) 4°c 10 min 
3 Dehydration - 70% ethanol 4°c 30 min 
4 Dehydration - 90% ethanol 20°c 30 min 
5 Dehydration - absolute ethanol 20°c 15 min 
6 Dehydration - absolute ethanol 20°c 15 min 
7 Dehydration - absolute ethanol 20°c 15 min 
8 Dehydration - absolute ethanol 20°c 15 min 
9 Intermediate solvent - Propylene oxide 20°c 30 min 
10 Infiltration - 50/50 propylene oxide and epoxy resin 20°c 30 min 
11 Infiltration - Spurr epoxy resin (Spurr ARJ, 1969) 60°C 60 min 
12 Infiltration - Spurr epoxy resin 60°C 60 min 
13 Polymerization - Spurr epoxy resin 60°C 48 h 
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Ultramicrotomy 
Semi-thin section (lµm) were cut with a Reichert Ultra cut ultramicrotome using glass knives. 
Sections were collected onto glass slides, heat-fixed, stained with 1 % alkaline toluidine blue 
and examined with a Nikon Optiphot photomicroscope. Fields of interest were selected and 
located on the block face, and the block trimmed to produce a "mesa" with a trapezoidal 
shape. Ultrathin section (50-60nm) were cut and collected onto uncoated Nickel grids prior to 
immunostaining 
Immunostaining (see Table 2) 
a. Etch Nickel grid by floating on a droplet of 5 % hydrogen peroxide for 5 min.
b. Place grid in a drop of distilled water for 1 min then jet wash into 10 ml distilled water and
dry on fibre free paper. 
c. Submerge grid in blocking medium (non-immune serum from species in which primary
antibody was raised) for 30 min and blot dry on filter paper. 
d. Incubate grid in a 30 µl droplet of primary antibody for 3 h. Optimised antibody dilution in 
50 mM Tris. (pH 7.2). 
e. Submerge grid in droplet of 50 mM Tris (pH 7.2) for l min then jet wash grid with 20ml
50 mM Tris. (pH7.2). 
f. Submerge grid in droplet of 50 mM Tris containing 0.2 % BSA (pH 7.2) for 5 min, then jet
wash grid with 20ml 50 mM Tris containing 0.2 % BSA (pH 7.2). 
g. Submerge grid droplet of 50 mM Tris containing I% BSA (pH 8.2) for 5 min.
h. Incubate grid secondary antibody (IgG against primary antibody-raised in a different
species conjugated to l 0nm immunogold particles) diluted 1 : 200 in 50 mM Tris (pH 8.2) for 
l h.
i. Droplet wash (1 min) and jet wash grid with 20ml of the following series ofreagents.
a) 50 mM Tris containing 0.2 % BSA (pH 7.2).
b) 50 mM Tris (pH 7.2).
c) Distilled water.
d) Counterstain with saturated ethanolic uranyl acetate for 5 min.
e) Jet wash in 20 ml distilled water and blot dry.
f) Incubate grid in Reynolds lead citrate for 3 min.
g) Jet wash well with distilled water and blot onto filter paper.
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TABLE2 I t . .  : mmunos ammg 
STEP PROCESS REAGENT TIME 
1 Etching 11202 (5 %) 3 min 
2 Wash 10 ml grid distilled 
3 Blocking Blocking medium (nonimrnune serum from rabbit 30min 
4 Incubation Primarv antibody (see notes) l 80min
5 Jet wash 50mM Tris (pH 7.2) -20 ml per grid 
6 Jet wash 50mM Tris+ 0.2% BSA (pH 7.2) 20ml/grid 
7 Jet wash 50 mM Tris + 1 % BSA (pH 8.2) 20ml/grid 5 min 
8 Incubation Secondary antibody (anti-rabbit) conjugated to 60 min 
l 0nm immunogold particles 1 : l 00) IN 50mM
Tris pH 8.2
9 Jet wash 50 mM Tris+ 0.2% BSA pH 7.2 20 ml per grid 
10 Jet wash 50mM Tris pH 7.2 20 ml per grid 
11 Jet wash Distilled water 20 ml per grid 
12 Stain Saturated ethanolic uranyl acetate 5 min 
13 Jet wash Distilled water 20 ml per grid 
14 Counterstai Reynold's lead citrate (Reynolds ES, 1963)* 3 min 
n 
15 Jet wash Distilled water 20 ml per grid 
Grid can be stored at room temperature in a grid box until viewed. 
Control samples : 
Method Control : Step ( d) : instead of primary antibody, 50 mM Tris pH 7.2 was used. 
Primary antibodies : 
ET 1 : rabbit anti ET 1 antibody (Biogenesis, Poole, UK) 
ETA receptor : rabbit anti ET A antibody ( donated by Werner MUiler-Ester!) 
ET 8 receptor: rabbit anti ET 8 antibody (donated by Werner MUiler-Ester!) 
Dilutions : 
ET i l : 100 
ETA 1 : 1000 
ETa I: 1000 
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A 2.7 JN SITU REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION (in 
situ RT-PCR) 
SOLUTIONS 
2 % 3-Aminopropyltriethoxysilan in acetone 
Add 2 ml 3-Aminopropyltriethoxysilan to 98 ml of acetone. 
0.1 % DEPC dH2O 
• Add I 00 µl of DEPC to I 00 ml dH2O i.e. I ml of DEPC to I L dH2O
1 M Phosphate Buffered Saline (PBS), pH 7.4 (1 L ) 
29.25g Na2HPO4 x H2O ; 4.90g KH2PO4; 160.00g NaC 
• Dissolve the above in 1000 ml distilled H20.
• Autoclave
0.05 M Phosphate Buffered Saline (PBS). pH 7.4 (1 L ) 
• 50 ml IM PBS, pH 7.4 (I l )  + 950 ml dH2O
4 % Paraformaldehyde in PBS 
• Dissolve 40 g of Paraformaldehyde in 800 ml of 0.05M PBS.
• Place on a heating plate with stirrer and heat the solution to about 80 °C.
• The paraformaldehyde has dissolved when the solution is clear.
• Top up the volume to I 000 ml with 0.05 M PBS and allow to cool.
• Filter the solution through 2 layers of Whatman filter paper No. I and store at 4°C.
I M  Tris HCl, pH 7.5 
• Dissolve 121 g Tris Base in 800 ml DEPC dH2O
• Adjust pH to 7.5 with concentrated HCI.
• Cool, determine final pH and bring volume to IL.
50 mM Tris HCl , pH 7.5 
• Dilute 10 ml l M Tris HCl , pH 7.5 with 190 ml DEPC dH2O
(Final Volume 200ml) 
0.5 % Acetic Anhydride 
• Mix 25 ml IM Tris HCl, pH 7.5; 225 ml DEPC dH2O andl250 µl Acetic Anhydride.
Prepare just before use
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Proteinase K Solution (1 mg/ml) 
• Dissolve 1 mg Proteinase K in 50 mM Tris-HCl, pH7.5, 5 mM EDTA (Stock Solution)
(**) Required dilution needs to be determined for each tissue.
20 X SSC 
• Dissolve 175.3 g NaCl and 88.2 g Sodium Citrate in 800 ml H20.
• Adjust the pH to 7.0 with a few drops of 10 N solution of NaOH.
• Adjust volume to lL.
• Autoclave.
2XSSC 
• Dilute 100 ml 20 X SSC with 900ml of DEPC dH20 . (Final Volume IL.)
SILANISATION OF SLIDES 
Require: 
Slides 






• Put slides into slide holder and immerse into chloroform for 30 min at room temperature.
• Remove slides, shake off excess chloroform and immerse the slides into absolute ethanol
for 30 min at room temperature.
• Air dry the slides for one h.
• Immerse slides in 2 % 3-Aminopropyltriethoxysilan in Acetone for 5 min.
• Quickly dip the slides into acetone - 2 times, and shake off excess acetone.
• Wash the slides by dipping into distilled H20 and shaking off excess water.





Wax embedded tissue (Place in the freezer for½ an hour) 
Silanated slides 
RNase Away 70 % Ethanol 
Water bath with DEPC dH2O 
Method 
1. Clean all equipment with RNAse away
2. Wipe the blade with xylene to remove any wax .
3. Fill a water bath with 0.1 % DEPC dH2O and maintain at 60 °C.
4. Cut 4 µm thick sections place on silan pre-treated slides and dry at 55 °C for 2h store in a
clean dust free slide box.
NOTES: Ensure that wax block is cold before cutting. 
Do not touch the blade or covering plate with your fingers (Becomes warm) .. 
FIXATION OF TISSUE 
Require 
Freshly prepared 4 % Paraformaldehyde in PBS (pH 7.5) 
0.05 M PBS 
Ethyl Alcohol series (70 %, 80 %, 90 % and 100 %) 
Xylol (Xylene) 
0.1 M HCl 
0.5 % Acetic Anhydride 
Method 
Dewax in xylene 3 X 10 min. 
Rehydrate in an alcohol series as follows: 
100 % - 2 X 5 min; 90 % - 1 X 5 min; 70 % - 1 X 5 min; 50 % - 1 X 5 min; 
DEPC dH2O - 1 X 5 min. 
Place in 4 % Paraformaldehyde - 1 X 60 min. 
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Wash in 0.05 M PBS - 1 X 10 min. 
Wash in 0.1 M HCI - 1 X 10 min (Denature proteins ) 
Wash in 0.05 M PBS - 2 X 10 min. 
Wash in 0.5 % Acetic Anhydride - 1 X 10 min. 
Wash in 0.05 M PBS -1 X 10 min. 
Dehydrate in an ethyl alcohol series: 50 % - 1 X 5 min; 70 % - 1 X 5 min; 90 % - 2 X 5 min 
and 100 % -2 X 5 min. Store at 4 °C in a dust free environment. 
PRE-TREATMENT OF SLIDES 
Require 
Frames 
Proteinase K Solution (I mg/ml) in 50 mM Tris-HCI, pH7.5, 5 mM EDT A (Stock Soln). 
(The Proteinase K concentration may need to be optimised) 
0.05 M PBS 
DNase (Boehringer Mannheim) 
50 mM Tris-HCI, pH7.5, 5 mM MgCh 
RNase Inhibitor (Boehringer Mannheim) 
Method 
1. Place a frame around the tissue so as to form a well.
2. Treat the tissue with pre-digested Proteinase K (I 0µg/ml) (Sigma) in a moist chamber at
37°C for 30 min (Proteinase K treatment must be empirically determined).
3. Wash with PBS - 3 X 10 min.
4. Incubate the slides at in a moist chamber at 37 °C overnight in the presence of a DNase
solution that consists of
RNase-free DNase (Concentration) 
RNase inhibitor (Concentration) 
1 M Tris HCl pH 7.5 















DEPC Treated H2O 
RNase inhibitor 
25 mM MgC!i 
Moloney Murine Leukemia Virus (M-MuLV) reverse transcriptase 
The above is obtained in the First Strand cDNA Synthesis Kit (Pharmacia Biotech) 
Specific Primer 
Method 
1. Make up RT mix using
Primer 2 µI ( 10 mM) 
DTT 2 µI 
DEPC dH2O 36 µI 
Bulk (Kit) 10 µl 
Total 50 µI 
2. Remove excess buffer from the slides.
3. Place 50 µI of the RT mix over the tissue and covered with parafilm
4. Incubate at 37 °C for 1 h
5. At this point the slides can be stored at -20 °C until the PCR step.
6. Incubate in the presence of 5 % BSA for 30 min at 3 7 °C.
7. Wash in PBS for 10 min
8. Incubate in the presence of 10 % Milk Blocker for 15 min
9. Wash in PBS for 10 min
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POLYMERASE CHAIN REACTION 
Require 
10 X Taq buffer 
25 mM MgCh 




nitroblue tetrazolium/ 5-bromo-4chloro-3ndoyl-phosphate (I :50 dil)- colour substrate 
Taq DNA Polymerase 
Cover slips (Plastic) 
Mineral Oil 
Method 
1. Make up the PCR mix as follows:
10 X Taq Buffer 
25 mM MgCh 
(I 00 mM) dATP, 













2. Carefully remove the RT solution off the tissue sections.
3. Place 50 µl of the PCR mix onto the tissue.
4. Cover with plastic cover slips and surround cover slip with Mineral Oil.
5. Place on the PCR block and set programme with the required parameters.
6. After the PCR reaction is complete, remove the plastic cover slips.
7. Place the slides into xylene for about IO - 20 sec to remove mineral oil (if used).
8. Wash slides twice in 0.1 X SSC at 45 °C for 20 min with continuous shaking.
9. Cover slides with freshly prepared colour substrate solution in 1 x detection buffer (1 mM
Tris, I mM NaCl, 0.5 mM MgCli, pH 9.5) and incubate in the dark at RT until a reddish­
purple colour precipitate is visible 





3.1 ASSESSMENT OF EXCESS FLUID DISTRIBUTION BY BIOELECTRICAL-
IMPEDANCE ANALYSIS 
Fluid retention frequently accompanies renal disease and renal failure. Measurement of total 
body water (TBW) by bioelectrical impedance analysis (BIA) is useful in assessing the state of 
hydration. Bioelectrical-impedance analysis of 5 transplant recipients, 4 patients with renal 
parenchymal disease and 3 control subjects was made, using the Biostat body composition 
analyser (BodyTrak, Cape Town, South Africa). 
Bioelectrical-impedance measurements 
Patient Weight BMl TBW (L) TBW(%) Weight 
(k�) Chan2e (k�) 
TP,. 63.3 19.7 41.5 65.8 Baseline 
TP 1 -Day 3 68.8 21.5 46.5 67.3 5.5 
TP 1 -Day6- AR 66.2 20.6 47.4 71.8 2.9 
TP 1-Week 6 63.2 19.7 42.9 68.1 -0.1
TP2 65 22.5 35.8 55.1 Baseline 
TP2-Day 3 70.2 24.2 41.8 59.7 5.2 
TP2-Day 9- AR 68 23.5 39.3 57.7 3 
TPi-Day 35 67.5 23.2 36.8 54.9 2.5 
TP3 57 22.5 26.6 46.7 Baseline 
TP3-Day 3 62 24.8 31.1 50.1 5 
TP3-Day 11 56.4 22.4 27.0 48.2 -0.6
TP4.AR 89.5 28.7 39.7 44.6 
TPs.AR 71.0 23.5 43.2 60.9 
RD 1.MCNS 34 16.0 21.7 63.8 
RD2.MCNS 79 28 36.2 45.8 
RD3.MCNS 65.4 28.1 30.5 46.9 
RD4.MN 64 23.2 36.6 57.2 
Control I 60 26.3 27.5 45.9 
Control 2 58 22.4 28.7 49.4 
Control 3 43.3 17.0 22.7 52.8 
Abbreviations: BMI= body mass index; kg= kilograms; L= litres; TP= transplant recipient; 
RD= primary renal disease; TBW= total body water; AR= acute rejection; MCNS= nephrotic 
syndrome due to minimal change disease; MN= membranous nephropathy 
As expected, body weight correlated with BMI (p<0.0001, linear regression; p=0.0076, 
Spearman's rank correlation). There was a significant correlation between body weight and 
total body water (p=0.0007, linear regression; P=0.0002, Spearman's rank correlation) and 
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between BMI and total body water (p=0.0024, linear regression; p=0.0023, Spearman's rank 
correlation), in keeping with the fluid retention present during acute rejection and renal 
disease. 
3.2 MEASUREMENT OF RENAL PLASMA FLOW 
Effective renal plasma flow (ERPF) was measured in 6 stable renal transplant recipients on 
day 3 post-transplant and one control subject using Sodium 131Jodohippurate. The glomerular 
filtration rate (GFR) was measured simultaneously, using 9901Technium-diethelenetriamine
pentaacetate (Tc-DTP A). ERPF measurement was repeated in 3 of the 6 patients, 2 of whom 
(patients 1 and 5) were undergoing an episode of acute rejection. ERPF was reduced during 
acute rejection. 
Patient Post TP GFR ECF ERPF 
Day ml/min ml ml/min 
1 3 44 16495 381 
1-AR 8 37 16495 190 
2 3 40 11711 184 
3 3 85 11794 340 
4 3 93 15066 372 
5 3 61 16177 277 
5-AR 6 51 10050 224 
6 3 35 22472 331 
6 - stable 6 41 21795 444 
Control - 114 18498 573 
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There was no correlation between GFR and ERPF (p=0.0535) and between GFR and ECF 
(p=0.6829, linear regression) probably because of the small sample size; it would be 
anticipated that a fall in GFR is the consequence of a decrease in renal blood flow and ERPF. 
resulting in an increase in ECF. 
3.3 ENDOTHELIN STUDY 
3.3.1 PATIENT DEMOGRAPHICS 
The total number of subjects in this sector of the study was one hundred and one. Of these, 
twenty six were kidney transplant recipients undergoing acute rejection, twenty nine were 
patients with glomerular and other renal disorders and twenty four were patients with end 
stage renal failure on dialysis. The twenty two controls comprised seventeen kidney donors 
prior to nephrectomy and five healthy volunteers. For the purposes of statistical analysis for 
measurement ofET-1 in plasma and urine, n= patient numbers. 
3.3.1.1 Acute Rejection Group 
Twenty six renal transplant patients with acute rejection were studied in this group. There 
were 24 males and 2 females; of these, 17 had received kidneys from living related donors, 2 
had received kidneys from living unrelated donors and 7 from cadaver donors. Their mean age 
was 38.27 years (range 16-53 years). There was no difference in age when compared to the 22 
control subjects (p=0.495, unpaired t test). In the acute rejection group, rejection was mild in 7 
patients, moderate in 12 and severe in 7 (Appendix 3.3.1.1). The severity of rejection was 
categorised according to the Banff 1995 classification. 
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3.3.1.2 Renal Disorders 
Twenty nine patients with various renal disorders were studied in this group. Of these, 16 
were males and 13 females, with a mean age of33.17 years (range 13-59 years). Six patients 
had mesangiocapillary glomerulonephritis (MCGN), 4 had class IV lupus nephritis (SLE), 5 
membranous nephropathy (MGN), 5 minimal change disease with nephrotic syndrome 
(MCNS), 4 immunoglobulin A (IgA) nephritis, 2 hypertensive nephrosclerosis (HPT neph), 2 
chronic interstitial nephritis (CIN) and 
glomerulonephritis [(MPGN); Appendix 3.3.1.2). 
3.3.1.3 Control Group 
patient with mesangioproliferative 
Twenty two subjects formed the control group; 17 were kidney donors who were studied prior 
to uni-nephrectomy; 5 were healthy volunteers. There were 13 males and 9 females with a 
mean age of 34.32 years (range 21-48 years). Their details are presented in Appendix 3.3.1.3 
3.3.2 PLASMA ENDOTHELIN-1 VALUES 
Literature suggests that plasma ET- I concentrations are elevated in the circulation in renal 
failure (Shichiri et al., 1990; Stockenhuber et al., 1992) or show a borderline increase (Saito et 
al., 1991 ). It has been suggested that plasma ET-I levels are elevated during acute rejection 
only if there has been concomitant endothelial cell damage (Watschinger et al., 1994). 
3.3.2.1 Controls 
The mean value for plasma ET-I in 22 control subjects measured 0. 76 pg/ml, median of 0.69 
pg/ml and range of 0.4-1.55 pg/ml (Table 3.3.2) 
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3.3.2.2 Acute Rejection Group 
i) The mean value for plasma ET-1 was 1.71 pg/ml with a median value of 1.50 pg/ml and
range of 0.63-5.25 pg/ml in the acute rejection group (n=26). There was no correlation 
between serum creatinine and plasma ET-1 in the patients with acute rejection; the correlation 
coefficient (r) equalled 0.29 and a p value of 0.17 (linear regression). 
ii) Circulating ET-1 levels were significantly increased in the rejection group when compared
to control subjects, with a p value of 0.0002 (unpaired-t test), as indicated in Table 3.3.2. 
Table 3.3.2 Plasma Endothelin-1 levels in acute rejection and controls 
Control Rejection 
n 22 26 
Mean±SEM 0.76 ± 0.065 1.71 ± 0.21 
SD 0.31 1.05 
Median 0.69 1.5 
Range 0.40-1.55 0.63-5.25 
p (unpaired t-test) 
0.0002 
n= Patient numbers; measurements: pg/ml 
3.3.2.2.1 Serial plasma endothelin-1 levels after renal transplantation 
Plasma ET- I levels were measured serially in renal transplant patients. The mean ± SEM and 
median values for plasma ET-1 were 2.01 ± 0.23pg/ml before transplantation (n= l 7), 1.42 ± 
0.14 pg/ml following transplantation on day 3-4 (n= I 8), I. 74 ± 0. I 8 pg/ml during acute 
rejection (n=16) and 1.37 ± 0.12 pg/ml after treatment and recovery from rejection (n= l 1) 
respectively; the median values were 1.84 pg/ml; 1.3 pg/ml, 1.56 pg/ml and 1.2 pg/ml 
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respectively and tabulated in 3.3.2.2.1. Plasma ET-I levels showed cyclical changes during 
acute rejection and the subsequent treatment phase. Following transplantation, plasma ET-I 
levels declined significantly (p=0.036, Mann Whitney test), but levels rose during acute 
rejection (p=0.47, Mann-Whitney test). Once the rejection episode was treated, plasma ET-I 
levels decreased again (p=0. I 2, Mann-Whitney test). This post-treatment value was lower 
than that measured prior to transplantation (p=0.04I2, unpaired t-test). 
Table 3.3.2.2.1 Serial Plasma Endothelin 1 levels in renal transplantation 
(i) Pre-TP ( ii) Post-TP (iii) Acute (iv)After
rejection Rejection Rx
n 17 18 16 11 
Mean±SEM 2.01 ± 0.23 1.42 ± 0.14 1.74 ± 0.18 1.37 ± 0.12 
SD 0.93 0.61 0.72 0.41 
Median 1.84 1.3 1.56 1.20 
Range 1.1 -4.29 0.71 -2.64 0.87-3.76 0.85-2.16 
p(Mann- (i) VS (ii) : 0.036 (iii) vs (iv) : 0.12
Whitney test) (i) vs (iv): 0.0412*; (ii) vs (iii) : 0.18 ; (i) VS (iii) ; 0.47
n= patient numbers *Unpaired t-test ; measurements: pg/ml 
3.3.2.3 Renal diseases 
The mean plasma value for ET-1 measured 1.98 pg/ml in this group (n=29}, with a median 
value of 1.6 pg/ml and a range of 0.45-5.56 pg/ml; the mean value was significant when 
compared to control subjects with a p value of <0.01 (Tukey Kramer multiple comparisons). 
There was a significant correlation between plasma ET-1 and serum creatinine levels in this 
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group, with r=0.55 and a two-tailed p value of 0.0019 (linear regression). For the purposes of 
further analysis, the renal diseases were grouped into proliferative and non-proliferative 
disorders. 
3.3.2.3.1 Proliferative glomerulonephritis 
Thirteen patients with proliferative glomerulonephritis (prolif. GN) had a mean plasma value 
for ET-1 of2.8lpg/ml, median of 3.0 pg/ml and range of 0.6-5.56 pg/ml. 
3.3.2.3.2 Non-proliferative glomerulonephritis 
The 16 patients with non-proliferative disorders had a mean plasma value for ET-1 of 1.3 
pg/ml, median of 1.07 pg/ml and range of 0.45-3 .0 pg/ml. 
Table 3.3.2.3 Plasma Endothelin-1 in Renal Disorders 
(i)Control (ii)Whole Group (iii)Prolif (iv) Non Prolif
GN GN
n 22 29 13 16 
Mean ± 0.76 ± 1.98 ± 0.26 2.81 ± 1.30 ±
SEM 0.065 0.42 0.21 
SD 0.31 1.39 1.50 0.85 
Median 0.69 1.60 3.0 1.07 
Range 0.40-1.55 0.45-5.56 0.60-5.56 0.45-3.0 
p* (i) vs (ii) : <0.01 (iii) vs (iv)< 0.01
(i) vs (iii) : <0.001; (i) vs (iv) 0.0096 (unpaired t-test)
n== Patient numbers; *Tukey Kramer multiple comparisons ; measurements: pg/ml 
The difference between these two histological groups was statistically significant, with the 
highest levels of plasma ET-I in proliferative GN (p<0.01). The difference between patients 
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with proliferative GN and control subjects was highly significant with a p value of <0.001. 
Plasma ET-1 was increased in patients with non-proliferative diseases compared to control 
subjects (p=0.0096, unpaired t-test). 
3.3.2.3.3 Hypertensive glomerulonephritic subjects 
Fifteen patients were hypertensive (HPT) in this group, with a mean plasma value for ET-1 of 
2.52 pg/ml, median of 2.53 pg/ml and range of 0.6-5.56 pg/ml. 
3.3.2.3.4 Normotensive glomerulonephritic subjects 
The 14 normotensive (NBP) patients had a mean plasma value for ET-1 of 1.39 pg/ml, median 
of 0.87 pg/ml and range of 0.45-4.0 pg/ml. 
Table 3.3.2.3 Plasma Endothelin-1 in Renal Disorders 
(i) Control (ii) HPT (iii) NBP
n 22 15 14 
Mean±SEM 0.76 ± 0.065 2.52 ± 0.37 1.39± 0.30 
SD 0.31 1.44 1.11 
Median 0.69 2.53 0.87 
Range 0.40-1.55 0.60-5.56 0.45-4.0 
p (unpaired t- (ii) vs (iii) : 0.0261
test) (i) vs (ii) :0.0001 *; (i) vs (iii) : 0.0155
n= patient numbers; * Mann Whitney test ; measurements: pg/ml 
Plasma ET-I was significantly increased in hypertensive patients when compared with 
normotensive patients, with a p value of 0.0261 (unpaired t test); the p value of 0.000 I was 
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highly significant when comparing the hypertensive patients with control subjects. Plasma 
ET-I was increased in patients with normotensive renal disorders compared with controls 
(p=0. 015 5, unpaired t test). 
3.3.2.3.5 Dialysis patients 
Patients on dialysis (n =26) had a mean value for plasma ET-I of 2.4 pg/ml; median 2.07 
pg/ml; range 0.29-5.56 pg/ml. 
3.3.2.3.6 Patients not requiring dialysis 
In comparison, 26 patients who were not dialysis-requiring had a mean value for plasma ET-1 
of I. 7 pg/ml, median of 1.6 pg/ml and range of 0.45-4.12 pg/ml. 
Table 3.3.2.3 Plasma Endothelin-1 in Renal Disorders 
(i) Control (ii) Dialysis (iii)Non-dialysis
n 22 26 26 
Mean±SEM 0.76 ± 0.065 2.40 ± 0.25 1.70 ± 0.22 
SD 0.31 1.27 1.13 
Median 0.69 2.07 1.60 
Range 0.40-1.55 0.29-5.56 0.45-4.12 
p (unpaired t- (i)vs(ii)<0.0001; (ii) vs (iii) : 0.0428
test) (i) vs (iii) : 0.0004
n= patient numbers ; measurements: pg/ml 
Plasma ET-I was significantly increased in both the dialysis and non-dialysis requiring 
groups. The difference between the dialysis-requiring and non-dialysis groups was significant 
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(p=0.0428); and also when comparing the dialysis-requiring group with control subjects 
(p<0.0001) and non-dialysis patients with control subjects (p=0.0004). 
3.3.3 URINE ENDOTHELIN-1 VALUES 
It has been suggested that ET-1 is generated in situ in the kidney in renal disorders and levels 
in the urine may reflect renal synthesis of the peptide. 
3.3.3.1 Urine endothelin-1 levels in acute rejection 
The mean value for urinary ET-I was 1.67 pg/ml in 17 patients with acute rejection with a 
median value of 1.23 pg/ml and range of 0.7-4.7 pg/ml; corresponding control values (n= l I) 
were mean = 0.37 pg/ml, median = 0.2 pg/ml and range of 0.0-1.58 pg/ml (Table 3.3.3). The 
difference was significant, with a p value of 0.005 (Mann Whitney test). There was no 
correlation between serum creatinine and urine ET-I levels, with r = 0.11 and p=0.66. 
Table 3.3.3 Urine Endothelin-1 levels 
(i) Control (ii) Rejection (iii) GN
n 11 17 11 
Mean±SEM 0.37 ± 0.13 1.67 ± 0.35 0.41 ± 0.13 
Median 0.20 1.23 0.38 
Range 0-1.58 0.70-4.70 0-1.09
p (i) vs (ii) : 0.005* (i) vs (iii) : 0.80*
n= patient numbers; *Mann Whitney; measurements: pg/ml 
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3.3.3.2 Urine endothelin-1 levels in renal disease 
Urinary ET-1 excretion in glomerulonephritis (n= l 1) measured a mean± SEM of 0.41 ± 0.13 
pg/ml, median of 0.38 pg/ml and range of 0.0 - 1.09 pg/ml. This was similar to controls 
(p=0.80; Mann-Whitney test) where the mean ± SEM was 0.37 ± 0.13 pg/ml, median of 0.20 
pg/ml and range of 0.0 - 1.58 pg/ml 
3.3.4 LOCALISATION OF ENDOTHELIN-1 AND THE ENDOTHELIN 
RECEPTORS ET A AND ET s IN THE KIDNEY 
Histological sections of one per patient, when viewed at a magnification of x40 showed 1-2 
glomeruli per section, whereas the tubules were numerous. Field means of immunolabel were 
derived in pixels per micron2 for the different regions of interest, namely glomeruli, tubules 
and renal blood vessels and compared statistically. Because of the complex nature of the study 
and access to tissue samples, it was not possible to always receive adequate numbers of tissue 
samples in each category. Therefore non-parametric tests were used, since it was not known 
whether the study population was normally distributed. 
3.3.4.1 Immonoperoxidase: Peroxidase-antiperoxidase (PAP) labelling 
The PAP-immunolabelled images were quantitatively analysed by the Kontron Elektron KS 
300 (Zeiss GmbH, Germany) analyser, running on Windows 95. The digital images were 
converted to grey images ranging in grey scale density from 0 to 255. The median maximal 
density of immunolabelling was calculated as field means in pixels per micron2 and 
statistically analysed. 
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3.3.4.1.] Control kidney tissue 
ET- I immunolabelling was observed in glomerular capillary loops, distal tubules and 
collecting ducts as well as the endothelium and smooth muscle cells of media of arterioles of 
control kidney tissue. [Fig 3.1 (C)]. EndothelinA (ETA) receptor immunolabelling was 
visualised in distal tubules and collecting ducts. Minimal labelling was observed in glomeruli 
and blood vessels [Fig 3.2 (C)]. Endothelin8 (ET 8) receptor was immunovisualised in distal
tubules and collecting ducts and minimally focally in the mesangium in control kidney tissue. 
In addition, immunolabelling of endothelium and smooth muscle cells of the media of blood 





3.3.4.1.2 Acute rejection 
Endothelin-1 
There was decreased immunolabelling for ET-I in glomeruli in acute rejection compared to 
control glomeruli [p=0.0095, Mann-Whitney test; Fig 3.1 (A)]. Although the values for 
rejection tubules were lower when compared to controls, the difference was not significant 
(p=0.20); the difference was not significant when comparing tubules in mild rejection 
(n=3) and severe rejection (n=2) with controls and with each other. 
Table 3.3.4.1 ET-1 in acute rejection (PAP immunolabelling) 
GLOMERULI TUBULES 
Control Rejection Control 
n 4 6 4 
Mean±SEM 138.33 ± 4.38 100.55 ± 5.37 94.01 ± 6.86 
SD 8.76 13.16 13.75 
Median 139.4 101.85 87.74 
Range 127. 77-146. 74 81.06-116.69 85.97-114.6 
p(Mann- 0.0095 
Whitney test) 











While there was increased ET A receptor labelling in acute rejection, the site and intensity of 
immunolabelling of the ETA receptor in glomeruli (p=0.14, Mann-Whitney test) and 
tubules (p=0.075) was not significantly increased in acute rejection when compared to 
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control kidney tissue (Table 3.3.4.1 ). There appeared to be no difference when comparing 
glomeruli from mild rejection (n=2) and severe rejection (n=5) or tubules from mild 
rejection (n=4) and severe rejection (n=6) with each other and with controls. The images 
are depicted in Figure 3.2. 
Table 3.3.4.1 ETA Receptor in acute rejection (PAP labelling) 
GLOMERULI TUBULES 
Control Rejection Control Rejection 
n 6 7 5 10 
Mean±SEM 113.64 ±5.01 127.14 ±7.71 127.52±31.92 147.16±4.59 
SD 12.26 20.41 71.36 14.52 
Median 116.74 136.55 97.94 147.76 
Range 90.85-124.61 96.84-144.03 91.1-255.0 116.29-165.71 
p(Mann- 0.14 0.075 
Whitney test) 
2 
n - number of h1stolog1cal sections ( one per patient); measurements: p1xels/m1cron 
ETB Receptor 
There was significantly increased ET 8 receptor immunolabelling of glomeruli in acute 
rejection (p=0.0022, Mann-Whitney test) and decreased immunolabelling of tubules 
(p=0.0076, Mann-Whitney test) when compared to control kidney tissue. Glomerular 
labelling in both mild (n=3) and severe (n=3) rejection was significantly increased when 
compared to controls (p<0.05, Tukey-Kramer multiple comparisons). There was no 
difference in the glomerular labelling when comparing mild and severe rejection. There 
was a significant decrease in tubular labelling when comparing mild rejection (n=3; 
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p=0.04 7) and severe rejection (n=3; p=0.038) with controls (Mann-Whitney test). The 
images are shown in Figure 3.3. 
Table 3.3.4.1 ET 8 Receptor in glomeruli in acute rejection (PAP labelling) 
GLOMERULI 
(i) Control (ii) Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 6 6 3 3 
Mean ± SEM 77.16±14.79 138.73±3.22 136.32±5.0 141.14±4.59 
SD 36.22 7.89 8.66 7.94 
Median 78.96 136.7 132.32 138.7 
Range 30.81-115.84 130.39-150.02 130.39-146.26 134.71-150.02 
p* (i)vs(ii) 0.0022; (i)vs(iii):0.023 (i)vs(iv):0.0238; (iii)vs(iv):0.4
*Mann-Whitney test; n = number of histological sections (one per patient);
measurements: pixels/micron2
Table 3.3.4.1 ET 8 Receptor in tubules in acute rejection (PAP labelling) 
TUBULES 
(i) Control (ii) Rejection (iii)Mild (iv)Severe
Rejection Rejection
6 9 3 4 
Mean±SEM 149.56±4.98 129.12±3.54 129.26±3.57 126.68±6.21 
SD 12.20 10.62 6.17 12.42 
Median 153.92 128.51 128.51 129.14 
Range 129.85-162.03 111.18-145.97 123.49-135.77 111.18-145.97 
p(Mann- (i)vs(ii):0.0076; (i)vs(iii):0.0476 (i)vs(iv): 0.038
Whitney) 
.2 




ET-1 immunolabelling was decreased in glomeruli (p=0.049, Mann-Whitney test), and 
similarly in tubules (p=0.90) in glomerulonephritis when compared to control kidney 
tissue. Glomerular labelling was significantly decreased in proliferative glomerulonephritis 
(n=6) when compared to controls (p<0.001), and non-proliferative glomerulonephritis 
(n=2; p<0.01; Tukey-Kramer multiple comparisons). There was no difference in tubular 
labelling in proliferative (n=13) and non-proliferative (n=3) glomerulonephritis. The 
images are depicted in Figure 3.1 (B). 
Table 3.3.4.1.3 ET-1 in glomeruli in renal disease (PAP labelling) 
GLOMERULI 
(i)Control (ii) GN (iii)Non-prolif (iv)Prolif GN
GN
n 4 8 2 6 
Patients 4 8 2 6 
Mean±SEM 138.33±4.38 104.27±8.23 136.67±14.2 93.48±4.44 
SD 8.76 23.27 20.08 10.87 
Median 139.4 91.08 136.67 90.42 
Range 127.77-146.74 85.11-150.86 122.47-150.86 85.11-115.19 




n = number of histological sections measurements: 
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T able 3.3.4.1.3 ET-1 in tubules in renal disease (PAP labelling) 
T UBULES 
Control GN 
D 4 18 
Mean±SEM 94.01± 6.86 91.3± 6.6 
SD 13.75 28.02 
Median 87.74 100.78 
Range 85.97-114.6 25.52-135.81 
p (Mann-Whitney 0.90 
test) 
n = number of histological sections ( one per patient); measurements: pixels/micron2
ET A Receptor 
The images are depicted in Figure 3.2 (B). 
Table 3.3.4.1.3 ET A receptor in glomeruli in renal disease (PAP labelling) 
GLOMERULI 
Control GN 
n 6 7 
Mean±SEM 128.34±8.44 129.43±5.93 
SD 20.68 15.69 
Median 121.29 129.98 
Range 113.42-167.3 106.3-150.65 
p (Mann-Whitney 0.92 
test) 
n = number of histological sections ( one per patient); measurements: pixels/micron2
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ETA receptor immunolabelling was significantly increased in tubules (p=0.026, Mann­
Whitney test) and similarly in glomeruli (p=0.92) of renal biopsies with glomerulonephritis 
when compared to control kidney tissue (Table 3.3.4.1.3) 
Table 3.3.4.1.3 ETA receptor in tubules in renal disease (PAP labelling) 
(i) Control (ii Non-prolif GN (iv) Prolif GN
n 7 11 3 
Mean±SEM 109.1±9.8 133.22±5.52 130.2±6.49 
SD 25.94 18.31 11.24 
Median 100.85 130.87 135.94 
Range 90.96-167.21 105.33-162.82 117.25-137.41 
p (Mann (i) vs(ii) :0.026 (i)vs(iii) >0.05 (ii)vs(iii) >0.05 
Whitney test) 
n = number of histological sections ( one per patient); measurements: pixels/micron2
ETn Receptor 
ET 8 receptor immunolabelling was increased in glomeruli of glomerulonephritis kidney 
tissue but the increase was not statistically significant; the labelling was decreased in 
tubules in glomerulonephritis (non-proliferative p=0.0008, proliferative GN p= 0.0001; 
Mann-Whitney test; Table 3.3.4.1.3). There was no difference when comparing 
proliferative and non-proliferative glomerulonephritis. The images are depicted in Figure 
3.3 (B). 
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Table 3.3.4.1.3 ET 8 receptor in renal disease (PAP labelling) 
GLOMERULI DIST AL TUBULES 
(i)Control (ii)Non (iii) Prolif (a)Control (b)Non
Prolif GN GN Prolif GN
n(sections) 7 8 5 7 11 
Mean± 89.05 ± 127.62 ± 124.5 ± 151.79 ± 125.33 ±
SEM 17.25 4.31 3.49 3.78 3.92 
SD 45.64 12.18 7.8 10.0 13.0 
Median 93.97 129.79 125.86 153.94 124.24 
Range 30.81- 108.31- 113.07 - 134.16- 106.21-
160.39 142.82 131.83 163.64 154.79 











(i) vs (iii): 0.1061; (ii) vs (iii) :0.62 (a) vs (c): 0.0001; (b) vs (c) :>0.05
-n- number of patients also; measurements: p1xels/m1cron 2
3.3.4.2 Confocal microscopy: Immunofluorescent labelling 
The staining intensity of flourescent-labelled tissue sections was viewed by confocal 
scanning laser microscopy and quantitatively analysed using the Analysis 2.1 Pro system 
(Software GmbH, 1996, Germany). The mean intensity of immunolabelling was expressed 
in pixels x 100 per micron2 and statistically analysed. 
3.3.4.2.1 Acute rejection 
ET-1 
ET-1 labelling of proximal tubules in acute rejection was significantly increased in the 
rejection group as a whole when compared to controls (p=0.0016), and in mild rejection 
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compared to controls (p=0.0001) and severe rejection (p<0.05). Increased labelling was 
noted in distal tubules in mild rejection in comparison to severe rejection (p=0.0058) and 
controls (p=0.0499). While glomerular labelling was increased in rejection in comparison 
to controls, there was no statistical difference. The images are depicted in Figures 3 .4 ( A 
and B) and 3.5. 
Table 3.3.4.2.1 ET-1 in acute rejection ( immunofluorescent labelling) 
PROXIMAL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Re_jection
n 5 77 60 17 
(structures) 
Sections 4 19 15 4 
Mean± 11.6 ± 0.8 58.8 ± 7.6 69.3 ± 7.3 19.4 ± 6 
SEM 
Median 12.l 60.7 63.5 15.1 
SD 1.6 33.1 28.6 12.0 
Range 9.4-12.9 10.5-128.6 22.4-128.6 10.5-37 
p (i) vs (ii) : 0.0016(Mann Whitney); (i) vs (iv):>0.05**
(i) vs (iii) : 0.000I(Kruskal Wallis); (iii) vs (iv) <0.05**
** Dunn s multiple comparisons, measurements. p1xelsx 100/ micron L
171 
Table 3.3.4.2.1 ET-1 in acute rejection (immunofluorescent labelling) 
DIST AL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Re_jection Re_jection
n 4 56 52 4 
(structures) 
Patients 4 19 16 3 
Mean± 23.09±1.09 55.8 ± 7.8 63.8 ± 7.7 13 ± 1.8 
SEM 
Median 22.7 53.6 69 13.7 
SD 1.09 34 30.8 3.1 
Range 21.14-25.8 9.7-107 12.2-107 9.7-15.7 
p(Mann (i) vs (ii) : 0.47; (i) vs (iv):0.0571
Whitney) (i) vs (iii) :0.0499; (iii) vs (iv): 0.0058(Kruskal-Wallis)
measurements. pixelsx I 00/ micron 
Table 3.3.4.2.1 ET-1 in acute rejection ( immunofluorescent labelling) 
GLOMERULI 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 3 13 9 4 
(structures) 
Patients 3 13 9 4 
Mean± 4.2 ± 0.16 13.1 ± 3.5 15.4 ± 3.9 12.1 ± 5.6 
SEM 
Median 4.29 10.2 10.7 9.7 
SD 0.28 11.7 11.7 11.2 
Range 3.9-4.4 2.7-37.7 2.7-37.7 2.7-26.5 
p (Mann (i) VS (ii) : 0.64; (i) VS (iv):>0.05**
Whitney) (i) VS (iii) :0.33; (iii) VS (iv): 0.0727
2 I **Dunn s multiple comparisons; measurements: pixelsxl00/ micron 






While ET A receptor immunolabelling of proximal tubules was increased in both mild and 
severe rejection, it was not significantly so when compared to the control kidney. Similarly, 
while ET A receptor labelling of distal tubules was increased in rejection, it was not 
significant when compared to control kidney (p=0.09, Mann Whitney test), probably 
because of the small sample numbers. ETA receptor labelling of glomeruli was similar in 
rejection and control kidney. ET A receptor labelling of collecting ducts was significantly 
increased in rejection (p=0.0238, Mann Whitney test) compared to control kidney. The 
images are depicted in Figures 3.6 (A and B). 
Table 3.3.4.2.1 ETA receptor in acute rejection ( immunofluorescent labelling) 
PROXIMAL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Re_jection Rejection
n 17 17 9 8 
(structures) 
Patients 3 7 3 4 
Mean± 27.5 ± 8.9 92.l ± 31.6 69.l ± 33.7 109.2 ± 51.9 
SEM 
Median 35.2 84.7 84.l 109.2 
SD 15.4 83.6 58.3 103.8 
Range 9.7-37.5 4.8-199.2 4.8-118.5 19.3-199.2 
p (Kruskal (i) vs (ii) : 0.52**; (i) vs (iv):0.69
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv)>0.05
.1. **Mann Whitney, measurements. p1xelsxl 00/ micron 
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Table 3.3.4.2.1 ETA receptor in acute rejection ( immunofluorescent labelling) 
DIST AL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 8 17 12 5 
(structures) 
Patients 3 6 3 3 
Mean± 7.3 ± 6.4 43.6 ± 10.7 32.8 ± 9.8 54.4 ± 19 
SEM 
Median 1.7 41.1 32.2 73.4 
SD 11.1 26.3 17.1 32.9 
Range 0.1-20.1 16.1-73.5 16.1-50.1 16.4-73.5 
p (Kruskal (i) vs (ii) : 0.09 (Mann Whitney); (i) vs (iv):0.17
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv) >0.05
measurements. p1xelsx I oo/ micron 
Table 3.3.4.2.1 ETA receptor in acute rejection ( immunofluorescent labelling) 
COLLECTING DUCTS 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Re_jection
n 15 25 19 6 
(structures) 
Sections 3 6 3 3 
Mean± 21.8 ± 3.6 102.7 ± 15.5 82.1 ± 26.4 123 ± 9.2 
SEM 
Median 19.6 114 45.7 114 
SD 6.2 38 101.9 16 
Range 17.1-28.9 29.9-141.8 29.9-114.6 113.5-141.8 
p(Mann (i) vs (ii) : 0.0238; (i) vs (iv):<0.01 **
Whitney) (i) vs (iii) :>0.05; (iii) vs (iv) >0.05
**Tukey Kramer multiple compansons; measurements: p1xelsx 100/ micron 
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Table 3.3.4.2.1 ETA receptor in acute rejection 
(immunofluorescent labelling) 
GLOMERULI 
(i) Control (ii) Rejection
n 3 4 
Patients 3 4 
Mean±SEM 19.3 ± 9.4 7.3 ± 1.2 
Median 18.3 7 
SD 16.3 2.4 
Range 3.5-36.1 5-10.5
p(Mann (i)vs(ii) : 0.63
Whitney) 
measurements: p1xelsx I 00/ micron 
ET 8 receptor 
ET 8 receptor labelling of proximal tubules was significantly decreased in rejection 
(p<0.0364, Mann Whitney test) when compared to control kidney. While the label was 
decreased in distal tubules in severe rejection, the difference was not significant, probably 
because of small numbers. 
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Table 3.3.4.2.1 ET 8 receptor in acute rejection (immunofluorescent labelling) 
PROXIMAL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Re_jection Re_jection
n 15 32 17 15 
(structures) 
Patients 3 9 5 4 
Mean± 112.8 ± 5.2 29.6 ± 15 41 ± 27 15.3 ± 4 
SEM 
Median 98.9 15.3 14.2 18.1 
SD 89.2 45.1 60.5 8.1 
Range 31.3-208.1 3.9-148.9 9.3-148.9 3.9-21.2 
p(Tukey (i) VS (ii) : 0.0364**; (i) VS (iv): <0.01
Kramer) (i) vs (iii) :<0.01; (iii) vs(iv).:>0.05
** Mann Whitney, measurements. p1xelsxl00/ micron 
Table 3.3.4.2.1 ET 8 receptor in acute rejection (immunofluorescent labelling) 
DISTAL TUBULES 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 7 23 18 5 
(structures) 
Patients 3 7 4 3 
Mean± 43.6 ± 1.1 27.8 ± 22.9 44.6±40.2 5.4 ± 0.9 
SEM 
Median 51.2 4.9 5.6 4.9 
SD 11.1 60.6 80.4 1.6 
Range 21.7-58 2-165.1 19.9-165.1 4-7.1
p (Mann (i) VS (ii) : 0.12; (i) VS (iv):0.1
Whitney) (i) VS (iii) :0.4;(iii) VS (iv) 0.99
measurements: p1xelsx I 00/ micron 
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Table 3.3.4.2.1 ET 8 receptor in acute rejection (immunofluorescent labelling) 
GLOMERULI 
(i)Control (ii)Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 4 7 3 4 
(structures) 
Patients 4 7 3 4 
Mean± 47.4 ± 5.2 2.8 ±0.2 2.7 ± 0.21 2.9 ± 0.2 
SEM 
Median 49.2 2.7 2.7 2.8 
SD 10.4 0.4 0.3 0.5 
Range 34.3-57 2.3-3.5 2.3-3 2.5-3.5 
p** (i) VS (ii) : <0.05; (i) VS (iv):<0.05
(i) VS (iii) :<0.05; (iii) VS (iv):>0.05
7 * * Dunn s multiple compansons; measurements: p1xelsx I 00/ micron
Glomerular labelling, was significantly decreased in rejection when compared to control 
kidney. The images are depicted in Figures 3.7 {A and B). 
3. 3. 4. 2. 2 G/omerulonephritis
ET-1 
ET-1 immunolabelling of proximal tubules was very significantly increased in non­
proliferative (p=0.0059) and proliferative GN (p=0.0159, Mann Whitney test) when 
compared to control kidney; however there was no difference between non-proliferative 
and proliferative GN. ET-1 labelling of distal tubules was increased in GN when compared 
to control kidney (p=0.0286). There was a significant increase in tubular labelling when 
comparing proliferative and non-proliferative GN (p=0.0346). Glomerular labelling was 
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significantly increased in ON when compared to control kidney (p=0.044). The images are 
depicted in Figures 3.4 (C) and 3.5 (C). 




n 5 66 50 
(structures) 
Patients 4 18 13 
Mean± 11.7 ± 0.8 94.8 ± 24.3 88.8 ± 32 
SEM 
Median 12.1 78.7 45 
SD 1.6 100.3 115.4 
Range 9.5-12.9 11-449.5 11-449.5
p(Mann (i) vs (ii) : 0.007; (i) vs (iv):0.0159
Whitney) (i) vs (iii) : 0.0059; (iii) vs (iv): 0.12
.L measurements. p1xelsx 100/ micron 
Table 3.3.4.2.2 ET-1 receptor in renal disease 
(immunofluorescent labelling) 
DIST AL TUBULES 
(i)Control (ii)Non- (iii)Prolif
prolif GN GN
n 4 45 13 
(structures) 
Patients 4 13 4 
Mean± 23.1 ± 1.1 50.5± 7.8 103.1 ± 13.7 
SEM 
Median 22.7 49 108.4 
SD 2.2 28.1 27.4 
Range 21.1-25.8 15 -93.2 66.3-129.5 
p (Mann (i) vs (ii) :0.16; (i) vs (iii):0.0286
Whitney) (ii) vs (iii): 0.0346











Table 3.3.4.2.2 ET-1 in renal disease (immunofluorescent labelling) 
GLOMERULI 
(i)Control (ii)GN (iii)Non- (iv)Prolif
vrolif GN GN
n 3 12 9 3 
(structures) 
Patients 3 12 9 3 
Mean± 4.2 ± 0.16 47.7 ± 15.9 45.9 ± 20.8 53 ± 19.4 
SEM 
Median 4.3 31.4 31.4 63.8 
SD 0.28 55.2 62.4 33.7 
Range 3.9-4.4 5.5-208.1 5.5-208.1 15.3-80 
p(Mann (i) vs (ii) : 0.044; (i) vs (iv):0.20
Whitney) (i) VS (iii) :0.0727; (iii) VS (iv): 0.48
.l measurements. p1xelsx 100/ micron 
Endothelin receptors 
ETA Receptor 
While ETA receptor labelling of proximal tubules was increased in GN, it was not 
significantly increased when compared to control kidney. ETA receptor labelling of distal 
tubules was significantly increased in proliferative GN when compared to non-proliferative 
GN (p=0.004, Kruskal Wallis test) and control kidney (p<0.05). ET A receptor labelling of 
glomeruli was similar in GN and control kidney. The labelling of collecting ducts was 
similar in both non-proliferative and proliferative GN compared to controls. The images 
are depicted as Figures 3.6 (C). 
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Table 3.3.4.2.2 ETA receptor in renal disease (immunofluorescent labelling) 
PROXIMAL TUBULES 
(i)Control (ii)GN (iii)Non- (iv)Prolif
prolifGN GN
n 17 46 9 37 
(structures) 
Patients 3 17 4 13 
Mean± 27.5 ± 8.9 76.6 ± 15.3 47.8 ± 10 85.4 ± 19.2 
SEM 
Median 35.2 61.9 45.9 65.8 
SD 15.4 62.9 20 69.4 
Range 9.7-37.5 0.8-204.3 30-69.4 0.7-204.3 
p (Kruskal (i) vs (ii) : 0.26**; (i) vs (iv):0.34
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv)>0.05
.l **Mann Whitney, measurements. pixelsxl00/ micron 
Table 3.3.4.2.2 ETA receptor in renal disease (immunofluorescent labelling) 
DIST AL TUBULES 
(i)Control (ii)GN (iii)Non- (iv)Prolif
prolif GN GN
n 8 46 9 37 
(structures) 
Patients 3 16 4 12 
Mean± 7.3 ± 6.4 29.3 ± 8.9 2.8 ± 1.4 38.1 ± 10.8 
SEM 
Median 1.7 11.3 2.1 26.1 
SD 11.1 35.6 2.9 37.2 
Range 0.1-20.1 0.3-127.1 0.2-6.7 6.1-127.1 
p (Kruskal (i) vs (ii) : 0.37 (Mann Whitney); (i) vs (iv)<0.05
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv) <0.05
.2 
measurements. pixelsx 100/ micron 
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Table 3.3.4.2.2 ET A receptor in renal disease (immunofluorescent labelling) 
COLLECTING DUCT S 
(i)Control (ii)GN (iii) Non- (iv)Prolif
prolif GN GN
n 15 40 6 34 
(structures) 
Patients 3 8 3 5 
Mean± 21.8 ± 3.6 34 ± 7.3 21 ± 7 41.9 ± 9.6 
SEM 
Median 19.6 28.8 24.5 35.8 
SD 6.2 20.5 12.1 21.4 
Range 17.1-28.9 7.5-70.5 7.4-30.9 19.2-70.5 
p (Kruskal (i) vs (ii) : 0.38 (Mann Whitney); (i) vs (iv):>0.05
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv) :0.29
measurements. p1xelsx 100/ micron 
Table 3.3.4.2.2 ET A receptor in renal disease (immunofluorescent labelling) 
GLOMERULI 
(i)Control (ii)GN (iii) Non- (iv)Prolif
prolif GN GN
n 3 9 3 6 
(structures) 
Patients 3 9 3 6 
Mean±SEM 19.3 ± 9.4 8.4 ±2.7 12.9 ± 5.8 6.1 ± 2.8 
Median 18.3 4.9 15.2 3.1 
SD 16.3 8.1 10 6.8 
Range 3.6-36.1 0.1-15.6 2-21.6 0.1-15.6 
p (Kruskal (i) vs (ii) : 0.21 (Mann Whitney); (i) vs (iv):>0.05
Wallis) (i) vs (iii) :>0.05; (iii) vs (iv) :>0.05
measurements: p1xelsx I 00/ micron 
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ET 8 receptor 
While ET 8 receptor labelling was decreased in GN in proximal and distal tubules, 
collecting ducts and glomeruli, the difference was not significant probably because of the 
small sample size. The images are depicted in Figure 3.7 (C). 
Table 3.3.4.2.2 ET 8 receptor in renal disease (immunofluorescent labelling) 
PROXIMAL TUBULES 
(i)Control (ii)GN (iii)Non- (iv)Prolif
prolif GN GN
n 15 43 11 32 
(structures) 
Patients 3 11 4 7 
Mean± 112.8± 51.8 35.8 ± 10.1 44.5 ± 23.7 30.8 ± 9.8 
SEM 
Median 98.9 25.9 27.1 18.R
SD 89.2 33.5 47.4 25.9 
Range 31.2-208.1 9.1 -114.5 9.4-114.5 9.1-78.8 
p(Mann (i) vs (ii) : 0.0604; (i) vs (iv):0.067
Whitney) (i) vs (iii) :0.229; (iii) vs (iv):0.788
.1. measurements. p1xelsx I 00/ micron 
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Table 3.3.4.2.2 ET 8 receptor in renal disease (immunofluorescent labelling) 
DIST AL TUBULES 
(i)Control (ii)GN (iii)Non- (iv)Prolif
prolif GN GN
n 7 25 11 14 
(structures) 
Patients 3 11 4 7 
Mean± 43.6 ± 11.1 24.9 ± 8.6 22.6 ± 4.8 26.2 ± 13.6 
SEM 
Median 51.2 14 20.2 76.6 
SD 19.3 28.5 9.5 36.1 
Range 21.7-58 0.6-96.5 14-36 0.6-96.5 
p (Mann (i) vs (ii) : 0.17 ; (i) vs (iv):0.267
Whitney) (i) vs (iii) :0.23; (iii) vs (iv) :0.315
measurements. p1xelsx I 00/ micron 
Table 3.3.4.2.2 ET 8 receptor in renal disease (immunofluorescent labelling) 
GLOMERULI COLLECTING DUCTS 
(i)Control (ii)GN (i)Control (ii)GN
n (structures) 4 5 10 30 
Patients 4 5 4 3 
Mean± 47.4 ± 5.2 22.3 ± 8.4 51.7 ± 8.3 39.6 ± 3 
SEM 
Median 49.2 18.2 49.6 41.8 
SD 10.4 18.8 16.7 6.9 
Range 34.3-57 5.7-51.9 34.6-72.8 31.8-45.1 
p(Mann 0.38 0.4 
Whitney) 
measurements: p1xelsx I 00/ micron 
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ELECTRON MICROSCOPY: IMMUNOGOLD LABELLING 
3.3.3.2 Acute rejection 
ET-1 immuno-labelling was visualised in proximal and distal tubules (in the cytoplasm 
and, and to a lesser extent, in the nucleus), collecting ducts, endothelial cells of arteries and 
glomerular capillaries in control kidney. Gold particles occurred in clusters or singly, 
mainly along infoldings of the basolateral membranes, intercellular system, cytoplasmic 
vacuoles, mitochondrial cristae and endoplasmic reticulum. The distribution of gold 
particles was increased along the basolateral membranes of distal tubules during acute 
rejection, predominantly for ET-1 antibody. ETA and ET 8 receptor immuno-labelling was 
in a similar distribution to ET-I. Figures 3.8, 3.9 and 3.10 show the ultrastructural 
localisation of ET-1 and its receptors. Table 3-1 depicts the score of the imrnunogold 
particles for the sections examined. 
Table 3-1. IMMUNOGOLD LABELLING COUNTS IN ACUTE REJECTION 
ET-1 PTL PTB DTL DTB








Rejection (total count) 152 <1
9>
193 \'OJ 184 \,OJ 190 («J 
Control (mean/section) 4.1 5.77 4.27 3.25 
Rejection(mean/section) 8 7.42 7.36 8.64 
ETA 
Control (total) 90 (
9) 
81 (1
0) 57 p) 85 \
IJ 
Rejection (total) 290 (_I
) 




Control (mean/section) 10 8.1 11.4 12.14 





J 31 (•J 29 (J
) 
Rejection (total) 174 <





Control (mean/section) 8.3 11 7.75 9.67 
Rejection(mean/section) 8.29 7.27 11.7 12.19 
PTL = Proximal tubule, luminal portion; DTL = Distal tubule, luminal portion 
PTB = Proximal tubule, basal DTB = Distal tubule, basal; Figures in superscript = number of sections 
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3.3.4.1 Glomerulonephritis 
ET-1 immuno-labelling was visualised in proximal and distal tubules (in the cytoplasm 
and, and to a lesser extent, in the nucleus), collecting ducts, endothelial cells of arteries and 
glomerular capillaries in control kidney. ETA and ET 8 receptor immuno-labelling was 
visualised in a similar distribution to ET-1.Gold particles occurred in clusters or singly, 
mainly along infoldings of the basolateral membranes, intercellular system, cytoplasmic 
vacuoles, mitochondrial cristae and endoplasmic reticulum, in a similar distribution as in 
acute rejection. Figures 3. 8, 3. 9 and 3. l O show the ultrastructural localisation of ET-1 and 
its receptors. Table 3-2 depicts the score of the immunogold particles for the sections 
examined. 
Table 3-2. IMMUNOGOLD COUNTS IN GLOMERULONEPHRITIS 
ET-1 PTL PTB DTL OTB 
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Control (mean/section) 3 3.7 6.4 5.2 
GN (mean/section) 2.7 2.9 4.3 4.3 
ETA 








GN (total) 73 \L>
) 59 (11) 64 \I>
/ 
70 1161 
Control (mean/section) 3.1 2.5 3.9 4.1 
GN (mean/section) 3.2 3.5 4.97 4.4 
ETB 
Control (total) 13 \b/ 15 (S
) 15 (
6) 37 \YJ 
GN (total) 39 l"
I 48 \<L
J 77 \ib) 88 \-'>} 
Control (mean/section) 2.2 1.9 2.5 4.1 






3.3.S LOCALISATION OF ENDOTHELIN-1 mRNA IN THE HUMAN KIDNEY BY 
RT-PCR 
Table 3-3: Sequence ofEndothelin-1 primers and expected length of PCR product 






















F : Fonvard Primer; R : Reverse Primer 
Specific reverse primers for reverse transcriptase (RT) reactions, and forward & reverse 
primer sets for non-nested polymerase chain reactions (PCR) used in the in situ RT-PCR 
detection of mRNAs for ET-I. For the RT-PCR, a predicted length of cDNA product is 
expected. 
Microscopy 
Renal biopsies from ten patients with acute rejection were studied. Label was detected in 
epithelial cells of the distal tubule and collecting duct in control kidney. Increased label 
was observed in kidney biopsies with acute rejection; in addition, label was observed in 
endothelial cells of arterioles and glomerular capillaries as well as the epithelial cells of 
Bowman's capsule, as illustrated by the images in Figures 3.11. 
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ATRIAL NATRIURETIC PEPTIDE 
Electrolyte and volume status is altered in patients with renal disease. Changes in atrial 
natriuretic peptide (ANP) would be anticipated in renal disorders. 
3.4.1 Plasma ANP 
Plasma ANP was measured by radio-immunoassay (RlA) in 16 patients with acute 
rejection and 14 control subjects. In acute rejection, the mean plasma value for ANP was 
47.36 pg/ml (SEM ± 5.26 pg/ml), median of 48.8 pg/ml and range of 13.0-80.0 pg/ml. In 
control subjects, the mean value was 23.93 pg/ml, SEM ± 2.78 pg/ml, median of 20.65 
pg/ml, range of 11.7-42.5 pg/ml (Table 3.4.1). Plasma ANP was significantly increased 
during acute rejection when compared to control subjects (p=0.00 I 1, Mann-Whitney test). 
There was no correlation between plasma ANP and serum creatinine levels (p=0.33, linear 
regression; p=0.69, Spearman rank correlation). Similarly, there was no correlation 
between plasma ANP and the degree of peripheral oedema. 
Table 3.4.1 ANP RIA results 
PLASMA ANP (pg/ml) 
Control Acute Rejection 
n (patient numbers) 14 16 
Mean ± SEM (pg/ml) 23.93 ± 2.78 47.36 ± 5.26 
SD 10.41 21.06 
Median 20.65 48.8 
Range 11.7-42.5 13.0-80.0 
p (Mann-Whitney test) O.OOll
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3.4.2 Urinary ANP results 
Urine ANP was measured in 13 patients with acute rejection and 4 control subjects. The 
mean± SEM urinary ANP value was 29.68 ± 5.01 pg/ml, median of 25.0 pg/ml and range 
of 4.5-73.6 pg/ml in acute rejection; control values were 2.65 ± 0.14 pg/ml, 2.65 pg/ml and 
2.3-3.0 pg/ml respectively. 
Table 3.4.2 Urine ANP RIA results 
URINARY ANP (pg/ml) 
Control Acute Rejection 
n (patient numbers) 4 13 
Mean ± SEM (pg/ml) 2.65 ± 0.14 29.68 ± 5.01 
SD 0.29 18.07 
Median 2.65 25.0 
Range 2.3 -3.0 4.5- 73.6 
p (Mann-Whitney test) 0.0008 
Urinary ANP was significantly increased during acute rejection when compared to controls 
(p=0.0008, Mann-Whitney test). 
3.4.3 RENAL CELLULAR LOCALISATION OF ANP: LIGHT MICROSCOPY: 
IMMUNOPEROXIDASE (PAP) METHOD 
ANP immunolabelling by the PAP method was visualised predominantly in distal tubules 
and collecting ducts in acute rejection and glomerulonephritis as well as in control kidney 
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tissue. In addition, labelling was observed in epithelial cells of Bowman's capsule, and 
endothelium and smooth muscle cells of the media of arteries and arterioles. 
3.4.3.1 Analysis of ANP labelling in acute rejection 
There was significantly decreased immunolabelling of glomeruli m biopsies of acute 
rejection (p= 0.002, Kruskal-Wallis test) compared to control kidney tissue; the labelling 
was more significantly decreased in mild rejection. The images are depicted in Figures 
3.12. 
Table 3.4.3.1 ANP image analysis in acute rejection 
GLOMERULI 
(i) Control (ii) Rejection (iii)Mild (iv)Severe
Rejection Rejection
n 6 6 4 3 
Patients 6 6 4 3 
Mean±SEM 124.12 ± 1.93 104.96 ± 4.94 98.47 ± 4.02 114.9 ± 3.85 
SD 4.72 12.11 8.04 6.66 
Median 125.91 104.64 96.53 114.59 
Range 118.23 -128.24 92.01 -121.71 92.01 -108.8 108.4-121.71 
p(Mann (i)vs(ii):0.002 **; (i)vs(iii):0.0095 (i)vs(iv):0.095; (iii)vs(iv) 0.11
Whitney) 
n= number of sect10ns ; * *Kruskal-Walhs test) ; measurements:p1xels per micron 
2
Immunolabelling of tubules in rejection was similar to control kidney tissue. ANP 
immunolabelling of arteries was similar to control kidney in acute rejection. There was 
significantly decreased immunolabelling of collecting ducts in acute rejection (p=0.0087, 
Mann-Whitney test) compared to controls. 
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Table 3.4.3.1 ANP image analysis in acute rejection 
ARTERIES 
Control Rejection 
n 6 6 
Mean±SEM 100.47 ± 5.49 104.36 ± 3.23 
SD 13.44 7.91 
Median 105.08 103.16 
Range 77.41 - 113.51 96.57 -117.59 
p(Mann Whitney) 0.4 
n= number of sections (one per patient); measurements: pixels per micron2
Table 3.4.3.1 ANP image analysis in acute rejection 
DIST AL TUBULES 
Control Rejection 
n 6 7 
Patients 6 7 
Mean± SEM 116.49 ± 5.52 107.99 ± 3.40 
SD 13.52 8.99 
Median 110.79 110.65 
Range 106.99-142.03 95.04 -120.5 
p >0.05 (Mann Whitney)
-n- number of sections; measurements: pixels per micron 
L
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T bl 3 4 3 1 ANP . I . . a e . . . image analysis m acute re.1ection 
COLLECTING DUCTS 
(i) Control (ii)Rejection (iii(Mild
Re_jection 
n 6 6 4 
Patients 6 6 4 
Mean±SEM 136.84± 2.36 113.48± 5. 75 102.5 ± 4.46 
SD 5.78 14.08 8.91 
Median 138.88 110.18 102.8 









p(Mann- (i)vs(ii):0.0087 (i)vs (iii) 0.0095
Whitney) (iii)vs(iv): 0.53 (i) vs (iv) <0.01 **
n- number of sections, ** Tukey-Kramer, measurements. pixels per micron 2
3.4.3.2 Analysis of ANP labelling in glomerulonephritis 
There was significantly decreased immunolabelling of glomeruli in glomerulonephritis (p= 
0.002, Kruskal-Wallis test) compared to control kidney tissue. 
Table 3.4.3.2 ANP image analysis of glomeruli in renal disease 
GLOMERULI 
(i) Control (ii) GN iii)Non-prolif (iv)Prolif GN
GN
N 6 6 2 3 
Mean ±SEM 124.12 ± 1.93 108.03 ± 1.64 104.73 ± 0.52 109.98± 2. 78 
Median 125.91 107.24 104.73 108.04 
Range 118.23-128.24 104.21-15.47 104.21-105.25 106.44-115-4 7 
p(Mann Whitney) (i)vs(ii):0.002*; (i)vs(iii):0.07 {iii)vs(iv):0.2; (i)vs (iv):0.02 
n= number of sections and number of patients; *Kruskal-Wallis; measurements: pixels per 
micron2
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Table 3.4.3.2 ANP image analysis of arteries in renal disease 
ARTERIES 
Control GN 
n 6 6 
Patients 6 6 
Mean ±SEM 100.47 ± 5.49 106.9 ± 5.96 
Median 105.08 104.1 
Range 77.41- 117.59 93.87 - 133.98 
p >0.05 (Mann Whitney)
-n- number of sect10ns, measurements. pixels per micron 2
Table 3.4.3.2 ANP image analysis in renal disease 
DIST AL TUBULES 
(i) Control (ii) GN (iii)Non-prolif (iv)Prolif GN
:;N
N 6 6 2 3 
Patients 6 6 2 3 
Mean±SEM 116.49 ± 5.52 110.42 ± 5.27 126.35 ± 4. 78 101.92 ± 1.97 
Median 110.79 104.82 126.35 101.34 
Range 106.99- 142.03 98.84 - 131.13 121.58 - 131.13 98.84 - 105.59 
p* (i)vs(ii): >0.05; (i)vs(iii) 0.29 (i)vs(iv) 0.024; (iii)vs(iv) : 0.2
2 -* Mann Whitney test; n- number of sections, measurements. pixels per micron
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Table 3.4.3.2 ANP image analysis in renal disease 
COLLECTING DUCTS 
(i) Control (ii) GN (iii)Non-prolif (iv)Prolif GN
GN 
6 8 5 3 
Patients 6 8 5 3 
Mean± SEM 136.84 ± 2.36 98.6 ± 8.07 123.88 ± 6.14 91.84 ± 2.66 
Median 138.88 94.5 125.71 94.25 
Range 126.48-142.19 59.94 -138.12 103.87-138.12 86.52-94.74 
p* (i) vs (ii):0.0027;(i)vs (iii) 0.095 (i) vs (iv) 0.0238; (iii) vs (iv) 0.0357
7 
*Mann-Whitney test; n= number of sections; measurements: pixels per micron
Immunolabelling of tubules was reduced in proliferative GN (p=0.024, Mann-Whitney 
test), compared to control kidney tissue. Labelling of collecting ducts was reduced in 
glomerulonephritis compared to control kidney tissue (p= 0.0027); labelling was reduced in 
proliferative glomerulonephritis compared to control kidney tissue (p=0.0238) and non­
proliferative glomerulonephritis (p=0.0357). The images are depicted in Figures 3 .12. 
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URINARY TISSUE KALLIKREIN 
The kallikrein-kinin system is known to be involved in inflammation and renal disease. 
This study measures tissue kallikrein as well as basal (endogenous) and generated kinin in 
urine in patients with acute renal allograft rejection and various renal disorders, the first 
time that such a study has been conducted. Kallikrein and kinins are produced in the kidney 
in renal disease; thus their assay in urine would reflect their status in renal disorders. 
3.5.1 PATIENT DEMOGRAPHICS 
Acute Rejection Group 
Twenty renal transplant patients with acute rejection were studied: there were 18 males and 
2 females; of these, 13 had received living related donor kidneys, 3 had received kidneys 
from living unrelated donors and 4 from cadaver donors. Their mean age was 35.8 years 
(range 16-52 years). Mild rejection was present in 5 patients, moderate rejection in I 0 
patients and severe rejection in 5 patients (Appendix 3.3.1.1 ). 
Renal Disorders 
Twenty nine patients with various renal disorders were studied: 20 were males and 9 
females, with a mean age of 34 years (range 13-60 years). Six patients had 
mesangiocapillary glomerulonephritis (MCGN), 3 had class IV lupus nephritis (SLE), I 
membranous nephropathy (MGN), 3 minimal change disease with nephrotic syndrome 
(MCNS), 3 imrnunoglobulin A (lgA) nephritis, 3 hypertensive nephrosclerosis (HPT neph), 
10 with miscellaneous causes (reflux nephropathy, obstructive uropathy, end stage diabetic 
nephropathy); 14 patients were on dialysis at the time of the study (Appendix 3.3.1.2}. 
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Control Group 
Twenty subjects formed a control group; these were kidney donors who were studied prior 
to uni-nephrectomy. There were 8 males and 12 females with a mean age of 34.8 years 
(range 22-48 years). Their details are presented in Appendix 3.3 .1.3. Further controls were 
a group of24 healthy volunteers (8 males and 16 females), mean age 45.9 years, (range 27-
64 years); 16 kidney donors (12 females and 4 males), mean age 34.5 years (range 25-52 
years) following nephrectomy who served as single-kidney controls; and 20 stable kidney 
transplant recipients, 12 males and 8 females, mean age 35.7 years (range 17-58 years) who 
served as immunosuppressive controls. 
3.5.2 MEASUREMENT OF TISSUE KALLIKREIN 
3.5.2.1 ENZYMIC ACTIVITY 
Tissue kallikrein (TK) was measured in the urine of 20 kidney donors pre-operatively and 
16 donors at 7 months to 6 years post-nephrectomy by an amidase assay; these served as 2 
and single kidney controls respectively; 20 stable transplant recipients served as an 
immunosuppressive control group. Twenty transplant recipients with acute rejection and 29 
patients with glomerulonephritis were studied. Annexure 3.5.1 outlines the details. 
3.5.2.1.1 Control subjects 
Kidney donors 
Kidney donors (prior to nephrectomy) had a mean± SEM urinary TK excretion of 50.19 ± 
20.39 ng/ug protein (range 0.02-314 ng/ug protein), with a median value of 8.09 ng/ug 
protein. The results are summarized in Table 3.5. l 
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Kidney donors (post nepltrectomy) 
Following uni-nephrectomy, mean ± SEM urinary TK excretion measured 2.13 ± 0.42 
ng/ug protein (range 0 - 5.59 ng/ug protein), with a median of 1.47 ng/ug protein. The 
difference between these donor groups before and after nephrectomy was significant, with 
a two-tailed p value of 0.017 (Mann-Whitney test). 
Stable kidney transplant recipients 
Urinary TK excretion in stable transplant recipients measured a mean± SEM of 2.07 ± 0.4 
ng/ug protein (range 0 - 6.94 ng/ug protein) and median of 2.03 ng/ug protein. Urinary TK 
excretion was similar in stable transplant recipients and donors post-uninephrectomy 
(p=0. 799; Mann-Whitney test) but was very significantly decreased when compared to 
donors pre-nephrectomy (p=0.0069; Mann-Whitney test). 
Table 3.5.1 Urinary tissue kallikrein enzymic activity 
(i) Donors (ii) Donors (iii) Stable
Pre-op Post-op Transplants
n 20 16 20 
Mean±SEM 50.19 ± 20.39 2.13 ± 0.42 2.07 ± 0.4 
SD 91.16 1.69 1.77 
Range 0.02 -314.0 0.0- 5.59 0.0-6.94 
Median 8.09 1.47 2.03 
p (Mann- (i) vs (ii): 0.017; (i)vs(iii) : 0.0069; (ii)vs(iii): 0. 799
Whitney test) 
n= patient numbers; measurements: ng/ug protein 
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3.5.1.1.2 Acute rejection 
Mean ± SEM urinary TK excretion measured 1.35 ± 0.37 ng/ug protein during acute 
rejection, with a median of 0.63 ng/ug protein and range 0 - 5.67 ng/ug protein. TK was 
very significantly decreased during rejection when compared to donors pre-nephrectomy 
(p=0.001). While urinary TK excretion was decreased during acute rejection, it was not 
significant when comparing the rejection group with donors post-uninephrectomy 
(p=0.0672) and stable renal transplant recipients (p=0.133; Mann-Whitney test). 
Table 3.5.2.1 Urinary tissue kallikrein enzymic activity 
(i)Donors (ii) Donors (iii) Stable (iv) Acute
Pre-op Post-op Transplants Rejection
n 20 16 20 20 
Mean±SEM 50.19 ± 20.39 2.13 ± 0.42 2.07 ± 0.4 1.35 ± 0.37 
SD 91.16 1.69 1.77 1.65 
Range 0.02-314.0 0.0-5.59 0.0-6.94 0.0-5.67 
Median 8.09 1.47 2.03 0.63 
p (i)vs(iv):0.001 (iii) vs (iv) : 0.133
(Mann-
Whitney test) (ii) vs (iv) : 0.0672; (ii) vs (iii) : 0. 799
n= patient numbers; measurements: ng/ug protein 
3.5.2.1.3 Serial urinary TK enzymic measurements following transplantation 
While TK excretion increased after renal transplantation, decreased during acute rejection 
and increased again after treatment of rejection, there was no significant difference in serial 
urinary TK excretion pre- and post- transplant. 
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Table 3.5.2.1.3 Serial urinary TK enzvmic activity followim! renal transolantation 
(i) Pre-TP (ii) Post TP (iii) Acute (iv) After Rx of
(D3-4) Rejection Rejection
n (patients) 12 12 17 16 
Mean±SEM 1.99 ± 0.69 3.41 ± 0.85 1.22 ± 0.40 3.05 ± 1.57 
SD 2.37 2.93 1.63 6.26 
Range 0.01 - 8.36 0.008 - 7.55 0.38-2.06 0.0-24.31 
Median 1.30 2.88 0.45 0.87 
p(Dunn's (i) vs (ii) : > 0.05 (iii) vs (iv) : > 0.05
multiple 
(i) vs (iii) : > 0.05; (i) vs (iv) : > 0.05
comparisons) 
measurements: ng/ug protein 
3.5.2.4 Renal disease 
Urinary TK excretion in this group measured a mean± SEM of 7.37 ± 2.42 ng/ug protein, 
with median of 3.0 ng/ug protein and range 0.01-48.02 ng/ug protein. TK excretion was 
markedly decreased in renal disease compared to controls [( donors prior to nephrectomy), 
p=0.0158; unpaired t test]. Urinary TK excretion was significantly decreased during acute 
rejection when compared to renal disease (p=0.0068; Mann-Whitney test). 
T able 3.5.2 Urinary tissue kallikrein enzvmic activi1 
(i)Controls (ii) Acute (iii) Renal
(Donors Pre-op) Rejection Disease
n (patients) 20 20 29 
Mean±SEM 50.19 ± 20.39 1.35 ± 0.37 7.37 ± 2.42 
SD 91.16 1.65 13.02 
Range 0.02 - 314.0 0.0-5.67 0.01 - 48.02 
Median 8.09 0.63 3.0 
p(Mann- (i) vs (iii) : 0.0158; (ii) vs (iii) : 0.0068
Whitney test) 
measurements: ng/ug protein 
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3.5.2.5 Correlation between enzymic urinary TK activity and serum creatinine 
There was no correlation between enzymic TK activity and serum creatinine by linear 
regression during acute rejection (p=0.874) and with renal disease (p=0.8566) 
3.5.3 URINARY TISSUE KALLIKREIN ELISA ASSAY 
Four groups served as controls: kidney transplant donors pre-and post-nephrectomy, 
volunteer subjects and stable renal transplant recipients. Immunoreactive tissue kallikrein 
was measured by ELISA in these control groups, serially following renal transplantation, 
during acute rejection and in patients with renal disease. Results are depicted in Table 3.5.3 
3.5.3.1 Control subjects 
Donors pre-nephrectomy 
The mean± SEM value for TK in 19 donors pre-nephrectomy measured 46.88 ± 9.4 ng/ml, 
median of 42.0 ng/ml, range of 0 - I 65.4 ng/ml. 
Donors after uni-nephrectomy 
Sixteen donors studied post-nephrectomy had TK measurements of mean ± SEM of 18.48 
± 8.3 ng/ml, median of 8.1 ng/ml and range of 0 - 128.24 ng/ml. Tissue kallikrein 
excretion was significantly decreased in donors post- nephrectomy compared to pre -
nephrectomy (p=0.0328; unpaired t test). 
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Combined group (normal volunteers and donors pre-nepltrectomy) 
Normal volunteer subjects (n=24) and kidney donors pre-nephrectomy (n= l 9) were 
combined for statistical analysis and the combined mean ± SEM was 61.14 ± 6.14 ng/ml, 
median of 66.25 ng/ml and range of0-165.39 ng/ml. 
Stable renal transplant recipients 
In 21 stable transplant recipients, TK values were mean± SEM of 47.54 ± 10.64 ng/ml, 
median of 33.2 ng/ml and range of 0 - 129.39 ng/ ml. The difference between the stable 
transplant recipients and combined controls was not significant (p=0.24; unpaired t test); 
however, TK was significantly increased in stable transplant recipients compared to donors 
post-nephrectomy (p=0.0482; unpaired t test). 
Table 3.5.3.1 Urinary Tissue Kallikrein ELISA measurements 
(i) Donors (ii) Donors (iii)Donors (iv) Stable
Pre-op Post-op preop+volunteers transplants
n 19 16 43 21 
Mean±SEM 46.88 ± 9.37 18.48 ± 8.30 61.14 ± 6.14 47.54 ± 10.64 
SD 40.83 33.21 40.25 48.74 
Range 0.0-165.39 0.0-128.24 0.0-165.39 0.0-129.39 
Median 42.0 8.1 66.25 33.2 
p (unpaired t- (i) vs (ii) : 0.0328 (iii) vs (iv) : 0.24
test) (ii) vs (iv) : 0.0482
n= patient numbers; measurements: ng/ml 
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3.5.3.2 Acute rejection 
Urinary TK excretion during 20 episodes of acute rejection was a mean ± SEM of 48.50 ± 
11.22 ng/ml, median of 42.5 ng/ml and range of 0 - 157.14 ng/ml. Urinary TK ELISA was 
significantly increased during acute rejection compared to donors post-nephrectomy 
(p=0.0474; unpaired t test); however there was no difference when compared to the stable 
transplant group (p=0.95). 
Table 3.5.3.2 Urinary Tissue Kallikrein ELISA measurements 
(i) Donors (ii) Donors (iii)Donors (iv) Stable (v) Acute
Pre-op Post-op +volunteers transplants rejection
19 16 43 21 20 
Mean±SEM 46.88± 9.37 18.48 ± 8.30 61.14± 6.14 47.54± 10.64 48.5 ± 11.22 
SD 40.83 33.21 40.25 48.74 50.18 
Range 0.0-165.39 0.0 -128.24 0.0-165.39 0.0 - 129.39 0.0 -157.14 
Median 42.0 8.1 66.25 33.2 42.5 
p(unpaired (ii) vs (v) : 0.0474; (iii) vs (iv) : 0.24; (iv) vs (v) : 0.95
t-test)
n= patient numbers; measurements: ng/ml
3.5.3.3 Serial urinary tissue kallikrein measurements following renal transplantation 
The mean, median and ranges for urinary TK are shown in Table 3.5.3.3. There was no 
statistical difference in TK excretion during the different phases at any period post­
transplantation in this group. 
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Table 3.5.3.3 Serial Tissue Kallikrein ELISA following renal transplantation 
(i) Pre-TP (ii) Post-TP (iii) During (iv) After Rx
(D3-4) acute Rei of Rejection 
n(patient 11 13 17 17 
numbers 
Mean±SEM 30.2 ± 16.42 36.20± 13.92 40.57 ± 11. 79 40.91 ± 7.45 
SD 54.45 50.19 48.60 30.72 
Range 0.0 -165.36 0.0-132.36 0.0-157.14 0.0-81.0 
Median 0.0 8.0 35.0 46.0 
(i) vs (ii) : 0.78 (iii) vs (iv): 0.98
p (unpaired 
t-test) (i) vs (iv): 0.51; (ii) vs (iii): 0.81; (i) vs (iii): 0.60
measurements: ng/ml
3.5.3.4 Renal disease 
Urinary TK excretion in 13 patients with renal disease measured a mean± SEM of 31.47 ± 
14.56 ng/ml, median of O and range of O - 165.39 ng/ml (Table 3.5.3.4). TK was 
significantly decreased in this group compared to the combined 2-kidney control group 
(p=0.0347; unpaired t test). 
Table 3.5.3.4 Urinary tissue kallikrein ELISA measurements 
(i)Donors and (ii) Acute (iii) Renal
Volunteers Rejection disease
n=numbers 43 20 13 
Mean±SEM 61.14 ± 6.14 48.5 ± 11.22 31.47 ± 14.55 
SD 40.25 50.18 52.45 
Range 0.0-165.39 0.0-157.14 0.0-165.39 
Median 66.25 42.5 0.0 




3.5.3.5 Correlation between urinary tissue kallikrein and serum creatinine 
There was no correlation between TK ELISA and serum creatinine by linear regression 
during acute rejection (p=0.7021) and with renal disease (p=0.2556). 
3.5.4 KININS 
Basal urinary kinin excretion was measured in 32 normal subjects (kidney donors and 
normal volunteers), 15 kidney donors post-nephrectomy, 22 stable transplant recipients, 20 
kidney transplants with acute rejection and 19 patients with glomerulonephritis, followed 
by measurement of generated kinin in their urine. Table 3.5.4 summarizes their 
measurements. Basal kinin excretion in the urine was decreased in kidney donors post-
nephrectomy when compared to the normal subjects (p < 0.001). 
T bl 3 5 4 B a e . . asa urmary nm measuremen s ki t 
(i)Normal (ii)Donors (iii)Stable TP (iv)Ac (v) GN
controls post-op rejection
n=numbers 32 15 22 20 19 
Mean± 3.88 ± 0.02 ± 0.44± 15.45 ± 27.39± 23.22 
SEM 0.62 0.41 0.11 6.86 
SD 3.50 1.60 0.52 30.67 101.19 
Median 3.18 1.40 0.27 5.45 2.80 
Range 0.26 - 18.41 0.40-6.40 0.19 - 2.60 0.20- 137.5 0.20-444.8 
p (Dunn's (i) vs (ii) : < 0.001; (iii) vs (iv) : <0.001
multiple 
comparisons) (i) VS (iii) :< 0.001; (ii) VS (iii) :< 0.05; (i) VS (v) :> 0.05
measurements: ng/ml 
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Basal kinin excretion was significantly decreased in stable transplant recipients compared 
to normal subjects (p<0.001), and increased when compared to donors post nephrectomy 
(p<0.05; Dunn's multiple comparisons). Basal urinary kinin excretion was significantly 
increased during acute rejection when compared to the stable transplant recipients 
(p=<0.001). While basal kinin excretion was increased in glomerulonephritis when 
compared to normal controls, this did not reach statistical significance (p>0.05). There was 
no correlation between serum creatinine and basal kinin by linear regression during acute 
rejection (p=0.63) and renal disease (p=0.59). 
Urinary kinin generation was decreased in kidney donors post nephrectomy compared to 
normal control subjects (p=<0.00 I). Significantly decreased kinin was generated in the 
urine during acute rejection (p=0.001) and glomerulonephritis (p<0.01; Dunn's multiple 
comparisons test), compared to normal controls. There was no correlation between serum 
creatinine and generated kinin during acute rejection (p=0.56) and renal disease (p=0.43 ). 
Table 3.5.4 1 Generated urinary kinin measurements 
(i)Normal (ii)Donors (iii)Stable TPs (iv)Acute (v) GN
controls post-op Rejection
n= numbers 33 15 22 20 19 
Mean± 88.57 ± 18.67 ± 46.6 ± 25.35 ± 40.19± 
SEM 10.64 6.45 4.05 5.91 9.63 
SD 61.11 24.99 18.98 26.43 41.97 
Median 71.72 0.0 41.65 24.20 29.4 
Range 20.25 -270.8 0.0-70.5 19.0-92.3 12.98-37.72 0.0-138 
p* (i) vs (ii):< 0.001; (i) vs (iv): 0.001; (i) vs (v): < 0.01
*Dunn's multiple comparisons; measurements: ng/ml
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3.5.5 CONFOCAL MICROSCOPY: IMMUNOFLUORESCENT TK LABELLING 
Confocal images of anti-TK antibody immunolabelling in kidney biopsies of acute 
rejection, glomerulonephritis and control kidney tissue were subjected to image analysis. 
3.5.5.1 TK 
TK was immuno-visualised maximally in the connecting tubules and collecting ducts of 
control kidney tissue (Figure 3 .13 ). 
3.5.5.1.1 Acute rejection 
There was decreased TK immunolabelling in the distal tubules during rejection, 
significantly so in severe rejection when compared to control kidney (p=0.0357; Mann­
Whitney test). The data is shown in Table 3.5.5.1.1 
Table 3.5.5.1.1 TK immunofluorescence: Distal tubule 
(i) Control (ii)Mild (iii)Severe
Re.iection Rejection
n(structures) 15 14 5 
Patients 3 4 5 
Mean ±SEM 162 ± 30.3 57.8 ± 32.1 44.6 ± 15.3 
Median 154 35 30 
Range 114-218 9-152 12-87
SD 52.4 64.1 34.1 
p* (i) vs (ii): 0.11; (i) vs (iii): 0.0357
*Mann- Whitney; measurements: p1xelsx 100/micron 2
214 
3.5.5.1.2 Glomerulonephritis 
There was decreased immunolabelling of distal tubules in both non-proliferative and 
proliferative disorders; labelling was significantly reduced in non-proliferative GN 
(p=0.0238; Mann-Whitney test) when compared to control kidney. 
Table 3.5.5.1.2 TK immunofluorescence: Distal tubule 
(i) Control (ii)Non (iii)Proliferative
Proliferative GN GN 
n(structures) 15 7 3 
Patients 3 6 3 
Mean±SEM 162.0 ± 30.3 23 ± 13.5 40.6 ±29.2 
Median 154 10.1 16.5 
Range 114-218 2-89.5 6.5-98.7 
SD 52.5 33.1 50.6 
p* (i) vs (ii) :0.0238; (i) vs (iii) :0.10





Appendix B 3.1 Demographics of patients from whom kidney tissue samples were obtained at autopsy 
AGE RACE SEX CAUSE OF DEATH TIME BETWEEN AUTOPSY 
AND DEATH 
21 y African Male Stab chest 16 h 
25 y African Male Stab chest 15 h 
25 y African Male Stab chest 16 h 
30y African Male Gun shot chest 16 h 
40 y Indian Male Acute myocardial infarction 23 h 
24y Caucasian Male Acute carbon monoxide poisoning 22h 
46y Indian Male Hanging 6h 
31 y Indian Male Hanging 6h 
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I - Indian 
B - Black 
W - White 






















































































,ppen 1x . . .  ahent pro I e an A d' B 3 2 3 P fil d plasma ET I. - m renal disease 
Pt Race Age Sex BP Creatinine 
µmol/1 
1 I 18 F H Dialysis 
2 B 30 M H 132 
3 B 16 M H 92 
4 B 35 M N 180 
5 I 43 F H Dialysis 
6 I 34 M H 108 
7 I 25 M H 113 
8 I 45 F N 84 
9 I 24 M H 250 
IO w 48 M H 396 
11 B 39 M H 393 
12 I 26 F H 113 
13 I 47 F H Dialysis 
14 I 13 M N 56 
15 B 21 F N 65 
16 B 33 F N 53 
17 B 59 M H 325 
18 C 22 M N 140 
19 B 24 M H 290 
20 I 35 F N 120 
21 B 30 F N 77 
22 B 32 F N 80 
23 B 32 F N 72 
24 B 26 F N 70 
25 I 26 M N 91 
26 B 34 F N 86 
27 B 55 M N 350 
28 I 38 M H 156 
29 B 52 M H 766 
Blood pressure : H = hypertensive; N= normotensive 
SLE IV= Class IV lupus nephritis 































MCNS = nephrotic syndrome due to minimal change disease 
MPGN = mesangioproliferative GN 
MGN = membranous GN 
MCGN = mesangiocapillary GN 
HPT neph = hypertensive nephrosclerosis 
CIN = chronic interstitial nephritis 
NS = nephrotic syndrome 
M = male B = black I =  Indian 
F = female W = white C = coloured 
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Renal Plasma ET-1 Urine ET 
Histoloi?y (D!!/ml) (pg/ml) 
SLEIV 4,5 
MCGN 1,6 
MPGN 0,6 0.04 
MCGN 4,0 
SLEIV 3,0 0.5 







MCGN 2,53 0.4 
SLEIY 4,12 0.95 
SLEIV 5,56 
MCNS 1,41 0 
MGN 0,45 0 
MCNS 0,63 0.38 
MGN 1,94 1.09 
lgA and 2,0 0.22 
NS 
CIN 2,8 





MCNS 1, I 
MGN 3,0 
CIN 2,1 
HPT Neph 1,6 
HPT Neph 1,04 0.98 
Appendix B 3.2.4:Plasma ET-1 in patients with end stage renal failure on dialysis 
Subject Age Sex BP 
1 51 M H 
2 35 M H 
3 43 M H 
4 12 M H 
5 52 M H 
6 53 M N 
7 33 M H 
8 16 M H 
9 22 M H 
10 23 F H 
11 33 M H 
12 52 M H 
13 35 M H 
14 37 M H 
15 23 M H 
16 47 F H 
17 42 F H 
18 35 M H 
19 28 M H 
20 26 M H 
21 36 M H 
22 35 M N 
23 60 F N 
24 36 F H 
M = male; F = fem ale 
H = hypertension; N = normotension 
GN= glomerulonephritis 
MCGN =mesangiocapillary GN 
SLE = systemic lupus erythematosis 
lgA= immunoglobulin A nephritis 
Diagnosis Plasma 
(pg/ml) 
Membranous GN 1,68 
MCGN 1,23 





Unknown GN 2,34 
Unknown 1,89 











Unknown GN 2,0 
Renal cortical necrosis 1,4 
Chronic interstitial 0,29 
Nephritis 
Unknown 1,6 



























B3.2.5 Serial ET-1 measurements before and following transplantation 
Pt Pre-TP Post-TP Acute Re_jection Post Rx Rejection 
1 1.68 2.64 1.56 1.12 
2 1.86 1.12 
3 1.23 0.82 0.87 1.12 
4 0.93 1.11 
5 4.29 2.0 
6 1.1 0.75 1.5 
7 1.1 0.95 
8 2.34 0.96 3.76 1.25 
9 1.84 1.55 
10 1.9 1.1 2.3 1.04 
11 0.8 2.33 2.16 
12 1.1 1.78 1.78 
13 2.4 � 1.45 1.98 1.5 
14 2.63 1.28 1.55 
15 1.43 1.59 1.23 0.85 
16 3.13 2.35 
17 1.35 1.03 
18 3.38 1.25 
19 2.12 1.32 
20 1.11 2.4 2.42 1.94 
21 1.5 1.73 
22 0.71 1.05 
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B 3.4.1.Donor Controls 
Donor Age Sex Race TKAmidase TKELISA BASAL GEN 
ng/ug protein ng/ml KININ KININ 
(ne/ml) (ne/ml) 
S1D 38 M I 12.77 70 
S5D 40 F I 3.29 73 
S8D 27 F B 14.3 56 
S12D 30 F I 28.63 15.23 
S23D 45 M I 50.68 65 
S27D 35 M I 24.22 26 1.2 98.2 
S28D 40. M I 1.37 69 2.05 100.7 
S32D 26 F I 225.9 101 2.0 174.6 
S36D 44 F B 0.02 18 
S39D 35 F I 1.37 0.0 1.9 89.2 
S41D 30 M I 64.2 70 
S42D 43 F I 314 7 2.7 113.7 
S45D 22 M B 2.43 18 
S48D 48 F I 2.79 43 3 80.9 
S51D 25 F I 222 7.4 
S52D 28 M I 29.5 42 5.0 113.7 
S53D 27 F C 3.41 12.12 
S54D 25 F B 0.02 40 7.6 40.7 
S15D 39 F I 2.52 0.0 
S18D 48 M C 0.46 165.39 
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B3.4.2 Volunteers Controls 
Patient Age Sex TKELISA TKAMIDASE KININ Gen KININ 
n�/ml n�/mmrot Basal 
249 46 F 75.97 2.18 6.05 52.78 
250 36 F 7.9 0.05 6.04 21.83 
251 42 M 25.88 0.06 8.52 41.68 
385 47 F 0 0.08 5.25 20.25 
386 38 F 50.24 0.5 4.46 20.94 
387 27 M 75.83 0.18 6.02 20.9 
388 40 M 48.01 0.18 5.86 20.45 
390 52 F 0 1.4 18.41 56.09 
448 59 F 85.13 0.15 4.27 71.72 
449 35 F 114.47 1.92 3.99 120.01 
450 so F 86.48 0.37 3.35 68.17 
451 47 F 68.76 0.25 1.18 68.09 
453 40 M 74.92 0.31 2.18 126.65 
454 43 M 118.02 0.42 1.37 74.12 
455 39 F 115.6 0.24 4.3 55.42 
456 52 M 111.91 1.23 3.96 71.13 
457 64 M 106.38 0.47 0.26 45.75 
460 42 F 88.33 0.49 0.75 67.74 
461 50 F 66.25 0.94 1.76 270.8 
462 42 F 56.98 1.11 1.54 251.5 
463 40 F 55.27 0.38 0.97 164.4 
464 48 M 85.67 0.77 1.11 155.4 
505 58 F 121.02 1.57 0.89 110.1 





B 3.4.5 Stable Transplant Patients 
TK TK KININ KININ 
Patient Sex Age ELISA AMIDASE BASAL GEN 
475 M 20 0 0.76 0.22 19 
476 M 30 60.94 2.4 0.34 56.5 
477 M 23 72.09 2.52 0.26 47.9 
478 F 42 0 2.42 0.37 30.1 
481 F 24 0 1.14 0.25 36.2 
482 M 25 33.2 
483 F 41 129.39 6.94 0.23 23.7 
484 M 43 0 0.83 0.2 40.3 
485 F 58 5.79 2.57 0.23 51 
487 M 21 9.67 0 0.48 41.7 
488 M 46 125.84 4.2 0.27 31.7 
489 M 32 0 0.12 0.53 80.4 
490 F 43 116.02 2.41 0.27 44.2 
491 M 35 66.23 4.55 0.57 92.3 
492 F 27 71.35 1.97 0.33 82.8 
493 M 47 91.74 0 0.19 40 
494 F 36 115.02 3.71 0.19 36.8 
495 M 39 0 2.09 0.36 35 
497 F 46 0 1.39 0.26 47.4 
498 M 44 86.29 0.11 0.28 65.3 





4.1 FLUID VOLUME STATUS AND EFFECTIVE RENAL PLASMA FLOW 
Total body water (TBW) was measured in 5 transplant recipients immediately pre­
transplant following dialysis, when they were assessed as having reached "dry" weight, 
namely showing no evidence of fluid retention. TBW was measured following 
transplantation and during rejection in 3 patients, when fluid retention was apparent; and 
again when kidney function had stabilised, demonstrating reduction in body weight and 
fluid retention and hence a reduction in TBW. Effective renal plasma flow was measured in 
6 transplant patients, and was shown to be reduced in patients during rejection. 
4.2 ENDOTHELINS IN RENAL FUNCTION AND RENAL DISEASE 
Endothelin-1 (ET-1) affects renal physiology by influencing sodium and water excretion 
and vascular and mesangial tone. It also acts as a growth factor by promoting cell 
proliferation and matrix formation. ET-1 may activate and be chemotactic for monocytes, 
which can in turn secrete ET-1 (Martin-Nizzard et al., 1991; Achmad and Rao, 1992), and 
may thus influence renal inflammation. 
4.2.1 Endothelins in acute renal allograft rejection 
ET-1 in tlze circulation and urine 
Plasma ET-1 levels were reported to be elevated in pre-dialysis patients with chronic renal 
failure and in patients on regular haemodialysis whereas they were found to be normal in 
stable renal transplant patients treated with cyclosporine A [(CyA); Stockenhuber et al., 
1992]. An association between increased plasma ET-1 levels and CyA was first suggested 
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in a renal transplant patient receiving high (toxic) doses of Cy A (Fogo et al., 1990). After 
administration of Cy A, plasma ET-1 levels increase only transiently in transplant patients, 
because ET-1 is rapidly metabolised and cleared from the systemic circulation (Grieff et 
al., 1993). Cyclosporine and related immunosuppressants such as Tacrolimus (FK506) 
directly stimulate ET-1 release from mesangial and/or endothelial cells (Langman and 
Yatscoff, 1994; Goodall et al., 1995; Kohno et al., 1995). Cyclosporine A increases renal 
ET-1 mRNA expression (Iwasaki et al., 1994). Anti-ET antibodies and ET receptor 
antagonists an1eliorated acute CyA-induced renal vasoconstriction (Kon and Awazu, 1992; 
Lanese and Conger, 1993; Conger et al., 1994; Brooks and Contino, 1995; Kon et al., 
1995). Chronic oral administration of CyA increases urinary ET-1 in the rat. Both acute 
and chronic CyA toxicity are associated with reduced renal function and elevated plasma 
ET-1. As Cy A levels reach therapeutic levels and renal function improves, urinary ET- I 
levels return to baseline (Perico et al., 1992). Mixed ET antagonist SB209670 prevented 
acute vasocontriction and reduction of renal function induced by high dose Cy A (Brooks 
and Contino, 1995). Little is known about the effect of steroids on ET-1 production and 
release. In vitro, pre-treatment of rat vascular smooth muscle cells with dexamethasone 
resulted in an attenuated response to ET- I due to down-regulation of ET A receptors. Other 
steroids (prednisolone and hydrocortisone) gave similar responses but were less effective 
(Nambi et al., 1992). 
In the present study, plasma endothelin-1 levels were measured serially, in patients prior to 
renal transplantation, post-transplantation when stable, during acute rejection and 
subsequently after treatment of rejection. The highest levels of ET-l were observed prior to 
transplant, in patients with chronic renal failure on dialysis. Following transplantation, ET-
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1 levels decreased, increased during episodes of acute rejection and decreased again after 
treatment of rejection. This corresponded with elevated urinary ET-I levels during acute 
rejection, suggesting that ET-1 is produced by the kidney, probably by inflammatory cells 
within the renal cellular structures and interstitium, reflecting endogenous renal ET-1 
synthesis (Abassi et al., 1992). 
Cellular localisation of ET-I 
Immunofluorescent studies showed increased ET-1 labelling of proximal and distal tubules 
during rejection Electron microscopy revealed ET-1 immunolabelling in epithelial cells of 
proximal and distal tubules and endothelial cells of blood vessels and glomerular 
capillaries, specifically in cytoplasm of cells, endoplasmic reticulum and mitochondria. 
Label was found in increased amounts adjacent to the intercellular system and within 
vacuoles and secretory vesicles. ET-I is stored within these vesicles and released at the cell 
surface after an appropriate stimulus. The characteristic feature of acute rejection is 
infiltration of the graft by host mononuclear cells; these lymphocytes and macrophages 
infiltrate the interstitium and tubular epithelium. The interstitial infiltrate is associated with 
oedema. In this study, ET-1 label was also demonstrated in the mononuclear cells 
infiltrating the tubules during acute rejection by electron microscopy as well as by the 
immunoperoxidase method. ET-I mRNA was upregulated in the tubular epithelial cells 
and capillary endothelial cells, as well as the inflammatory infiltrate, during acute rejection 
as demonstrated by in situ RT-PCR. The inflammatory process of acute cellular rejection is 
predominantly confined to the interstitium, and marked intragraft upregulation of ET-I 
may occur without significant changes in ET-I plasma concentrations (Watschinger et al., 
1995), unless there is endothelial damage as occurs with vascular rejection (Watschinger et 
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al., 1994). Possible causes and effects of increased ET-1 production during acute renal 
allograft rejection are suggested in Fig 4.1. 
Fig 4.1: Possible causes and effects of increased ET-1 production during acute renal 
allograft rejection. 










Ref: Watschinger B and Sayegh M H (1996), Am J Kid Dis, 27: 151-161 (I 56). 
Abbreviations: RPF= renal plasma flow; GFR= glomerular filtration rate; TXA2= 
thromboxane; OKT3= Orthoclone; PDGF= platelet-derived growth factor 
Activated mononuclear cells infiltrate the allograft and stimulate the secretion of cytokines 
which influence the production of ET-1 by other cells in vitro: tumour necrosis factor a 
increases ET-1 mRNA and causes secretion of ET-1 by capillary endothelial cells, 
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epithelial cells and rat mesangial cells (Kohan, 1991 ); similarly IL-Ip induces ET-1 release 
from renal epithelial cells (Ohta et al., 1990). Platelet activation triggers the release of 
transforming growth factor (TGFP), thromboxane A2, PDGF and thrombin from platelets 
that accumulate in the graft as a consequence of the rejection process. This results in ET- I 
secretion and upregulation of ET-1 gene expression in endothelial, vascular smooth 
muscle, renal mesangial and epithelial cells (Kurihara et al., 1989; Watschinger and 
Sayegh, 1996). Increased expression of the intracellular adhesion molecule-I (ICAM-1) 
expression occurs in the glomeruli of rat renal allografts undergoing acute rejection 
(Azuma et al., 1994). 
Cellular localisation of endotlte/in receptors 
Immunoperoxidase localisation showed decreased ET 8 receptor labelling in tubules during 
acute rejection; as well as an increase in ET A receptor immunofluorescent labelling in 
collecting ducts during rejection. The small numbers in each sub-category made statistical 
analysis difficult. Electron microscopy revealed ET receptor immunolabelling in epithelial 
cells of proximal and distal tubules and endothelial cells of blood vessels and glomerular 
capillaries. The clinical features of hypertension and oedema that occur during acute 
rejection may be mediated by the ET A receptor (promoting vasoconstriction) and by down­
regulation of the ET8 receptor, resulting in an anti-natriuretic effect respectively. 
Chronic rejection 
Chronic rejection is recognized as a sequelae of acute rejection, and may thus follow on as 
a result of the secretion of growth factors. Periglomerular and perivascular macrophages 
236 
secrete cytokines that are profibrogenic, including platelet-derived growth factor (PDGF) 
and TGF-p. The gradual functional deterioration caused by the development of 
glomerulosclerosis and arterial obliteration may also cause systemic hypertension which 
results in the remaining functional glomeruli to hyperfilter before eventually fibrosing, a 
process that progressively leads to renal damage (Neuringer and Brenner, 1992). Renal 
allografts with chronic rejection and transplant-associated arteriosclerosis have been 
reported to express 6-fold more ET-I in the neointima of the vasculature, when compared 
to allografts with acute rejection or normal control kidneys (Simonson et al., 1998). 
4.2.2 Endothelins in renal parenchymal disease 
ET-1 in the circulation and urine 
This study demonstrated that increased plasma ET-I levels were present in renal disease, 
compared to normal controls; the elevated plasma ET-I levels were found in both 
proliferative and non-proliferative glomerulonephritis (GN), with significantly higher 
levels in proliferative glomerulonephritis. Both hypertensive and normotensive patients 
with glomerulonephritis had increased plasma ET-1 levels, but with significantly higher 
levels in the hypertensive patients. Plasma ET-1 values were elevated in both dialysis- and 
non dialysis-requiring patients when compared to normal controls; plasma ET- I was 
significantly higher in dialysis patients compared to patients not requiring dialysis. Urinary 
ET-1 levels were similar in patients with glomerulonephritis and controls. 
ET-1 may be important in increasing vascular resistance in hypertension. ET- I potentiates 
the vasoconstrictor response to sympathetic stimulation (Haynes and Webb, 1998). The 
endothelin system in human hypertension resembles animal models of salt-sensitive 
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hypertension; ET-I is elevated in black hypertensives compared to white hypertensives and 
black normotensives (Ergul et al., 1996). Endothelin levels were significantly elevated in 
normotensive black adolescents with a family history of hypertension; ET- I was markedly 
increased in response to acute stressors (Treiber et al., 2000). 
Cellular localisation of ET-I 
Immunofluorescent immunocytochemistry showed increased ET-I labelling of proximal 
and distal tubules in proliferative GN biopsies. Proximal tubular labelling was observed 
mainly in the brush border, as reported by Wilkes et al. (1991). Electron microscopy 
demonstrated the presence of ET-1 in the proximal and distal tubules and glomeruli as well 
as blood vessels; the localisation was predominantly in the cytoplasm, as well as 
mitochondria and within secretory vesicles. ET-I label was present in endothelial cells of 
glomerular capillaries and arterioles as well as vascular smooth muscle cells. ET-I acts as 
an autocrine/ paracrine substance, as circulating plasma levels are lower than those 
required to elicit most of the biological actions of ET-I. The concentration of ET-I at the 
vascular smooth muscle may be several orders of magnitude higher than that in plasma 
(Yoshimura et al., 1995; Benigni, 2000). Angiotensin II stimulates the expression of ET-I 
gene in endothelial and renal cells. Part of the mitogenic effect of Angiotensin II is 
mediated by ET-I, as suggested by studies with monoclonal antibodies against ET-I 
(Bakris and Re, 1993). Data in animals with progressive nephropathies suggest that 
angiotensin conve11ing enzyme inhibitors (ACE-I), besides reducing glomerular protein 
traffic, also inhibit the exaggerated synthesis of ET-I (Zoja et al., 1998). ET-I synthesis in 
proximal tubular cells can be influenced by proteinuria (Zoja et al., 1995). 
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Cellular localisation of emlotltelin receptors 
ETA receptor labelling was increased in distal tubules in proliferative GN. ET8 receptors, 
visualised by immunoperoxidase, showed decreased labelling in tubules in GN biopsies. 
The small numbers in each sub-category made statistical analysis difficult; further studies 
with larger sample numbers would help in confirming these findings. Electron microscopy 
demonstrated the presence of ET receptors in the proximal and distal tubules and glomeruli 
as well as blood vessels. ET receptor label was present in endothelial cells of glomerular 
capillaries and arterioles as well as vascular smooth muscle cells. The role and interaction 
of the two endothelin receptors in vivo remains unclear. Activation of ET A or ET 8 receptors 
on vascular smooth muscle cells produces a pressor response through vasoconstriction, 
while activation of ET 13 receptor on the vascular endothelium produces a depressor 
response by evoking the release of vasodilators. ET 8 receptors on the vascular endothelium 
may play a role in clearing circulating ET-I, thereby reducing its predominant ETA
mediated presser actions. Activation of ET 8 on the renal tubular epithelium can act as a 
depressor mechanism by promoting natriuresis and diuresis. 
ET-1 ill renal infla111111atio11 
Mesangial proliferation is a common finding in glomerular inflammation, suggesting that 
local overproduction of ET-I might serve as a pro-inflammatory signal in glomerular 
injury. Pro-inflammatory agents, such as IL-I and TGFp, stimulate ET-1 secretion in 
endothelial and mesangial cells, supporting this hypothesis. ET-1 induces platelet-derived 
growth factor (PDGF) A and B chain expression in human mesangial cells; AP-1 
transcription factors probably mediate induction of the collagenase gene by ET-1 in 
mesangial cells (reviewed by Simonson, 1993). There is evidence to suggest that ET-1 is 
involved in the pathogenesis of proliferative glomerulonephritis. Renal ET-1 production 
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was increased in experimental and human glomerulonephritis (Murer et al., 1994; 
Roccatello et al., 1994; Nakamura et al., 1995a; Yoshimura et al., 1995). ET-I is a potent 
mitogen and partly mediated the proliferative effects of several cytokines (Bakris and Re, 
1993; Kohno et al., 1994; Nitta et al., 1995). Inflammatory cytokines and proteinuria per se 
augmented renal ET-I production (Zoja et al., 1995). ET 8 receptor expression was 
upregulated in glomerulonephritis in the rat (Yoshimura et al., 1995). ET receptor 
antagonists reduced mesangial cell proliferation in experimental mesangial proliferative 
glomerulonephritis (Fukuda et al., 1996) and decreased renal injury in murine lupus 
nephritis (Nakamura et al., 1995b). 
Endothelin-1 also contributes to excessive accumulation of extracellular matrix 
components and fibrosis by increasing renal cell fibronectin and collagen production, tissue 
inhibitor of metalloprotease levels and the release of cytokines that stimulate matrix 
accumulation (Ong et al.. 1994; Ruiz-Ortega et al., 1994). ET-1 antagonism decreased 
matrix accumulation in experimental models of glomerulonephritis (Fukuda et al., 1996). 
Chronic treatment with an ETA receptor antagonist (FR 139317, Fujisawa, Osaka, Japan) 
attenuated increases in glomerular mRNA levels of collagen, laminin, tumour necrosis 
factor, TGF-�. PDGF and basic fibroblast growth factor in diabetic rats (Nakamura et al., 
1995c). Once substantial renal scarring occurs, there is an inevitable progression to end 
stage kidney disease, a process involving gradual glomerular sclerosis and interstitial 
fibrosis. Endothelin receptor blockade reduced proteinuria and glomerulosclerosis, and 
protected against hypertension and elevations in serum creatinine levels in the 5/6 
nephrectomy rat model (Benigni et al., 1993 and 1996). Endothelin receptor antagonists 
(ETA and combined ETA/ET 8 antagonists) reduced proteinuria and the amount of periodic 
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acid Schiff (PAS) positive material as well as decreasing the over-expression of fibronectin 
and typeIV collagen in diabetic nephropathy in rats with streptozotocin-induced diabetes 
(Hocher et al., 2001). 
ET-I am/ endotltelin receptors in re11alfunctio11 
Fluid retention and hypertension accompany renal disease. Clinically, glomerular disease 
presents with oedema and an elevated blood pressure. Alterations in ET-1 in the renal 
vasculature and renal tubules have differing effects. In the vasculature, increases in ET-I 
predominantly cause vasoconstriction with a hypertensive effect. Increased ET-1 in the 
nephron probably enhances sodium and water excretion, favouring hypotension (reviewed 
by Markewitz and Kohan, 1995; Schiffrin, 1995). The ET 8 receptor was down-regulated in 
proximal and distal tubules and collecting ducts, and is probably implicated in impaired 
natriuresis. This observation may account for the fluid retention and hypertension occurring 
with acute rejection and glomerulonephritis: ET s receptors have a potentially important 
hypotensive effect via inhibition of sodium and water reabsorption in the distal nephron 
(Webb et al., 1998). The amiloride-sensitive renal epithelial sodium channel is an essential 
component for the regulation of sodium balance, blood volume and blood pressure. In vitro 
studies suggest that activation of ET 8 receptors inhibits the activity of the renal epithelial 
sodium channel in the renal collecting duct epithelium (Gallego and Ling, 1996). 
Activation of ET 8 receptors leads to down-regulation of the epithelial sodium channel in 
the renal tubule via increased production of nitric oxide (Plato and Garvin, 1999). Mean 
arterial pressure was significantly higher in ET 8 receptor deficient mice; excess dietary salt 
upregulated renal ET-1 in these rodents (Ohuchi et al., 1999). Thus ET 8 receptor activation 
has a hypotensive effect via promotion of renal sodium and water excretion. 
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Endothelin receptor antagonists have been shown to be reno-protective, namely, to 
decrease blood pressure, improve renal function and reduce proteinuria in models of renal 
disease, for example, combined ET NB receptor antagonist in immune-complex nephritis 
(Gomez-Garre et al., 1996); ETA receptor antagonist FR 139317 (Fujisawa, Osaka, Japan) 
in murine lupus nephritis (Nakamura et al., 1995b ); ET A receptor antagonist LU 135252 
(Knoll AG, Ludwighafen, Germany) and ACE inhibitor had an additive effect compared to 
either agent alone in accelerated passive Heymann nephritis (Benigni et al., 1998a); ET A 
receptor antagonist (Nakamura et al., 1995c) and mixed ET A/B receptor antagonist (Benigni 
et al., 1998b) in Streptozotocin-induced diabetes. Bosentan, a mixed ET A/ET 8 receptor 
antagonist, administered to patients with mild-moderate essential hypertension was as 
effective as enalapril (inhibitor of angiotensin converting enzyme) in controlling blood 
pressure, suggesting that ET-1 contributes to hypertension in these patients (Krum et al., 
1998). 
4.3 MODULATION OF RENAL FUNCTION AND ROLE IN RENAL DISEASE OF 
ATRIAL NATRIURETIC PEPTIDE 
Circulating atrial natriuretic peptide (ANP) is produced primarily as a response to increased 
intravascular volume; elevated levels of ANP are found in hypertensive patients, nephrotic 
syndrome and acute and chronic renal failure. 
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4.3.1 ANP and acute rejection 
Plasma concentrations of all three natriuretic peptides were elevated in chronic renal 
failure, probably because of reduced clearance (Prins et al., 1996). Infusion of doses of 
ANP slightly above the physiological range in patients with moderate chronic renal failure 
secondary to glomerulonephritis resulted in a natriuretic response similar to that of normal 
controls, together with a marked increment in the urinary excretion of urea, potassium and 
phosphate (De Nicola et al., 1997). Plasma and urinary ANP concentrations were 
significantly elevated during acute rejection, compared to normal control subjects in the 
current study. ANP concentrations decrease after a successful kidney transplant and levels 
increase again when the transplant fails (Zuber et al., 1993). In these patients, increased 
plasma ANP levels in acute rejection may occur as a response to increased intravascular 
volume and hypertension: ANP production may be stimulated by excess ET-1 being 
present. ANP inhibited uptake of IgG complexes by macrophages and increased cGMP 
levels in macrophages. This alteration in macrophage-dependant phagocytosis may be 
important in the modulation of immune complex mediated tissue injury (Mattana and 
Singha!, 1993). Immunocytochemistry revealed decreased labelling of glomeruli and 
collecting ducts during acute rejection whereas immunolabelling of tubules and arteries 
was similar to control kidney. 
Studies in renal transplant recipients (Bricker et al., 1956) and in subjects with autonomic 
failure (Gill and Bartter, 1966) suggest that renal denervation impairs sodium conservation 
in the presence of dietary sodium restriction. Efferent sympathetic nerve stimulation 
increases tubular sodium and water reabsorption and produces a fall in GFR and renal 
blood flow mediated by preglomerular vasconstriction (Kopp and Di Bona, 1982). Head­
out water immersion studies in stable renal transplant recipients showed a diuretic and 
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natriuretic response with elevations in plasma ANP and urinary tissue kallikrein excretion; 
plasma renin activity did not suppress with head-out water immersion, probably as a result 
of a reduction in sympathetic nerve traffic to the juxtaglomerular apparatus (Al-Haidary et 
al., 1990). Low dose ANP infusion to stable renal transplant recipients resulted in 
immediate natriuresis and urinary cyclic GMP excretion as well as albuminuria, in contrast 
to the delayed response seen in normal subjects (Lipkin et al., 1992). Intravenous infusion 
of ANP during acute renal allograft rejection in a canine model resulted in increased urine 
flow rates and an increase in GFR, together with a fall in mean arterial pressure in the 
presence of an unchanged haematocrit (Lewis et al., 1993). 
4.3.2 ANP and renal parenchymal disease 
Plasma ANP is elevated in animals and humans with acute and chronic renal failure, due to 
enhanced release from the atria following volume expansion and reduced clearance by the 
kidneys. Predialysis ANP levels were higher in haemodialysis than CAPO or healthy 
subjects and fell to levels similar to CAPO following dialysis. Haemodialysis patients with 
moderate and severe hypertension had higher levels of plasma ANP, proANP and cGMP 
compared to normotensive or mild hypertensives. ANP was increased in moderate and 
severe hypertension and correlated with blood pressure and left ventricular hypertrophy. In 
nephrotic syndrome, plasma ANP was normal or elevated, reflecting the plasma volume 
status of these patients; however the urinary sodium excretion in response to ANP infusion 
is blunted, irrespective of plasma ANP levels (reviewed by Awazu and Ichikawa, 1993). 
ANP stimulates kallikrein excretion transiently and is dependent on distal sodium delivery 
(Klein et al., 1989). Low supraphysiological doses of ANP to patients with moderate 
chronic renal failure due to glomerulonephritis were natriuretic, together with an increased 
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excretion of urea, potassium and phosphate (resulting in a 15-20% decrease in plasma 
levels) without any drop in blood pressure. 
There was decreased immunolabelling of glomeruli and collecting ducts m 
glomerulonephritis; labelling of tubules and arteries was similar to that of control kidney 
tissue. ANP immunoreactivity was reduced in hypertensive nephrosclerotic distal tubules, 
probably as a result of reduced renal tubular mass (Figueroa et al., 1990). Upregulation of 
the A receptor subtype occurred in hypertensive rats, together with increased levels of ANP 
and BNP (Yoshimoto et al., 1995). Renal ANP gene expression is upregulated in the 5/6 
nephJectomised Munich-Wistar rats, suggesting that local synthesis of ANP may 
participate in increasing renal sodium excretion to maintain sodium and water homeostasis 
in the face of reduced nephron numbers (Totsune et al., 1998). 
This study confirms the widespread immunolocalization of ANP in the normal human 
kidney. In the present study, the decreased immunolabelling of the collecting ducts during 
acute rejection and glomerulonephritis may be a reflection of impaired natriuresis and 
diuresis, resulting in fluid retention occurring in these patients. 
4.4 THE KALLIKREIN KININ CASCADE IN RENAL FUNCTION AND 
DISEASE 
Kallikreins are proteolytic enzymes which interact with their substrate the kininogens to 
form the vasoactive peptides, kinins. Kinins bind to their receptors at target organs and 
exert potent effects in vasodilatation, reduction of blood pressure, vascular permeability, 
natriuresis, diuresis and renal blood flow. 
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4.4.1 Tissue kallikrein in renal transplantation 
Urinary tissue kallikrein enzymic activity was significantly decreased in stable renal 
transplant recipients and in kidney donors after unilateral nephrectomy, compared to 
normal controls. This supports the findings of Spragg et al., (1985) that tissue kallikrein 
excretion rate may be a useful indicator of distal tubular mass. Serial measurements of 
urinary tissue kallikrein enzymic activity were made prior to kidney transplant, on day 3 or 
4 post transplant when the patient was stable, during an episode of acute rejection and with 
recovery after treatment of rejection. While tissue kallikrein levels rose from their pre­
transplant levels on day 3 or 4 after renal transplant, decreased again during rejection and 
rose again after treatment of rejection, the difference did not reach statistical significance .. 
Lower urinary kallikrein excretion was found in transplant recipients compared to controls, 
probably related to reduced renal function or reduced renal mass (Koolen et al., 1984b; 
Marin-Grez et al., 1982). 
There was no correlation between serum creatinine and tissue kallikrein during acute 
rejection. Serial ELISA measurements did not show any difference in total immunoreactive 
tissue kallikrein at any stage of transplantation. Tissue kallikrein showed a significant 
decrease in donors post-nephrectomy compared to pre-nephrectomy; an increase in urinary 
tissue kallikrein was observed during rejection, compared to levels in donors post 
nephrectomy. Urinary excretion of tissue kallikrein was reduced in renal transplant 
recipients and more markedly so following acute rejection (Moodley et al., 1996). Increase 
in urinary kallikrein excretion 1-3 days before clinical rejection suggests that activation of 
the kallikrein kinin cascade is associated with acute rejection (Brouhard et al., 1982; 
Koolen et al., 1984b ). In addition to kallikrein, elevations in factor XIIa, plasminogen and 
antithrombin III have been observed 2-3 days before clinical signs of rejection (Schrader et 
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al., 1988). Decreased kallikrein excretion follows cylosporine administration (Spragg et al., 
1988; Martinez et al., 1990). Short term cyclosporine administration decreaseskallikrein 
and kinin B2 receptor mRNA expression in rat kidney cortex (Bompart et al., 1996). 
Hypertension frequently accompanies renal transplantation. Proposed mechanisms for 
hypertension include acute rejection, chronic rejection, therapy with steroids and 
cyclosporine, renal insufficiency, presence of the recipient's own diseased kidneys, 
transplant renal stenosis, increased activity of the vasoconstrictor systems (for example 
renin-angiotensin, endothelin) and decreased activity of vasodilator systems. Urinary 
kallikrein excretion was found to be decreased in hypertensive patients and in those with 
renal complications (more markedly decreased with acute tubular necrosis than acute 
rejection). Urinary kallikrein excretion was also lower in cadaver graft recipients who tend 
to be more hype11ensive (O'Connor et al., 1982). 
Renal tissue kallikrein is predominantly localized in the granular portions of the distal 
tubule and cortical collecting ducts (Tomita et al., 1981; Omata et al., 1982; Figueroa et al., 
1984), where it is concentrated mainly on the luminal side of the cell and at both sides of 
the nuclei. Decreased labelling was observed in the distal tubules during acute rejection. 
TK immunoreactivity was reduced in acute rejection both on immunocytochemistry and 
electron microscopy; while TK was observed mainly at the luminal side of distal 
connecting tubules and collecting ducts, there was a shift in immunolabelling to the 
basolateral membranes (Ramsaroop et al., 1997). 
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4.4.2 Kinins in renal transplantation 
Basal urinary kinin excretion was decreased in donors following nephrectomy and in stable 
transplant recipients compared to normal control subjects but rose significantly during 
acute rejection. Kinin generation in the urine was significantly decreased in donors post­
nephrectomy and during acute rejection, compared to controls. The turnover of kinins 
depends on both the rate of formation and the rate of destruction. After kinins are formed, 
they are rapidly destroyed by the enzymic action of peptidases. Kininases, which inactivate 
plasma kinins, are distributed in 2 major portions of the nephron: in the proximal tubules 
and the medullary collecting ducts and may contribute to the decreased levels in the urine. 
4.4.3 Kinin receptors in acute rejection 
The kinin B2 receptor localises in the entire nephron in the normal control kidney and is 
down-regulated in acute rejection (Naidoo et al., 1996). The B 1 receptor is not present in 
the normal control kidney and but is strongly induced during acute rejection (Bhoola et al., 
2001 ). 
4.4.4 Role of the kallikrein-kinin system in renal transplantation 
Several factors may affect the kallikrein-kinin system in renal transplantation. The 
uninephrectomised donor and the renal allograft recipient have a single functioning kidney: 
therefore, the lower urinary tissue kallikrein excretion demonstrated in these subjects may 
be a reflection of decreased distal tubular mass. Cyclosporine A forms part of the 
immunosuppressive regimen in the majority of kidney transplant recipients. Although it is 
effective in increasing graft survival, it is also well known that its therapeutic benefits are 
counterbalanced by major side effects, including vascular toxicity, hypertension and renal 
insufficiency (Sturrock and Struthers, 1994); the hypothesis being that CyA may induce an 
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imbalance between renal vasoconstrictor ( endothelins, renin-angiotensin, thromboxane) 
and vasodilator (nitric oxide, prostaglandins, kallikrein-kinins) systems, leading to an 
increase in renal vasoconstriction. A decreased kallikrein excretion has been reported in 
renal transplant patients receiving Cyclosporine (Martinez et al., 1990) as well as a 
reduction in kinin B2 receptor mRNA expression in the cortex of the kidney (Bompart et 
al., 1996). 
The renal transplant recipient is frequently hypertensive; the blood pressure is further 
elevated during episodes of acute rejection together with deterioration in renal function; 
both of these factors have been associated with a reduced kallikrein excretion, which may 
be partially responsible for the sodium and water retention known to occur in these patients 
(and thereby further increase the blood pressure). The acute rejection process, by damaging 
the distal tubule, would decrease tissue kallikrein excretion. 
4.4.5 Tissue kallikrein in renal parenchymal disease 
Urinary kallikrein excretion is markedly increased in patients with nephrotic syndrome, 
irrespective of the level of renal function (Cumming and Robson, 1985), whereas patients 
with glomerulonephritis (without nephrotic syndrome) show reduced urinary kallikrein 
excretion compared to healthy volunteers. Kallikrein excretion correlates with plasma renin 
activity but not with plasma volume (Cumming et al., 1989). Urinary tissue kallikrein 
enzymic activity was significantly decreased in patients with renal disease compared to 
controls and was even further decreased during acute renal allograft rejection compared to 
renal disease. ELISA measurements confirmed the reduced excretion of urinary tissue 
kallikrein in renal disease. There was reduced immunolabelling of TK in distal tubules. In 
patients with renal parenchymal disease and hypertension with impaired renal function, a 
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more marked decrease in unnary kallikrein excretion was recorded, compared to 
hypertensive subjects with normal renal function, in whom a reduced urinary kallikrein 
excretion was also noted but less so (Mitas et al., 1978). Similarly in subjects with 
advanced hypertensive nephropathy, there was a reduction in the percentage of tubules and 
cells with immunoreactive tissue kallikrein (Figueroa et al., 1992). 
4.4.6 Kinins in renal parenchymal disease 
Although basal kinin levels in unne were similar for renal disease and controls, 
significantly decreased kinins were generated m the unne of patients with 
glomerulonephritis, reflecting a reduction in the kinin-producing enzyme TK during renal 
inflammation. Kinins are potent stimulators of phospholipase A2, and promote synthesis of 
arachidonic acid metabolites, including thromboxane A2 (Regoli and Barabe, 1980). 
Increased glomerular synthesis of thromboxane has been suggested as a cause of 
proteinuria in nephrotic syndrome (Remuzzi et al., 1985). 
4.4. 7 Kinin receptors in renal disease 
The constitutive B2 receptor, present along the entire nephron, was down-regulated in renal 
disease. A novel finding has been the increased expression of the inducible kinin B 1 
receptor in these patients (Naicker et al., 1999). Prevalence of the 0
699 
➔ C polymorphism 
of the kinin BI receptor was reported to be significantly less frequently in several 
aetiological subgroups of uraemic patients (Bachvarov et al., 1998). Thus, the 
polymorphism of the kinin B 1 receptor promotor may be a marker of prognostic 
significance for the preservation of renal function. 
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4.4.8 Role of kallikrein kinin system in renal parenchymal disease 
The decreased urinary kallikrein activity may be a reflection of reduced distal nephron 
function in these patients and may mediate the hypertension that accompanies renal disease 
(Margo Ii us et al., 1971 ). Clinical studies have shown that blood pressures of hypertensive 
patients can be temporarily lowered by oral administration of porcine pancreatic kallikrein 
(Overlack et al., 1981 ). Long-term infusion of tissue kallikrein via mini pumps has been 
shown to have beneficial effects by attenuating glomerulosclerotic lesions and tubular 
injury in hypertensive Dahl salt-sensitive rats (Uehara et al., 1990). A single injection of 
the human tissue kallikrein gene into the spontaneously hypertensive rat has been shown to 
reduce blood pressure for up to 10 weeks (Chao and Chao, 1997). Sub-depressor doses of 
purified rat urinary kalikrein infused for 4 weeks in Dahl salt-sensitive rats fed a high salt 
diet resulted in decreased urinary protein excretion, increased GFR and attenuated 
glomerulosclerosis, arterial and tubular injury, together with increased urinary excretion of 
NO and cGMP. These effects were diminished by co-administration of HOE-140, 
suggesting that reno-protection is mediated by the kinin B2 receptor (Hirawa et al., 1999). 
Urinary kallikrein activity was lower in hypertensive compared to normotensive 
individuals and more markedly diminished in patients with renal parenchymal disease and 
hypertension. Inhibitors of ACE, a member of the kininase (K-11) group of enzymes that 
rapidly inactivate kinins and also convert the decapeptide angiotensin 1 to an octapeptide 
angiotensin II, are probably the best examples of drugs acting on the kinin system that are 
used in clinical medicine. The mode of action of ACE inhibitors as antihypertensive agents 
have been shown to be due to both the inhibition of angiotensin 11 (a potent 
vasoconstrictor) production, as well as an increase in circulating levels of kinins 
(Shimamoto et al., 1990). The hypotensive efficacy of these inhibitors has also been shown 
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to correlate with the reduced activity of ACE in the brain, kidney, and vascular smooth 
muscle (Unger et al., 1987). Angiotensin converting enzyme (ACE) inhibitors prevent the 
conversion of Angiotensin I to Angiotensin II and increase urinary kinin excretion, while 
the effect on plasma kinins is controversial with different studies showing an increase, a 
decrease or no change (Carretero and Scicli, 1981 ). The hypotensive effect of the ACE 
inhibitor, perindopril, in spontaneously hypertensive rats, on low and high sodium diets, 
was attenuated by the kinin B2-receptor antagonist HOE 140 (Bouaziz et al., 1994). The 
beneficial effects of ACE inhibitors may be related also to the formation of nitric oxide and 
prostacyclin by kinins (Linz et al., 1993). Icatibant acetate (HOE 140), a B2 receptor 
antagonist, given together with captopril, attenuated the hypotensive effect of captopril by 
53% in black and white subjects on a low sodium diet (Gainer et al., 1998). This study 
provides evidence that kinins contribute substantially to the hypotensive effects of ACE 
inhibition. 
4.5 INTER-RE LA TIO NS HIP OF V ASOACTIVE PEPTIDES IN RENAL 
FUNCTION AND DISEASE 
Genetic and environmental factors interact to determine an individual's blood pressure. The 
kidney plays an important role in maintaining body fluid and electrolyte balance, and blood 
pressure homeostasis through actions of various humoral and paracrine/autocrine factors on 
renal medullary haemodynamics, tubular reabsorption and urine concentration. Nephron 
development is coordinated by the interaction of cell adhesion molecules, components of 
the extracellular matrix and peptide growth factors. Renal ontogeny and function are 
modulated through complex molecular interactions of endothelins, kinins, atrial natriuretic 
peptides and angiotensin. 
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Recent studies have shown that the endothelins are essential for normal foetal 
development, and that endothelin ET-1 plays an important physiological role in the 
regulation of basal vascular tone and blood pressure in healthy humans (Parris and Webb, 
1997). The spotted lethal rat carries a naturally occurring deletion of the ET 8 receptor gene 
that prevents expression of the ET 8 receptor and results in aganglionic megacolon. These 
animals also represent a model of salt sensitive hypertension; the animal is normotensive 
until challenged by a high salt diet, which significantly increases arterial pressure. The 
hypertension is completely ameliorated by the epithelial sodium channel inhibitor, 
amiloride (Pollock, 2000). In a rat model of renal disease progression, upregulation of ET-I 
during development of renal injury occurs progressively, initially in tubules and 
subsequently in glomeruli. ET-I plays a role in the progression of chronic renal disease in 
different experimental models, including renal mass reduction, lupus nephritis and 
streptozotocin-induced diabetes (Bruzzi et al., 1997). 
Endogenous ANP may help to maintain basal renal function in the normal foetal kidney 
(Silberbach et al., 1995). In addition to its vasodilator and natriuretic effects, ANP has 
antiproliferative effects. Infusion of CNP inhibits mesangial proliferation and matrix 
accumulation in a model of proliferative glomerulonephritis independent of haemodynamic 
changes (Wolf et al., 2000). 
The developing kidney expresses an endogenous, functionally active kallikrein-kinin 
system (KKS). Gene expression of the KKS is activated post-natally and appears to be 
regulated primarily at the transcriptional level. Ontogenetic studies have revealed that the 
kinin B2 receptor is over-expressed in the developing rat kidney. As kinins are potent 
vasodilator and growth-promoting factors, it has been suggested that endogenous kinins 
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mediate developmental renal growth and differentiation and modulate the maturational 
changes in renal haemodynamics (el-Dahr, 1997). 
All components of the renin-angiotensin system are highly expressed in the developing 
kidney. Antagonism of angiotensin (AT) suggests that the renin-angiotensin system may be 
an important contributor to renal ontogeny in the developing human. Maternal dietary 
protein restriction caused suppression of the foetal renin-angiotensin system, resulting in 
impaired structural and functional development (Woods, 2000). Pregnant women treated 
with ACE inhibitors for hypertension have an increased rate of foetal wastage, 
oligohydramnios, and intrauterine growth retardation; infants of ACE inhibitor-treated 
mothers have an increased incidence of severe systemic hypotension and anuria, and the 
kidneys have various structural abnormalities. Targeted mice, homozygous for a null 
deletion of the angiotensinogen gene, show a decreased maturity of glomeruli, together 
with renal vascular hypertrophy and increased glomerular matrix, associated with marked 
upregulation of TGFp. Mice devoid of ACE showed a similar phenotype. Administration 
of an AT 1 receptor blocker in neonatal rats induced irreversible renal abnormalities, 
including tubulointerstitial inflammation, papillary atrophy and pelvic dilatation and a 42 
% reduction in the number of nephrons. An increased incidence of congenital anomalies of 
the kidney and urinary tract was detected in mice deficient in the angiotensin II type 2 
(AT2) receptor. Impairment of AT2 receptor function may cause pelvi-ureteric junction 
obstruction and primary obstructive megaureter, as this receptor is postulated to be 
involved in the development of the lumen of the ureter through apoptic resorption of cells. 
The A T2 receptor was also shown to tonically decrease ACE activity in mice (reviewed by 
Hohenfellner et al., 1999). 
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ET-1, ANP, kinins and angiotensin II have been implicated in the regulation of renal 
medullary function; studies have shown that these vasoactive peptides either act alone or 
interact with each other to influence medullary/papillary blood flow and urinary water and 
sodium excretion (Cowley et al., 1995; Navar et al., 1996; Chou et al., 1990). In the cortex, 
angiotensin II and ET- I act as vasoconstrictors to decrease renal blood flow and GFR, 
whereas kinins cause vasodilatation and increase glomerular capillary permeability. In the 
medulla, angiotensin II and ET-1 cause constriction of the outer medullary vasa recta and 
thereby decrease vasa recta and papillary blood flow, whereas kinins exert opposite effects 
(Navar et al., 1996). The renin-angiotensin-aldosterone system plays an essential role in 
salt and blood pressure homeostasis and is governed mainly by renin. Local factors 
(prostaglandins, NO, ET-I) produced in the immediate vicinity of the juxtaglomerular 
apparatus (JGA) affect renin secretion and renin gene expression. Prostaglandin E2 and 
prostacyclin increase renin secretion and gene expression by activating cAMP produced in 
JG cells. The effect of NO on JG cells is not very clear but appears to stimulate renin via 
cAMP and cGMP-induced inhibition of cAMP-phosphodiesterase III. ET-1 inhibits renin 
by cAMP acting via calcium-phosphokinase C-related mechanisms (reviewed by Wagner 
et al., 1998). 
The distribution of AT 1, ET A, ET 8 and kinin B2 receptors closely overlaps at several 
anatomical sites, including renal vasculature, glomeruli and the inner stripe of the outer 
medulla. In the cortex, the distribution of AT 1 and ET 8 receptors is similar in the glomeruli 
and proximal tubules; kinin B2 receptor density is low in the cortex. In the inner medulla, 
ET 8 and B2 receptors are abundant, whereas AT I receptors are not readily detected in this 
region. Effects of angiotensin II, ET-I and kinins on cell proliferation and extracellular 
matrix synthesis in renal medullary interstitial cells imply an important interactive role in 
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chronic progressive renal disease (Zhuo et al., 1998). Angiotensin II upregulates the 
expression of growth factors and cytokines [TGFP, TNFa, osteopontin, vascular cell 
adhesion molecule-I, nuclear factor-KB (NF-KB), PDGF, bFGF, IGF], most of which 
promote cell growth and fibrosis. Angiotensin II also stimulates oxidative stress, which 
may potentiate its vasoconstrictor effect partly by increased catabolism of NO. 
Angiotensinogen gene is stimulated by NF-KB activation. Angiotensin converting enzyme 
inhibitor inhibits NF-KB activation in renal disease (Klahr and Morrissey, 2000). Multiple 
vasoactive peptides interact to exert endocrine and/ or paracrine influence on renal 
medullary microcirculation, tubular function and mitogenesis; NO, ANP and kinins may 
counteract the vasoconstrictor and mitogenic effects of ET-I and Angiotensin II. 
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CHAPTERS 
SUMMARY AND CONCLUSIONS 
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1. The kidneys play a pivotal role in maintaining body fluid and electrolyte balance
and blood pressure homeostasis through actions of various humoral and paracrine/autocrine 
factors on renal medullary haemodynamics, tubular reabsorption and urine concentration. 
Multiple vasoactive peptides interact to exert autocrine and/ or paracrine influence on the 
renal microcirculation, tubular function and mitogenesis. ET- I, ANP, kinins and 
angiotensin II have been implicated in the regulation of renal medullary function; studies 
have shown that these vasoactive peptides either act alone or interact with each other to 
influence medullary/papillary blood flow and urinary water and sodium excretion. Local 
factors (prostaglandins, NO, ET-I) produced in the immediate vicinity of the 
juxtaglomerular apparatus affect renin secretion and renin gene expression. NO, ANP and 
kinins may counteract the vasoconstrictor and mitogenic effects of ET-1 and Angiotensin 
II. 
2. Total body water (TBW) was measured in 5 transplant recipients immediately pre­
transplant following dialysis, when they were assessed as having reached "dry" weight, 
namely showing no evidence of fluid retention. TBW was measured following 
transplantation and during rejection in 4 patients, when fluid retention was apparent, and 
again when kidney function had stabilised, demonstrating reduction in body weight and 
TBW. Effective renal plasma flow was measured in 6 transplant patients and was shown to 
be reduced in patients during rejection, a reflection of the increased vasoconstriction 
present in this condition. 
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3. The primary aim of my study was to determine circulatory and cellular actions of
ET-1, ANP and kinins in human models of renal inflammation: in acute renal allograft 
rejection and renal parenchymal disease (mainly glomerular disease). 
4(i) Plasma ET-1 levels were measured serially in patients prior to renal transplantation, 
post- transplantation when stable, during acute rejection and subsequently, after treatment 
of rejection. The highest levels of ET-1 were observed prior to transplant and in patients 
with chronic renal failure on dialysis. Following transplantation, ET-1 levels decreased, 
increased during episodes of acute rejection and decreased again after treatment of 
rejection. This corresponded with elevated urinary ET- I levels during acute rejection, 
suggesting that ET-1 is produced by the kidney, specifically by inflammatory cells within 
the renal substance, reflecting endogenous renal ET-1 production. Increased plasma ET-1 
levels were present in renal disease, compared to normal controls; the elevated plasma ET-
1 levels were found in both proliferative and non-proliferative glomerulonephritis (GN), 
with significantly higher levels in proliferative glomerulonephritis. Both hypertensive and 
normotensive patients with glomerulonephritis had increased plasma ET-1 levels, with 
significantly higher ET-1 levels in hypertensive patients. Plasma ET-1 was elevated in both 
dialysis- and non dialysis-requiring patients compared to normal controls; plasma ET-I 
was significantly higher in dialysis patients compared to patients not requiring dialysis. 
Urinary ET-1 levels were similar in patients with glomerulonephritis and controls. 
4(ii) Immunocytochemistry, using immunoperoxidase and fluorescent methods, showed 
increased ET- I labelling of proximal and distal tubules during rejection, mediated by the 
ET A receptor as suggested by increase in ET A receptor labelling in collecting ducts during 
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rejection. Endothelin-B receptor labelling was decreased in distal tubules and glomeruli 
during rejection. Immunocytochemistry showed increased ET- I labelling of proximal and 
distal tubules in proliferative GN biopsies. Proximal tubular labelling was observed mainly 
in the brush border, as reported by Wilkes et al. (1991 ). ET A receptor labelling was 
increased in distal tubules in proliferative GN. ET 8 receptor labelling was decreased in 
tubules in GN biopsies. Further studies with larger sample numbers are required to confirm 
these findings. 
4(iii) Immuno-electron microscopy revealed ET-I and ET receptor labelling in epithelial 
cells of proximal and distal tubules, endothelial cells of blood vessels and glomerular 
capillaries, specifically in cytoplasm of cells, endoplasmic reticulum and mitochondria. 
Label was found in increased amounts adjacent to the intercellular system and within 
vacuoles and secretory vesicles. ET- I is stored within these vesicles an<l released at the cell 
surface after an appropriate stimulus. The characteristic feature of acute rejection is 
infiltration of the graft by host mononuclear cells; these lymphocytes and macrophages 
infiltrate the interstitium and tubular epithelium. In this study, ET-I label was also 
demonstrated in the mononuclear cells infiltrating the tubules during acute rejection by 
electron microscopy as well as peroxidase-anti peroxidase method. ET-I mRN A was 
upregulated in the tubular epithelial cells and capillary endothelial cells, as well as the 
inflammatory infiltrate, during acute rejection as demonstrated by in situ RT-PCR. 
4(iv) The down-regulation of the ET 8 has not been previously reported in renal 
inflammation and is probably implicated in impaired natriuresis. This observation may 
account for the fluid retention and hypertension occurring with acute rejection and 
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glomerulonephritis: ET B receptors have a potentially important hypotensive effect via 
inhibition of sodium and water reabsorption in the distal nephron. In vitro studies suggest 
that activation of ET B receptors inhibits the activity of the renal epithelial sodium channel 
in the renal collecting duct epithelium. Activation of ET B receptors leads to down­
regulation of the epithelial sodium channel in the renal tubule via increased production of 
nitric oxide. Thus ET B receptor activation has a hypotensive effect via promotion of renal 
sodium and water excretion. Activation of ET A or ET B receptors on vascular smooth 
muscle cells produces a pressor response through vasoconstriction, while activation of ET B
receptor on the vascular endothelium produces a depressor response by evoking the release 
of vasodilators. ET B receptors on the vascular endothelium may play a role in clearing 
circulating ET-I, thereby reducing its predominant ET A-mediated pressor actions. 
4(v) Endothelin receptor antagonists have been shown to be reno-protective, that is to 
decrease blood pressure, improve renal function and reduce proteinuria in models of renal 
disease for example, combined ET NB receptor antagonist in immune-complex nephritis 
(Gomez-Garre et al., 1996); ETA receptor antagonist in murine lupus nephritis (Nakamura 
et al., 1995b ); ET A receptor antagonist and ACE inhibitor had an additive effect compared 
to either agent alone in accelerated passive Heymann nephritis (Benigni et al., I 998a); ET A 
receptor antagonist (Nakamura et al., 1995c) and mixed ET NB receptor antagonist (Benigni 
et al., I 998b; Hocher et al., 2001) in Streptozotocin-induced diabetes. Bosentan, a mixed 
ET A/ET B receptor antagonist, administered to patients with mild-moderate essential 
hypertension was as effective as enaiapril (inhibitor of angiotensin converting enzyme) in 
controlling blood pressure, suggesting that ET-I contributes to hypertension in these 
patients (Krum et al., 1998). Angiotensin II stimulates the expression of ET-1 gene in 
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endothelial and renal cells. Part of the mitogenic effect of Angiotensin II is mediated by 
ET-I. Data in animals with progressive nephropathies suggest that ACE-I, besides reducing 
glomerular protein traffic, also inhibit the exaggerated synthesis of ET-1 (Zoja et al., 1998). 
Chronic treatment with an ET receptor antagonist attenuated increases in glomerular 
mRNA levels of collagen, laminin, tumour necrosis factor, TGF-P, PDGF and basic 
fibroblast growth factor in diabetic rats (Nakamura et al., 1995c). Once substantial renal 
scarring occurs, there is an inevitable progression to end stage kidney disease, a process 
involving gradual glomerular sclerosis and interstitial fibrosis. Endothelin receptor 
blockade reduced proteinuria and glomerulosclerosis and protected against hypertension 
and elevations in serum creatinine in the 5/6 nephrectomy rat model (Benigni et al., 1993 
and 1996). 
5. Plasma and urinary ANP concentrations were significantly elevated during acute
rejection, compared to normal control subjects in this study. Increased plasma ANP levels 
in acute rejection may be a response to increased intravascular volume and hypertension in 
these patients. ANP production may be stimulated by excess endothelin present. ANP 
stimulates kallikrein excretion transiently and is dependent on distal sodium delivery 
(Klein et al., 1989). Immunocytochemistry revealed decreased labelling of glomeruli and 
collecting ducts during acute rejection and glomerulonephritis; reduced immunolabelling of 
tubules was present in proliferative GN. This study extends knowledge of the widespread 
immunolocalization of ANP in the normal kidney. The decreased immunolabelling of the 
collecting ducts during acute rejection and glomerulonephritis may be a reflection of 
impaired natriuresis and diuresis, resulting in fluid retention occurring in these patients. 
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6(i) Urinary tissue kallikrein enzymic activity was significantly decreased in stable renal 
transplant recipients and in kidney donors after unilateral nephrectomy, compared to 
normal controls. This supports the findings of Spragg et al., (1985) that tissue kallikrein 
excretion rate may be a useful indicator of distal tubular mass. Serial measurement of 
urinary tissue kallikrein enzymic activity were made prior to kidney transplant, on day 3 or 
4 post transplant when the patient was stable, during an episode of acute rejection and after 
treatment of rejection. Tissue kallikrein levels rose from their pre-transplant levels on day 3 
or 4 after renal transplant, decreased again during rejection and rose again after treatment 
of rejection. Basal urinary kinin excretion was decreased in donors following nephrectomy 
and in stable transplant recipients compared to normal control subjects but rose 
significantly during acute rejection. Kinin generation in the urine was significantly 
decreased in donors post-nephrectomy and during acute rejection, compared to controls. 
The turnover of kinins depends on both the rate of formation and the rate of destruction. 
This finding may be a reflection of the reduction in tissue kallikrein as a consequence of 
decreased renal mass and renal inflammation. Confocal microscopy demonstrated 
decreased TK immunolabelling in the distal tubules during rejection. 
6(ii) Urinary tissue kallkrein enzymic activity was significantly decreased in patients 
with renal disease compared to controls and was even further decreased during acute renal 
allograft rejection compared to renal disease. ELISA measurements confirmed the reduced 
urinary tissue kallikrein in renal disease. There was reduced TK immunolabelling in distal 
tubules in renal disease. While basal kinin levels in urine were similar in renal disease and 
controls, significantly decreased kinins were generated in the urine of patients with 
glomerulonephritis, reflecting the reduction in the kinin-producing enzyme TK during renal 
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inflammation. The decreased unnary kallikrein activity may be a reflection of reduced 
distal nephron function in these patients and may mediate the hypertension that 
accompanies renal disease. 
6(iii) A previous study showed that the constitutive B2 receptor, present along the entire 
nephron, was down-regulated in renal disease. The B 1 receptor was induced in the kidney 
in these patients (Naicker et al., 1999; Bhoola et al., 2001 ). Other studies provide evidence 
that reno-protection is mediated by the B2 receptor (Hirawa et al., 1999) and that kinins 
contribute substantially to the hypotensive effects of ACE inhibition (Gainer et al, 1998). 
Promising studies have shown that blood pressures of hypertensive patients can be 
temporarily lowered by oral administration of porcine pancreatic kallikrein (Overlack et al., 
1981 ); infusion of tissue kallikrein via mini pumps has been shown to have beneficial 
effects by attenuating glomerulosclerotic lesions and tubular injury in hypertensive Dahl 
salt-sensitive rats (Uehara et al., 1990); a single injection of the human tissue kallikrein 
gene into the spontaneously hypertensive rat has been shown to reduce blood pressure for 
up to l O weeks (Chao and Chao, 1997); sub-depressor doses of purified rat urinary 
kalikrein infused for 4 weeks in Dahl salt-sensitive rats fed a high salt diet resulted in 
decreased urinary protein excretion, increased GFR and attenuated glomerulosclerosis, 
arterial and tubular injury. 
6(iv) Inhibitors of ACE, a member of the K-1 l group of enzymes that rapidly inactivate 
kinins, and also convert the decapeptide angiotensin 1 to an octapeptide angiotensin 11, are 
probably the best examples of drugs acting on the kinin system that are used in clinical 
medicine. The mode of action of ACE inhibitors as antihypertensive agents have been 
264 
shown to be due to both the inhibition of angiotensin 11 (a potent vasoconstrictor) 
production, as well as an increase in circulating levels of kinins (Shimamoto et al., 1990). 
The hypotensive efficacy of these inhibitors has also been shown to correlate with the 
reduced activity of ACE in brain, kidney, and vascular smooth muscle (Unger et al., 1987). 
Angiotensin converting enzyme (ACE) inhibitors prevent the conversion of Angiotensin I 
to Angiotensin II and increase urinary kinin excretion, while the effect on plasma kinins is 
controversial with different studies showing an increase, a decrease or no change (Carretero 
and Scicli, 1981 ). The hypotensive effect of the ACE inhibitor, perindopril, in 
spontaneously hypertensive rats on low and high sodium diets was attenuated by the kinin 
B2-receptor antagonist HOE 140 (Bouaziz et al., 1994). The beneficial effects of ACE 
inhibitors may be related to the formation of nitric oxide and prostacyclin, enchanced by 
the kinins released (Linz et al., 1993). lcatibant acetate (HOE 140), a B2 receptor 
antagonist, given together with captopril, attenuated the hypotensive effect of captopril 
7. Thus, as multiple mediators impact on renal disease, single agent therapy similarly
has its limitations; exceptions are agents such as ACE inhibitors which block angiotensin II 
and affect ET- I, NO, prostacyclin and kinins. 
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